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I Abstract 
Introduction - Parkinson’s disease (PD) is a neurodegenerative disorder characterized by a 
series of motor and non-motor symptoms that collectively impact the independence and quality 
of life of this population. Symptoms of postural instability are amongst the most disabling and 
appear to be significantly influenced by a reduced capacity to control the trunk segment due to 
impaired trunk muscle function, muscle weakness and reduced inter-segmental mobility. 
Considering the trunk comprises approximately 60% of the body’s weight and that standard 
pharmacological therapies are known to be largely ineffective for the management of 
symptoms affecting this segment (i.e. axial symptoms), it is clear that alternative therapies are 
required to ensure postural stability during dynamic tasks. Exercise has been shown to be 
successful for improving various measures of clinical balance and motor function in people 
with PD, but the evidence for its capacity to improve dynamic postural stability and reduce 
falls in this population is less conclusive. The inconsistent findings presented in previous 
studies may be explained, at least in part, by the tendency for such research to rely upon clinical 
tests of mobility and balance that incorporate Likert scales that lack the capacity to detect subtle 
changes in function. With recent advances in the usability of wearable sensor technologies, it 
is now possible to incorporate these highly sensitive devices to improve the objectivity of 
postural stability assessments. Despite the potential of these systems, there is a need for clearer 
guidelines regarding the best placements and outcome measures to use to help guide their use 
in clinical settings. To address the apparent shortcomings of the existing literature, the four 
studies presented in this dissertation sought to determine whether wearable sensors could be 
used to improve clinical assessments of postural stability in people with PD and to examine 
whether a 12-week trunk-specific exercise intervention was capable of improving measures of 
static and dynamic postural stability in this population. 
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Methods – To determine the extent to which wearable sensors might be suitable for assessing 
postural stability in people with PD, a systematic search of three scientific databases was 
performed to identify papers that had previously used these devices to assess standing and 
walking stability in this population. Of the 340 articles identified through the search, 26 were 
considered suitable for inclusion in the review and were subsequently appraised for 
methodological quality and synthesized. For Study 2, patients with idiopathic PD were invited 
to participate in a cross-sectional experiment aimed at examining the relationship between 
clinical tests and movement symmetry. Of the participants involved in Study 2, those who 
reported experiencing one or more falls or two or more near misses in the past year were also 
invited to participate in a randomized controlled trial seeking to investigate the effects of a 
trunk-specific exercise program on static (Study 3) and dynamic (Study 4) postural stability. 
At baseline, participants completed clinical tests of disease severity, mobility, balance, balance 
confidence and quality of life and laboratory assessments of walking stability and trunk muscle 
function. Following baseline, participants involved in Studies 3 and 4 were randomised to 
either a 12-week supervised trunk-specific exercise program or a 12-week falls prevention 
education program. Following the completion of the 12-week intervention, participants were 
reassessed using the same test battery completed at baseline and following a further 12-week 
retention period (i.e. 24 weeks following baseline). To determine whether the 12-week 
exercise-based intervention was successful at improving clinical and objective measures of 
static and dynamic postural stability, linear mixed model analyses were conducted with the 
level of significance set at p<0.05. For the assessments of static postural stability, daily 
levodopa equivalent dose and age were entered as covariates, while daily levodopa equivalent 
dose and walking speed were included as covariates in the models examining dynamic postural 
stability. 
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Results – The results of the systematic review (Study 1) indicated that accelerometers placed 
on the head and trunk were the most commonly used wearable sensor for assessing postural 
stability in people with PD. The most successful measure used was identified differences in 
postural stability was the harmonic ratio; a measurement of movement symmetry. For the 
cross-sectional study (Study 2), patients were stratified based on disease stage into either a 
Mild (Hoehn & Yahr Stage 1) or Moderate (Hoehn & Yahr Stages 2 to 3) PD group. The results 
highlighted that the Moderate PD group had poorer quality of life (p=0.001), reduced balance 
confidence (p<0.001) and increased gait and falls difficulty (p=0.040). Furthermore, for these 
patients, gait disability and the number of previous falls were both negatively correlated with 
multiple components of all head (ρ=-0.537 to -0.693, p≤0.05) and most trunk (ρ=-0.595 to -
0.766, p≤0.015) movement symmetry. For the Mild PD group, six-meter walk time was 
positively correlated with medial-lateral head symmetry (ρ=0.573, p=0.041) and linear 
regression highlighted a significant predictive relationship (p=0.036) between these outcomes. 
For Mild and Moderate PD, balance confidence predicted anterior-posterior trunk (p=0.012) 
and vertical head (p=0.047) movement symmetry, respectively. 
For those participants involved in the 12-week phase II randomised controlled trial 
(Studies 3 and 4), the results indicated that neither therapy (exercise or education) led to a 
significant change in clinical measures of symptom severity, mobility, balance, balance 
confidence, gait and falls difficulty, and quality of life. However, the statistical analyses 
revealed that, without vision on a foam surface, patients in the Exercise group had reduced 
sway area and sway variability at both the 12- (p=0.003-0.01; medial-lateral variability only) 
and 24-week (p=0.001-0.04; medial-lateral and anterior-posterior variability) time points 
compared with baseline. In contrast, the education group demonstrated increased postural sway 
area at 24-weeks (p=0.04) compared with baseline. 
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With respect to the measures of head and trunk symmetry, medial-lateral trunk 
symmetry (p=0.002) had declined in the Education group at 12 weeks relative to the baseline 
measures. These declines were complemented by clinical reductions in peak and baseline 
activation of the upper (peak: p=0.02; baseline: p<0.001) and lower (peak: p<0.001; baseline: 
p<0.001) erector spinae at 24-weeks. In contrast, the Exercise group demonstrated improved 
anterior-posterior head symmetry (p=0.04) at 24-weeks and improved anterior-posterior trunk 
symmetry at the 12- (p<0.001) and 24-week (p=0.01) time points compared with baseline. In 
regards to movement amplitude, pairwise comparisons revealed greater vertical head (p<0.001) 
and anterior-posterior (p<0.001), medial-lateral (p<0.001) and vertical (p=0.003) trunk 
movement amplitudes for the Education group at 12-weeks relative to baseline. While vertical 
head (p<0.001) movement amplitude had decreased by the 24-week assessment, anterior-
posterior (p=0.01), medial-lateral (p=0.01) and vertical (p<0.001) trunk movement amplitudes 
all remained elevated at 24-weeks relative to baseline. Similar changes were highlighted in 
movement amplitude for the Exercise group, with vertical head (p<0.001) movement amplitude 
increasing at 24-weeks relative to baseline and medial-lateral trunk movement amplitude 
increased at 24-weeks relative to the baseline (p<0.001) and 12-week (p<0.001) assessments. 
 
Conclusions - This thesis presents evidence to suggest that more objective measures 
can provide greater insight into small, yet meaningful changes in symptom severity for people 
with PD. Clinical variables of disease severity, mobility, balance, and balance confidence were 
not influenced by the exercise intervention, however, objective and continuous measures of 
movement symmetry, movement amplitude, postural sway, and muscle function did.  As an 
end result, this thesis has demonstrated that a low-intensity trunk specific exercise program can 
be useful for improving functioning in PD, and that accelerometers can be an alternative 
method for improving the assessment of postural stability in clinical settings. Furthermore, the 
ix 
presented findings provide evidence on specific ways to improve the treatment and assessment 
of postural instability in PD, which should assist with promoting an improved independence 
and overall quality of life of these individuals. 
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1.0 Introduction 
Parkinson’s disease (PD) is an age-related neurodegenerative condition resulting from 
the loss of the dopaminergic innervation within the basal ganglia that are involved in regulation 
of many functions, including movement. The depletion of dopamine results in an overall 
increase in the inhibition of movement, leading to slower and sometimes completely arrested 
performance [248]. Currently, the triggers for these degenerative changes remain unclear and 
although multiple risk factors have been identified, age and gender are the only risk factors 
supported by moderate evidence for the development of PD [120]. Males are approximately 
1.5 times more likely to develop PD than females [231], and the prevalence increases 
incrementally across the lifespan. As such, approximately 1 in 300 people aged between 55 
and 64 years are likely to develop the condition, compared with approximately 9 in 300 people 
aged 85 years and older [189]. With the loss of the dopaminergic cells and the development of 
PD, a number of deficits in motor control may emerge and these may include slowness of 
movement (bradykinesia), resting tremor, and muscle rigidity [154]. 
With progression of the disease, symptoms affecting postural stability and gait can also 
develop and may include a stooped or flexed trunk posture, slower walking speed and reduced 
arm swing while ambulating; all of which can increase the risk of falls. Traditionally, both 
clinical and biomechanical methods have been employed to assess standing and walking 
balance in people with PD. Accelerometers are amongst the most commonly used 
biomechanical devices for the collection of the continuous data used to identify differences in 
gait [232] and head stability [25] across a range of age groups and pathologies. Furthermore, 
recent research has tested the ability of different acceleration-based measures to predict the risk 
of falls in older individuals [58, 249], but the suitability of accelerometers to assess postural 
stability in people with PD is currently less clear. 
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While motor symptoms are more often examined in research, people with PD may also 
experience non-motor symptoms that significantly impair their health and quality of life. 
Common non-motor symptoms experienced by people with PD include: depression, anxiety, 
cognitive impairment, insomnia, loss of smell (anosmia), and altered digestive function [154]. 
The severity of symptoms may be dependent on the rate of disease progression and the fact that 
each patient can experience vastly different symptoms adds to the complexity of 
comprehensively and effectively managing this condition. 
While PD presents a number of significant challenges to the physiological and 
psychological health and wellbeing of individuals and their loved ones, it also poses a 
significant financial burden to these people and the public health system. In 2011, a report 
prepared for Parkinson’s Australia identified that the costs associated with PD totalled an 
estimated $8.3 billion per annum for the Australian population [189]. In other populations, the 
annual estimated costs of PD are reported to be $23 billion USD (≈$29.3 billion AUD) [107] 
and ₤600 million (≈$1.2 billion AUD) [68] for the United States of America and the United 
Kingdom, respectively. In each case, these estimates represented the direct costs associated 
with the condition and, hence include the costs incurred by individuals and those attributable 
to the medical treatment and health care provided by the governments. However, if one 
considers that 19% of those diagnosed with PD are of working age (15-64) [189], it is clear 
that the economic impact of the condition is further influenced by a number of significant 
indirect costs, including income lost due to reduced productivity within the workforce. Given 
that the number of Australians living with PD (64,000 in 2011) is expected to double by 2031 
[189], it is likely that the economic and social costs associated with the disease will also 
increase at a similar rate. 
Impairments of balance are among the most debilitating consequences of the ageing 
process for otherwise healthy individuals. Such age-related changes are known to contribute to 
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the increased number of falls experienced by people aged 65 years and older, with research 
consistently reporting that one in three older adults fall at least once each year [125, 134]. Forty 
percent of the falls experienced by individuals aged 65 years and over result in injuries 
requiring hospital treatment [125] and, hence, influence an individual’s mortality, morbidity 
and quality of life. Unfortunately, the incidence of falling is increased for high-risk populations, 
such as people with PD, with up to 68% of these individuals reported to fall at least once each 
year [43, 259]. While a number of disease-specific characteristics have been implicated as 
contributors to this increased risk, the motor symptoms experienced by patients are believed to 
be the most significant contributors to postural instability in this cohort. 
In bipedal stance and locomotion, it is the role of the postural control system to maintain 
the centre of gravity within the body’s base of support, such that balance and postural stability 
can be controlled and falls are prevented. However, even relatively healthy older adults 
demonstrate an age-related decline in postural stability during tasks that require dynamic 
postural control (such as walking, turning), which can put ageing individuals at an increased 
risk of falling [39]. From a mechanical perspective, the trunk is believed to play a significant 
role in dynamic postural control by attenuating movement-related forces and stabilising the 
head [116]. Head stability has a well-recognised role in the maintenance of equilibrium, as it 
houses the vestibular and visual systems, which contribute to the inertial guidance required for 
stable locomotion [199]. People with PD have impaired head and trunk control [43], which 
contributes to the postulation that decreased trunk control and balance are potentially related 
to the higher rate of falls in people with PD [43, 83, 86]. While it is currently unclear whether 
these deficits stem from insufficient or inappropriate muscle recruitment patterns or excessive 
segmental stiffness, these findings suggest that it is important to improve postural control for 
people with PD. 
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To date, extensive research has been focused on determining the efficacy of various 
interventions for improving balance and reducing falls risk in people with PD [2, 6, 63]. On 
the basis of such research, it has become widely recognised that exercise is an effective means 
of improving and/or maintaining cardiovascular health, physical endurance, and muscular 
strength; all of which enhance systemic functioning and independence. Exercise has also been 
shown to be effective in improving postural stability and reducing falls [10, 216], while also 
improving symptoms of anxiety and depression [73] in otherwise healthy older adults. In a 
population of people with PD, exercise was shown to be an effective means of improving motor 
symptoms on the Unified Parkinson’s Disease Rating Scale (UPDRS) motor score [139] and 
decreasing the overall falls risk score derived from knee extensor strength, the coordinated 
stability test and the Freezing of Gait questionnaire [2]. Furthermore, exercise may improve 
measures of postural sway performed during the Sensory Organisation Test in people with PD 
[99, 238]. However, currently few studies have investigated whether exercise can improve head 
and trunk control during dynamic activities, such as walking. Given that 45-48% of falls occur 
during walking and other forms of locomotion [7, 17], there is clear need for research to 
determine whether targeted exercise interventions can improve dynamic postural stability in 
people with PD. 
Given the apparent gaps in the existing literature, this program of research sought to 
establish the utility of wearable sensors for the assessment of stability under static and dynamic 
conditions in people with PD and determine whether the outcomes derived from these devices 
offer additional diagnostic information over common clinical assessments. Furthermore, this 
research aimed to determine whether a 12-week exercise-based intervention was effective at 
improving measures of static and/or dynamic postural stability in people with PD. It was 
hypothesised that the use of wearable sensors for the assessment of static and dynamic stability 
would offer additional insight into the balance and gait problems experienced by people with 
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PD. Furthermore, given that previous research has consistently highlighted the benefits of 
regular exercise for a range of populations, it was hypothesized that a trunk-specific exercise 
program would contribute to improvements in the stability of people with PD under both static 
and dynamic conditions. 
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2.0 Literature Review 
2.1 Parkinson’s disease and basal ganglia dysfunction 
Parkinson’s disease is a neurodegenerative hypokinetic disorder that results in complex 
collection of motor and non-motor symptoms and is characterised by movements that are 
reduced in speed and amplitude. The symptoms of the condition are caused by a reduction in 
the amount of dopamine produced within the basal ganglia. From a structural perspective, the 
basal ganglia are comprised of a collection of nuclei that include the caudate nucleus, putamen, 
globus pallidus (pallidum), subthalamic nucleus and substantia nigra [109]. However, a number 
of these structures are often sub-divided in practice due to differences in their cytoarchitecture 
and/or function. Specifically, the caudate nucleus and the putamen are collectively referred to 
as the striatum, as these structures act as a relay centre receiving dopaminergic signals from 
the substantia nigra, as well as sensory and motor signals from other regions of the central 
nervous system. It is postulated that this information is sent to the basal ganglia to assist with 
the scaling and modulation of movement. The substantia nigra are located within the midbrain 
and are considered to have both a compact (pars compacta) and reticular (pars reticulata) 
component, while the globus pallidus is considered to comprise both an internal (globus 
pallidus internus) and external (globus pallidus externus) part. The cell bodies of the dopamine-
producing neurons in the basal ganglia are located in the substantia nigra pars compacta and, 
from here, their axons project to the nuclei of the striatum [109].  
For the most part, structures forming the basal ganglia are comprised of neurons that 
are inhibitory in nature and, hence, activation of these structures serves to inhibit or prevent 
the action of the cells with which they synapse. The only exceptions to this rule are the neurons 
within the subthalamic nuclei, which are excitatory and, hence, facilitate the action of the cells 
with which they synapse. To date, two primary neural pathways with complementary functions 
have an accepted involvement in motor control. These pathways are intuitively referred to as 
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direct and indirect pathways. Action potentials passed through the basal ganglia via the direct 
pathway serve to disinhibit the motor thalamus and, hence promote movement, while neural 
commands passing along the indirect pathway inhibit the motor thalamus and reduce 
movement. As stated earlier, most neurons in the basal ganglia are inhibitory in nature, 
however, dopaminergic input from the substantia nigra pars compacta excites the striatum in 
the direct pathway while inhibiting the striatum in the indirect pathway.  
To completely appreciate how the motor thalamus is influenced differently by these two 
independent pathways, it is necessary to consider each in detail. In the direct pathway, 
dopaminergic input from the substantia nigra pars compacta and excitatory signals from the 
motor cortices activate the inhibitory striatal neurons that project to the globus pallidus internus. 
The excitation of the inhibitory striatal neurons results in the output of the globus pallidus 
internus and/or substantia nigra pars reticulata being heavily inhibited and leads to reduced 
inhibition of the motor thalamus and the promotion of movement (Figure 1A). In the indirect 
pathway, dopaminergic input from the substantia nigra pars compacta inhibits striatal neurons 
while the cerebral cortices excite striatal neurons that project to the globus pallidus externus. The 
combination of these two signals results, overall, in the inhibition of the nuclei in the globus 
pallidus externus. As the neurons that project from the globus pallidus externus to the 
subthalamic nucleus are inhibitory in nature, inhibition of these structures reduces their capacity 
to inhibit the excitatory neurons of the subthalamic nucleus. As such, activation of the excitatory 
neurons projecting from the subthalamic nucleus to the globus pallidus internus and/or substantia 
nigra pars reticulata is increased; ultimately increasing their capacity to inhibit the motor 
thalamus and movement (Figure 1B). Given this understanding, it is evident that the direct and 
indirect pathways work synergistically together to scale and control movement based on the input 
from the motor cortices that is dictated by the specific demands of a task. 
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Figure 1: Visual representation of the A) direct; and B) indirect pathways in a healthy adult. 
Black lines represent dopamine input, green lines represent glutaminergic input (excitatory) and red lines represent GABAergic input 
(inhibitory). The weight of the line represents the strength of the output from one structure to the next, such that a heavier red line represents 
greater inhibition of the target structure. 
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In the direct pathway, death of dopaminergic cells within the substantia nigra pars compacta 
results in reduced excitation of the striatum via the substantia nigra pars compacta results in an 
overall reduction in the inhibition of the globus pallidus internus. In turn, the inhibitory output of 
the globus pallidus internus is increased, which ultimately leads to greater inhibition of the motor 
thalamus and reduced movement (Figure 2A). In contrast, reduced dopamine in the indirect 
pathway reduces the inhibition of the striatum allowing it to further inhibit the globus pallidus 
externus. The increased inhibition of the globus pallidus externus further reduces its capacity to 
inhibit the excitatory nuclei of the subthalamic nucleus, allowing them to further activate the 
inhibitory nuclei of the globus pallidus internus and/or substantia nigra pars reticulata. As an end 
result, the globus pallidus internus and/or substantia nigra pars reticulata inhibit the motor thalamus 
to a greater extent and ultimately impair movement (Figure 2B) [109]. In summary, the loss of 
dopaminergic innervations within the substantia nigra pars compacta leads to reduced facilitation 
of movement via the direct pathway and increased inhibition of movement via the indirect pathway 
and, hence, helps us to understand the hypokinetic symptoms that characterise the condition. 
The concomitant activity of the direct and indirect pathways is believed to influence 
movement in much the same way that a brake pedal in a car can influence its motion. In a perfect 
scenario, the body’s movements are neither over nor under regulated, hence they are smooth and 
controlled. However, if activity along the indirect pathway is inadequate, the motor thalamus is 
insufficiently inhibited (i.e. the brake pedal is released) and movements become uncontrolled 
(hyperkinetic). In contrast, insufficient activity along the direct pathway and/or excessive activity 
along the indirect pathway will result in insufficient excitation of the motor thalamus (i.e. too much 
pressure on the brake pedal) and result in slow or completely arrested movements (hypokinetic). 
By modulating the activity between the direct and indirect pathways (regulated by dopamine), the 
basal ganglia can assist with scaling movements to meet the demands of the task. Dysfunction of 
the pathways within the basal ganglia can lead to impairment of normal neurological function 
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between the basal ganglia, thalamus, and numerous motor and perceptual areas of the cerebral 
cortex. Eventually, these impairments lead to the development of the complex collections of motor 
and non-motor symptoms that are not easily managed [192]. 
Despite the universal acceptance that the motor and non-motor symptoms of PD arise due 
to the degeneration of dopaminergic innervation within the basal ganglia [248], the specific 
‘trigger’ or pathophysiology that leads to these changes still remains largely unknown. 
Nevertheless, there is moderate to strong evidence of a number of risk factors that are believed to 
be associated, to some extent, with the development of PD. The factor with the strongest link to the 
development of PD is age and it is typically considered quite rare for individuals under the age of 
40 years to develop the condition [51]. Approximately 1 to 2% of people aged over 60 years have 
PD, but the incidence of developing the condition rises sharply during later life, with 3 to 4% in 
individuals aged over 80 years [46] and 4 to 5% over 85 years [248]. In addition to age, advances 
in genetic science have also provided evidence to suggest that first-degree relatives of people with 
PD (e.g. parents, siblings) face a 2.7 to 4.4 times greater risk of developing PD than those without 
familial links to the condition [233]. The increased risk associated with having a family link to PD 
is believed to be the result of specific genetic mutations. One such mutation that has been widely 
researched is the Leucine-Rich Repeat Kinase 2 gene mutation, which has been linked with the 
development of PD in some patient groups [79, 178]. Although these factors are supported by a 
growing body of research, the evidence supporting other reported risk factors including 
environmental exposures to pesticides, herbicides and heavy metals remains relatively weak [51]. 
Several studies have shown that people who smoke and/or regularly consume caffeinated products 
(e.g. coffee) have a reduced risk of developing PD, but the protective mechanisms are unclear [51]. 
Also, these habits may increase the individual’s risk of other health-related conditions and, in the 
absence of stronger scientific evidence [51], would not be promoted. 
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Figure 2: Visual representation of the A) direct; and B) indirect pathways in a person with PD. 
Black lines represent dopamine input, green lines represent glutaminergic input (excitatory) and red lines represent GABAergic input 
(inhibitory). The weight of the line represents the strength of the output from one structure to the next, such that a heavier red line represents 
increased inhibition of the target structure. 
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2.2 Symptoms of Parkinson’s disease 
While each individual with PD will likely experience a different collection of 
symptoms, the most common motor symptoms associated with the condition include resting 
tremor, reduced amplitude or speed of movement (bradykinesia), rigidity, and postural 
instability [248]. Bradykinesia is often considered one of the most disabling characteristics of 
the disease because approximately 80 to 90% of people with PD are affected by this symptom. 
In patients with greater symptom severity [143], bradykinesia can progress to an inability to 
initiate or continue movement (akinesia) and can present clinically as an inability to perform 
smooth and rapid alternating finger movements, speech problems, or difficulties with the 
initiation of gait and/or turning while walking [182]. The inability to initiate and/or continue 
walking is known as freezing of gait and is considered to be one of the main risk factors for 
falls in people with PD [37]. 
Like bradykinesia, resting tremor also occurs in 80 to 90% of PD cases and presents as 
rhythmic involuntary movements that typically affect the hands, legs, jaw or tongue and are 
only present when the patient is at rest. While resting tremor is usually the first and most visible 
symptom of the disease, it is rarely the cause of major disability for individuals [248]. This is 
likely due to the fact that patients often experience relief (or at least a significant diminution) 
from this symptom when the extremity affected is voluntarily moved [54] . 
Joint stiffness or muscle rigidity occurs in more than 90% of individuals with PD [248] 
and is characterised by involuntary and concomitant activation of limb flexors and extensors, 
which increase the joint’s resistance to passive movement. Such symptoms are most common 
in the extremities (e.g. wrists, ankles), but can also affect the axial skeleton (e.g. neck), 
particularly during the latter stages of the disease. Clinically, the joint stiffness observed in 
people with PD is often described as either an intermittent (cogwheel rigidity) or constant (lead-
pipe rigidity) resistance to passive movement [248]. 
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Changes in postural stability and gait often lead to significant disability for people with 
PD and while they are typically exacerbated in more advanced cases of the disease, they can 
also pose a significant burden to patients during the earlier stages of the condition. These 
symptoms have the potential to significantly impact a patient’s ability to safely navigate their 
home and community environments [248]; ultimately impacting their confidence, 
independence and overall quality of life. While the nature of these gait changes can vary 
considerably from patient to patient, previous research has identified a number of common 
differences in the walking patterns of people with PD. Specifically, Parkinson’s disease gait is 
often characterized by slower walking velocities [43, 131, 171, 222], shorter steps [30, 43, 131, 
171, 222], greater stride length variability [131], and less arm swing [154] than healthy aged-
matched controls. Other reported changes in walking patterns include decreased ankle joint 
range of motion [131, 172, 222], reduced joint power for the ankle at push off and decreased 
hip power generation and absorption [222]. Although many of the spatial characteristics of gait 
are known to be affected by PD (e.g. step length), multiple studies have shown that temporal 
characteristics, such as stride frequency (or cadence), are similar between individuals with PD 
and age-matched controls [30, 43, 222, 228]. 
More recently, it has been shown that the disease-related changes in walking patterns 
are more pronounced in people with PD who fall [8, 42, 43, 128], suggesting that declines in 
mobility may contribute to the increased risk of falling in this population. Specifically, 
individuals with PD who fall demonstrate increased variability in the time taken to complete 
each stride [42, 210] and exhibit reduced toe clearances compared with age-matched controls 
when walking on compliant surfaces [42]. The increased stride time variability and decreased 
toe clearance observed in PD fallers on compliant surfaces were not evident for PD non-fallers 
and, hence, could highlight an increased risk of falling for these individuals when transferring 
from different surfaces or encountering obstacles. This is supported by research showing that 
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two of the most common causes of falling in people with PD are tripping and walking on less 
predictable surfaces [7, 17]. In addition to these changes in gait characteristics, research also 
highlights changes in trunk function for people with PD [23], which may have impaired the 
capacity of these individuals to maintain postural stability. 
Unlike other symptoms, such as resting tremor, rigidity and bradykinesia, postural 
instability and gait difficulties typically do not respond well to common pharmacological 
therapies [19].  As such, even for optimally-medicated patients, the impaired motor function 
associated with these symptoms has the potential to significantly increase their risk of 
experiencing falls and fall-related injuries. 
 
2.3 The incidence and risk factors for falls 
The term ‘fall’ has been assigned multiple definitions within the literature, but 
researchers have typically considered a fall to be “an unintentional coming to the ground or 
some lower level not as a result of a major intrinsic event (e.g. stroke or syncope) or 
overwhelming hazard” [235]. While falls can be potentially harmful for any person, they pose 
a significantly greater problem for older adults who face an increased risk of injury due to age-
related changes in postural responses, muscular strength, and bone density [157, 220, 246]. 
According to prospective research, approximately one third of community-dwelling older 
adults aged over 65 years will fall at least once each year [125, 134], compared with 40% of 
adults aged 80 years over [125]. While these figures demonstrate the significant problem that 
falls can pose to an otherwise healthy population, it is important to consider that the risk of 
falling is often much higher for people with PD. Prospective research shows that between 65 
and 68% of people with PD fall a least once in a given a year, with 43 to 50% of these 
individuals experiencing recurrent falls [43, 259]. Furthermore, it was estimated that falls and 
fall-related injuries in people with PD cost the Australian Health Care System $27.5 million 
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AUD in 2010 [189], highlighting the significant economic burden that these incidents pose. 
Given that the incidence of PD is expected to almost double in Australia to 115,300 by 2031 
[189], a better understanding of the mechanism(s) that contribute to falls in these individuals 
will help in the treatment of the condition.  
According to previous prospective research that has sought to gain an improved 
understanding of the circumstances surrounding falls in community-dwelling older adults [7, 
17], falls most commonly occurred during ambulation (45 to 48%); often due to trips (29 to 
34%) or while carrying an object (6 to 9%). In contrast, examination of the circumstances 
surrounding the falls reported by people with PD indicate that while a similar proportion of 
falls are reported to occur during ambulation (45%), a further 32% and 21% are reported to 
occur while the patient is standing or transferring, respectively [7]. These statistics appear to 
highlight the importance of developing improved methods for managing symptoms of postural 
instability and gait disability, as the circumstance surrounding falls in people with PD are 
largely attributable to difficulties with postural control during static and dynamic activities. 
In addition to studies investigating the circumstances leading to falls, the efficacy of 
both clinical and experimental tests for identifying participants at an increased risk of falling 
has also been evaluated. Identifying factors to accurately predict patients with an increased risk 
of future falls is salient, as an improved understanding of these factors can lead to better 
treatment options for ‘at risk’ patients. A previous meta-analysis of six studies examining falls 
in people with PD demonstrated that a history of recurrent falls was the strongest independent 
predictor of future falls in people with PD; achieving a sensitivity and specificity of 68% and 
81%, respectively [196]. However, the use of previous falls as a predictor of future falls ignores 
the need to identify the underlying mechanism of the incident to limit the risk of future events. 
Interestingly, however, the addition of clinical measures of symptom severity (i.e. the UPDRS) 
and disease stage (i.e. the Hoehn and Yahr stage score (H&Y)) to the predictive model did not 
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improve the researchers’ capacity to predict future falls [196]. In contrast to these findings, two 
separate studies [41, 147] have provided evidence to suggest that reduced balance confidence 
is a significant independent predictor of future recurrent falls in people with PD.  
A common clinical test used by researchers to assess older adults [22, 29, 38] and 
people with PD [6, 20, 72, 119, 147] is the Timed Up and Go test. It consists of an individual 
being timed with a stopwatch while completing a single task of rising from a chair, walking 3 
meters, turning around, and returning to be seated. Longer performance times on the Timed Up 
and Go test have been associated with increased falls risk in individuals with PD [147]. In 
contrast to the Timed Up and Go test, the Berg Balance Scale includes multiple tasks that are 
individually scored on a Likert-based scale; allowing an overall composite score for balance to 
be derived. Lower scores (poorer performance) on the Berg Balance Scale are associated with 
an increased fall risk in older adults [38, 125]. However, despite the established relationships 
between falls risk and individual clinical scores, such as falls history, fear of falling, Timed Up 
and Go performance times and Berg Balance Scale total score, larger prospective research 
suggests that such clinical assessments have a poor capacity to predict future falls in people 
with PD [119]. Given the limited capacity for individual assessments to predict falls in PD 
populations, more recent research has sought to develop multivariate falls prediction models to 
improve the ability to identify patients who are at an increased risk of future falls. One such 
multivariate model included the UPDRS total score, the freezing of gait score, the occurrence 
of orthostatic hypotension, the total score for the Tinetti Balance and Gait test and the extent 
of anterior-posterior postural sway. The combination of these variables in a binary logistic 
regression model produced a multivariate model that was able to predict prospective falls in 
people with PD with a 78% sensitivity and 84% specificity [119]. Nevertheless, despite the 
promising outcomes of this multivariate model, it is worth noting that 42 of the 101 participants 
included in this cohort had a history of prior falls. Application of the multivariate model to the 
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59 patients who reported no history of prior falls yielded a similar sensitivity (77%), but a lower 
specificity (72%). A possible short-coming of the existing multivariate falls prediction models 
is that they have traditionally relied more heavily on patient self-report data and/or subjective 
clinical scales that are based on Likert scales. Given that a high percentage of the falls 
experienced by people with PD occur during dynamic activities and that the adequate control 
of the trunk and head segments is considered critical to postural stability, it may now be 
possible to improve these models by incorporating outcomes that better capture the dysfunction 
of the axial system in these patients.  
 
2.4 The role of the trunk in maintaining postural stability 
Given the trunk and head comprise 60% of the overall mass of the body [257], 
biomechanists have considered trunk control to be critical in maintaining postural stability, 
particularly during dynamic tasks. In a previous study examining segmental stability for 
different upper body regions in a healthy population, it was shown that trunk movements were 
smaller than those of the head and neck during walking [48]. However, separate research 
involving healthy individuals has demonstrated that trunk acceleration patterns are less regular 
than head accelerations during gait [116]. The authors argued that while the movements of the 
trunk may be smaller than the head and neck, the irregular trunk accelerations provide evidence 
that the segment acts as a low-pass filter to attenuate forces and ensure more regular and smooth 
movements of the head. 
As previously stated, head stability is believed to be salient for maintaining balance, as 
both the visual and vestibular systems are located in this region; systems fundamental for 
feedback during postural control. For example, an exaggerated forward tilt of the head during 
walking serves to lock the position of the head relative to the trunk, which improves head 
stabilisation [199]. However, if an individual was unable to adequately control the trunk 
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segment during dynamic tasks, then the exaggerated movements of the trunk would have a 
direct impact on head stability and overall balance. 
Multiple differences in trunk control have been observed in people with PD compared 
with other populations. For example, increased trunk stiffness (quantified as a reduced capacity 
to rotate the trunk) has been observed during sit-to-stand [179], gait [240] and turning [101] in 
people with PD compared with healthy age-matched controls. The mechanism for increased 
trunk stiffness in this population appears to be related to an underlying dysfunction of the trunk 
muscles, as research shows that patients have increased co-activation and background activity 
of the erector spinae and abdominal muscles during multidirectional translations [56]. 
Similarly, recent results have shown that people with PD who prospectively reported falling 
demonstrated significantly greater peak erector spinae activity during walking than age-
matched controls [40]. Furthermore, these patients had significantly greater levels of baseline 
activity (activity between muscle bursts) for the erector spinae compared with the controls. 
Interestingly, these differences in baseline activity were shown to be significant predictors of 
the medial-lateral pelvis, trunk and head displacement [40] that has been linked with future 
falls in previous research [42, 43]. The authors argued that the increased activation of the 
erector spinae may have been indicative of an underlying dysfunction of the deeper and more 
fatigue-resistant muscles involved in postural control (i.e. multifidus, transverse abdominus). 
If this were the case, the larger and more superficial muscles may have been required to 
compensate for this deficit and more actively contribute to trunk stability. However, given these 
superficial muscles of the trunk are considered prime movers, they are typically more easily 
fatigued than their deeper counterparts. As such, an increased reliance on these muscles may 
have potential implications for the overall stability of these individuals. Importantly, the PD 
patients who did not fall during the 12-month follow-up period exhibited erector spinae 
activations that were not dissimilar to the control groups, which the authors argued may imply 
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that such deficits in trunk muscle function may be unique to a sub-population of patients. 
Unfortunately, separate evidence suggests that these deficits in neuromuscular function and the 
associated increase in trunk stiffness (i.e. reduced mobility) are further compounded by 
disease-related declines in trunk muscle strength, which are reportedly evident even in patients 
who have very mild symptom severity [23].  By specifically targeting the improved function 
of the trunk extensors (erector spinae, multifidus), flexors (rectus abdominus) and rotators 
(obliques), it may be possible to improve the strength of these muscles and improve the overall 
mobility and stability of the trunk [24]. 
While there is currently a paucity of research that has specifically sought to explain 
how differences in trunk muscle activation may contribute to falls in people with PD, an 
understanding of the erector spinae’s role in trunk control during healthy gait may provide 
some insight into this relationship. In healthy individuals, the erector spinae muscles show a 
phasic increase in activation just after heel-contact to counter forward trunk flexion during 
walking [256]. This activation may stabilize the spine and attenuate the impact forces that travel 
vertically during walking. In general terms, the muscles turn on during heel contact and then 
become relatively inactive during the leg’s swing phase. If this pattern of activity becomes 
compromised, as described recently for people with PD who fall, trunk stiffness may 
potentially be increased (excessive activity) or decreased (reduced activity) and ultimately 
influence postural stability. For example, an increase in the activation of the erector spinae and 
abdominal muscles would serve to stiffen the trunk and potentially influence its capacity to 
attenuate the movement-related forces that project upwards from the feet. Without appropriate 
attenuation, these forces would likely impair the quality of the visual and/or vestibular 
information used in balance control and potentially increase the individual’s risk of falling. 
Given the established importance of the trunk for maintaining postural stability during dynamic 
tasks and the apparent deficits in trunk muscle activation reported for patients who fall, it would 
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seem reasonable to suggest that interventions that specifically target improving the mobility, 
strength and/or endurance of this region may be beneficial for patients who are unstable during 
walking.  
 
2.5 Exercise for improving postural stability 
The use of structured and progressive home-based exercise programs has demonstrated 
effectiveness for improving balance and reducing falls rates in older people prone to falls [10, 
216]. Furthermore, research shows that regular and structured exercise regimes contribute to a 
reduction in the severity of symptoms for individuals with PD [2, 112, 139] and lead to 
improvements in strength [47, 85] balance [47], and postural stability [55] for these individuals. 
Despite these benefits, the quality of evidence regarding the efficacy of exercise in reducing 
the rate of falls in people with PD requires strengthening [85]. Previously, it was demonstrated 
that an 8-week exercise program completed twice per week either at home or under the 
guidance of a physiotherapist produced significant improvements in the severity of motor 
symptoms for a group of 19 PD patients (based on Part III of the UPDRS) [139]. However, 
these interventions did not improve scores for a number of clinical measures of balance and 
mobility, including the Berg Balance Scale, Activities-specific Balance Confidence (ABC) 
scale, or the Timed Up and Go test. It was concluded that since improvements were only seen 
in the UPDRS motor subscale, there was a need for more sensitive and objective assessments 
to evaluate improvements in mobility and postural stability for individuals with mild to 
moderate PD. In a more recent study, researchers sought to reduce the rate of falls in a groups 
of 142 recurrent PD fallers by implementing a similar six-week home-based physiotherapy 
program aimed at improving lower-leg strength, joint range of motion (ankle, pelvic tilt, trunk 
and head), balance (static, dynamic and functional) and walking (inside and outside) [6]. The 
results of this study demonstrated that the six-week period of physiotherapy did not lead to any 
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significant improvements in the patients’ performances on clinical tests including, the 
Functional Reach test, the Berg Balance Scale, the Self-Assessment Parkinson’s Disease 
Disability Scale or the Quality of Life Thermometer test. Furthermore, in spite of their 
relatively large sample size, the authors were only able to report a trend towards a reduction in 
falls rates following the intervention; a finding that the authors attributed to insufficient 
statistical power [6]. Additional studies have implemented similar physiotherapy-based 
programs that were administered three times per week over a ten-week [84] or six-month period 
[2] aimed at improving lower leg strength and balance in people with PD. Based on the 
collection of prospective falls diaries, the results of these studies showed no significant changes 
in falls rates [84] and no significant improvement in falls risk score [2], Berg Balance Scale or 
the Timed Up and Go test [2, 84]. A possible limitation of these studies was that they have 
primarily used clinical tests of mobility and physiological function to evaluate postural 
stability, rather than using more quantitative tools that are known to be sensitive to small, yet 
meaningful changes in postural control. For example, an improvement in Timed Up and Go 
test time following an exercise intervention would mean that an individual has improved their 
mobility, but it would not necessarily mean that this individual was more stable while 
performing the task. As such, it may be important to incorporate independent outcome 
measures of mobility and stability when evaluating the efficacy of an exercise-based 
intervention to ensure that improvements in mobility do not inadvertently exacerbate a patient’s 
risk of falling. A second potential short coming of these studies is that they have primarily 
focussed exclusively on improving balance and the strength of the lower limb muscles in 
people with PD. However, given the significant role that the trunk segment plays in maintaining 
head stability and postural control during dynamic tasks [116], it seems reasonable to suggest 
that a more specific exercise program that focuses on improving trunk strength, endurance 
and/or mobility could help to improve postural stability. 
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Given its considerable size and mass, the trunk relies upon the precisely timed and 
scaled contraction of many muscles to maintain its stability and facilitate movement. While 
each of these muscles perform important functional roles, research suggests that the erector 
spinae and multifidus, which extend bilaterally and vertically along the length of the spine, are 
two of the most important for stabilising the trunk during human locomotion. As a superficial 
posterior trunk muscle, the erector spinae is considered to be a prime mover and is primarily 
responsible for extending, rotating and laterally flexing the spine.  In contrast, the multifidus 
muscles are situated deeper to the erector spinae and due to their reduced capacity to generate 
large forces (due to reduced moment arms) are considered to be major contributors to 
stabilizing the lumbar and thoracic spine [74]. During normal walking, the erector spinae [256] 
and multifidus muscles demonstrate a phasic pattern of activation that presents as prominent 
bursts that each coincide with heel strike. These precisely timed activations are reportedly 
responsible for resisting the forward flexion moment of the trunk that occurs during the braking 
phase of the gait cycle [5, 57] and ultimately serves to maintain the relatively vertical position 
of the spine. Given the involvement in maintaining trunk alignment during walking, it is 
perhaps not surprising that deterioration of these muscles has been shown to contribute to 
lumbar instability in people with lower back pain [74].  Given that those with PD have been 
shown to have reduced trunk muscle strength [23] and abnormal trunk muscle activations 
during gait [40] compared with controls, it seems reasonable to suggest that specific training 
of these muscles may be beneficial for regaining the function of these muscles and restoring 
dynamic stability. 
However, there is currently a paucity of research examining the effects of targeted 
exercises aimed at improving the strength and endurance of the trunk on functional improvements 
in individuals with PD. Given the deficits in trunk muscle strength and the increased trunk 
stiffness that is often evident in this patient group, exercises that target improvements in trunk 
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muscle strength and mobility could be vital to improving measures of balance. Support for this 
notion was provided in an earlier study that reported improvements in peak trunk torque and 
isometric trunk strength in people with PD following a 12-week exercise program completed 
twice per week [24]. However, as this study only reported changes in trunk muscle function under 
static conditions (i.e. isometrically), it remains unclear whether these improvements would 
translate to better stability for people with PD under static and/or dynamic conditions. 
Nonetheless, exercises aimed at improving core muscle function have been shown to improve 
postural stability in otherwise healthy older adults. For example, in older adults identified as 
being at a higher risk of falling, a year-long once-a-week group exercise program utilizing 
exercises designed to improve balance, coordination, aerobic capacity and muscle strength was 
associated with a reduced rate of falls during a prospective one-year follow-up when compared 
with an education group [10]. In addition to reducing falls rates, the exercise group also 
demonstrated improvements in three measures of balance 1) postural sway on a firm surface with 
eyes open; 2) postural sway on a firm surface with eyes closed; and 3) the coordinated stability 
test [10]. More recently, a six-week exercise program specifically targeting the muscles of the 
lower abdomen and posterior trunk significantly improved performances on the Berg Balance 
Scale in a group of elderly women [96]. Furthermore, aquatic balance training and core stability 
training were effective at significantly improving single leg balance in a group of 30 males when 
compared with age-matched controls [209]. However, the test of dynamic stability involved the 
participants balancing on their dominant leg while extending their non-dominant leg as far as 
possible in three different directions (Y-balance test). While this test may be a good measurement 
of maintaining single leg balance while manoeuvring the other leg, it would be interesting to see 
how such training translates to tasks like walking, where the body experiences forces that are 
sufficient to destabilise the trunk. 
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Studies that have sought to improve trunk mobility with the implementation of a trunk-
specific intervention are also limited, but Bartolo and Serrao [11] used a multi-faceted program 
incorporating stretching, gait training, muscle conditioning, and balance to improve trunk 
mobility in a group of PD patients with and without lateral trunk flexion. Their results 
suggested that the exercise program was effective at improving lateral trunk flexion range of 
motion for those patients presenting with lateral trunk flexion. A separate study contrasting the 
efficacy of usual physical therapy with kayaking-type exercises for improving trunk mobility 
reported that both interventions were effective for improving trunk rotation in people with PD 
[217]. Unfortunately, despite these promising findings [11, 217], neither study provided a 
comprehensive description of the exercises performed by the participants, which substantially 
limits the reproducibility of these interventions. 
In summary, there is a growing body of evidence indicating that structured exercise 
programs have the potential to improve muscle strength and symptom severity in people with 
PD. However, the existing literature has presented mixed findings concerning the efficacy of 
such therapies for improving postural stability, mobility and falls risk in this population. A 
possible reason for the inconsistent findings within the literature may be related to the fact that 
many of these studies have used clinical tests to evaluate these attributes and, given their 
design, may be incapable of detecting small, yet meaningful changes in function. With the 
improved portability of laboratory-grade equipment, it may now be possible to implement more 
objective measures of static and dynamic postural stability into these studies. The successful 
integration of sensitive instruments into such research would make it possible to determine how 
useful trunk-specific exercises can be for improving symptoms of postural instability and gait 
disability in people with PD. 
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2.6 Objective Assessments of Postural Stability 
Over the decades, multiple methods have been developed and implemented for the 
assessment of postural stability in both clinical and laboratory settings. Tests that have traditionally 
been used in clinical settings are designed to be time-efficient, cost-effective and to have relatively 
little need for specialised equipment. Some common tests that have been used to assess balance in 
people with PD include the Berg Balance Scale [3, 62, 65, 76, 96, 238], the Tinetti Balance and 
Gait assessment [76, 115, 203] and the Timed Up and Go test [119]. The Berg Balance Scale and 
Tinetti Balance and Gait assessment are both comprise numerous items that are each subjectively 
rated by the clinician or another trained assessor on a Likert scale. In contrast, the Timed Up and 
Go test is a clinical test of mobility that involves the assessor recording the time taken for the patient 
to stand from a seated position, walk 3-meters, turn 180° and return to the seat to sit down. While 
such assessments are convenient to use to assess balance and mobility in the clinical setting, they 
are generally limited by floor and ceiling effects and, hence, may not be sensitive to subtle changes 
in a patient’s performance. Given this limitation, it is possible that quantitative biomechanical 
methods, which provide more continuous datasets, may be more useful for monitoring gradual 
changes in symptoms and allowing “at-risk” patients to be more easily identified. 
Of the many different methods used to objectively examine balance and mobility in people 
with PD, the most common techniques include videography/motion analysis, posturography and 
wearable sensors. While they are often not suited to smaller clinical environments, two-
dimensional videography and three-dimensional motion analysis have been shown to provide valid 
assessments of balance during clinical tests (e.g. push and release, single leg stance, sit to stand) 
for healthy adults and people with and PD [191]. Nevertheless, such systems require regular 
calibration, participant preparation and additional time and expertise to accommodate setup and 
analysis of the data. In addition to being time-consuming, these systems can also be quite expensive 
making them impractical for small clinical practices operating on a limited budget.  
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A more cost-effective and portable technique that is commonly used to objectively evaluate 
standing balance is posturography, which uses centre of pressure data derived from a force platform 
to provide insight into the weight-shift patterns of the patient. Traditionally, force platforms were 
heavy and bulky pieces of equipment that were required to be secured to sturdy mounting brackets 
embedded within the floor of a laboratory. However, with the miniaturization of technology, these 
devices are now more portable and, hence, much easier to integrate into real-world settings. The 
Neurocom SMART Balance Master incorporates built in moveable force plates to provide an 
analysis of balance through increased difficulty based on the manipulation of the three sensory 
systems: vision, vestibular function, and somatosensation. The sensory organization test is a 
common test conducted using this specialized equipment to assess postural stability in people with 
PD [113, 126, 127, 176, 262]. Importantly, measures of postural sway have been shown to be 
sensitive to differences in postural sway between elderly adult fallers and non-fallers [125, 159, 
245] and have also been shown to predict future falls in people with PD [119]. Nevertheless, despite 
their many benefits, force platforms are limited to the assessment of postural stability during quiet 
stance and, hence are not particularly suited to the evaluating walking stability. 
Due to the shortcomings of posturography, wearable sensors (e.g. accelerometers, inertial 
sensors, gyroscopes) have become increasingly more popular in recent years, as they are relatively 
inexpensive, easy to use, and require minimal setup time. One such wearable sensor is an 
accelerometer, which intuitively assesses acceleration in one (uni-axial), two (bi-axial) or three (tri-
axial) dimensions. Descriptions of the method used within accelerometers to assess movement 
often refer to a mass-spring system [118]. In this model, movement compresses or stretches the 
spring in the mass-spring system, causing the spring to generate a force proportional to the amount 
that it is compressed or stretched [118]. Given the stiffness of the spring and the mass are both 
known quantities, the resultant acceleration can be determined from the amount by which the spring 
is displaced in response to the movement [118]. While numerous accelerometer types exist, one of 
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the most common forms is the microelectromechanical system capacitive accelerometer. 
Microelectromechanical system accelerometers are comprised of pairs of capacitors surrounding a 
silicon mass and as the mass is displaced by the patient’s movement and/or gravity, an electrical 
signal that is proportional to the magnitude of the displacement is generated from an imbalance 
between the opposing capacitors [118]. In PD, accelerometers have been shown to be a valid and 
reliable method for measuring postural sway during static tasks [152] and can also measure postural 
stability during dynamic tasks such as walking either in the laboratory [129, 138] or in real-world 
settings [251, 253]. If appropriately implemented, accelerometers have the potential to significantly 
improve the ways in which clinicians assess neurological populations both in the clinic and their 
real-world environments.  
 
2.7 Summary 
With an ageing demographic, age-related neurodegenerative conditions such as PD are 
likely to become increasingly prevalent in our society. While medical science has led to the 
development of many useful clinical assessments of physiological and psychological function, 
there is an apparent need to develop improved methods of objectively assessing postural stability 
in people with PD. Wearable sensors, such as accelerometers, are gaining improved popularity in 
the field, but there is currently no consensus regarding the best ways to implement these devices 
for the assessment of this population. Research is needed to address this, as improved assessments 
of movement have the potential to assist health care professionals with the treatment and 
management of PD symptoms. Furthermore, alternative therapy options are required to help 
manage symptoms of postural instability and gait disability in people with PD, as these symptoms 
are largely unresponsive to levodopa therapy and commonly lead to falls [19]. 
28 
3.0 Statement of the Problem 
Falls are a significant problem for community-dwelling older people, but pose an even 
greater threat to high-risk populations such as PD. Deficits in postural stability are a key factor 
in many of these falls, and could result from an impaired capacity to coordinate and/or control 
larger segments of the body, such as the trunk. Given that the trunk and head comprise 60% of 
the overall mass of the body [257], it seems reasonable to suggest that there is a need for the 
trunk to be well-controlled in order to maintain postural stability. However, the 
neurodegenerative changes associated with PD contribute to a number of significant alterations 
in trunk posture and function, including deficits in trunk muscle strength [23] and increased 
trunk muscle co-activation [56]. These changes ultimately contribute to an increase in trunk 
rigidity [101, 179, 240] and greater lateral [11] and/or forward [11, 43] flexion of the trunk, 
which presents in the stooped posture associated with this condition. Considering that these 
deficits influence postural stability, an important goal of managing patients with PD should be 
to improve the symptoms that affect the axial skeleton to minimise their effect on a patient’s 
overall postural stability. However, existing research indicates that current pharmacological 
and surgical therapies for the symptoms of PD are largely ineffective with respect to the 
management of motor symptoms affecting the axial system. This evidence highlights the clear 
need to identify and evaluate alternate therapies that may be effective for the management of 
these symptoms. Given that targeted strength and endurance exercises [24] and mobility 
training [11, 217] have been shown to be effective for improving the mobility and dynamic 
function of the trunk in people with PD, it seems reasonable to assess whether such 
interventions are also effective for improving objective measures of postural stability in this 
population. To date, a small number of studies have evaluated the efficacy of exercise-based 
interventions for improving clinical measures of balance and mobility in people with PD [6, 
84]. Furthermore, these studies have sought to determine whether regular exercise was 
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beneficial, with respect to reducing the rate and number of falls in this population. Despite 
these efforts, the evidence concerning the benefits of exercise for the management of these 
complex symptoms has been mixed, suggesting that further research is required to determine 
the potential benefits of this therapy. Given the established link between deficits in postural 
stability and falls in people with PD, many of these studies also evaluated the efficacy of their 
intervention using established clinical assessments of balance and mobility. However, these 
assessments generally rely upon patient self-report or Likert scales, which potentially limit 
their sensitivity to detecting small, yet meaningful changes in patient function. This limitation 
may assist with explaining why some interventions have reported no significant improvement 
in clinical measures of balance following an exercise intervention [6, 14, 61, 63, 88, 115], while 
others have reported significant improvements in these outcomes [14, 35, 76, 88, 115, 161, 
166, 229, 238, 258, 264]. 
On the basis of these collective outcomes, one might argue that although traditional 
tests are easily administered in clinical settings where time may be limited, these assessments 
may lack the sensitivity to describe subtle changes in patient function. With the use of more 
sensitive measures of postural stability it is postulated that clinically-important improvements 
in postural stability may have been observed in these patient cohorts. However, more objective 
methods for assessing mobility and postural stability (e.g. three-dimensional motion analysis) 
have traditionally been too expensive and impractical to integrate into most clinical settings. 
With the introduction of light-weight and inexpensive wearable sensors (e.g. accelerometers), 
it may now be possible to provide a more cost-effective and clinically-feasible alternative to 
improve the sensitivity of clinical assessments of balance and mobility. For example, research 
shows that an accelerometer positioned on the head and/or trunk can provide continuous and 
objective data that allows changes in standing and walking stability to be easily assessed for 
patient populations [25, 232]. Nevertheless, despite the potential that this technology offers, 
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there is currently a lack of consensus within the existing literature regarding the most 
appropriate site(s) for affixing such devices to people with PD (e.g. head, trunk and/or pelvis) 
and the most appropriate outcomes for assessing meaningful changes in static and dynamic 
postural stability in this population. With an improved understanding of the suitability of 
wearable sensors for assessing standing and walking stability, the specific deficits that increase 
a patient’s risk of falling can be identified and targeted interventions can be developed to 
improve trunk muscle function and overall postural stability. 
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4.0 Research Aims and Hypotheses 
The program of research outlined in this thesis ultimately sought to address four aims that 
would bridge a number of gaps in our understanding of the suitability of exercise-based 
interventions for improving postural stability in people with PD and the possible benefits of 
wearable sensors for assessing postural stability in this patient cohort. Four inter-related studies 
were developed (Figure 3) to specifically address the following aims: 
 
Aim 1: To systematically review the existing literature to determine the suitability of wearable 
sensors for assessing static and dynamic postural stability in people with Parkinson’s disease. 
To address this aim, Study 1 systematically reviewed the available literature that 
reported using wearable sensors to assess static or dynamic postural stability in people with 
PD. Specifically, this review had three primary goals, which included determining: 
i. The type(s) of wearable sensor most commonly used to assess postural stability in 
people with PD.  
ii. The anatomical landmark(s) most commonly reported for the placement of wearable 
sensors during the assessment of postural stability in people with PD. 
iii. The specific measures of postural stability most commonly shown to highlight postural 
stability deficits in people with PD. 
The results of this systematic review were used to inform the methods used in three subsequent 
experimental studies presented in this thesis. 
 
Aim 2: To determine whether common clinical assessments of balance and mobility were 
capable of providing insight into a patient’s postural stability during walking  
As outlined previously, many clinical tests have been developed to assess various 
aspects of balance and mobility. Due to their widespread use in hospital settings, these tools 
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have traditionally been used to assess the efficacy of exercise-based interventions. However, 
the tendency for these instruments to rely upon Likert scales and/or qualitative assessments of 
function is likely to have implications for their sensitivity to detect subtle changes in balance 
and/or mobility. To determine to what extent clinical tests of balance, balance confidence, gait 
difficulty and/or mobility were capable of providing insight into postural stability while 
walking, Study 2 used a cross-sectional design to correlate the outcomes of these clinical tests 
with the measure(s) found to be most commonly used to assess dynamic postural stability in 
Study 1 (i.e. the systematic review). It was hypothesised that clinical measures of mobility, gait 
difficulty, postural stability and balance confidence would not be related to objective measures 
of dynamic postural stability and, therefore, would offer limited insight into a patient’s balance 
during dynamic tasks, such as walking. 
 
Aim 3: To determine whether a 12-week trunk-specific exercise program was more effective 
than education at improving postural sway and clinical measures of symptom severity, balance, 
balance confidence and gait difficulty in people with PD. 
To address this aim, Study 3 was designed to be a blind phase II randomised controlled 
trial in which patients were allocated to either a 12-week exercise program aimed at improving 
trunk mobility and endurance or a 12-week education program aimed at reducing falls risk. 
Patients were assessed at three time points; i) prior to the intervention (baseline); ii) 
immediately following the intervention (12-weeks); and iii) 12-weeks following the 
completion of the intervention (24-weeks). It was hypothesized that the exercise group would 
demonstrate reduced postural sway and improved symptom severity, balance confidence and 
gait difficulty immediately following the 12-week intervention and that these improvements 
would be maintained up to 12-weeks following the completion of the program. 
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Aim 4: To determine whether a 12-week exercise program that focused on improving the trunk 
mobility and endurance was more effective than a fall-prevention education program for 
improving accelerometer-based measures of gait symmetry in people with PD. 
The aim of Study 4 was addressed using the same blind phase II randomised controlled 
trial approach adopted for Study 3. Head and trunk accelerations were assessed during 
unconstrained walking at Baseline, 12-weeks and 24-weeks using tri-axial accelerometers, 
while the activation patterns of the thoracic and lumbar erector spinae were evaluated using 
surface electromyography. It was hypothesised that the patients receiving the 12-week exercise 
program would demonstrate greater improvements in accelerometer-based measures of gait 
symmetry than patients in the education group and that these improvements would be retained 
up to 12-weeks after the completion of the program. Furthermore, it was hypothesised that 
involvement in the exercise program would influence the activation patterns of the thoracic and 
lumbar erector spinae.  
 
 
 
 
 
 
 
 
 
Figure 3: Summary of the four inter-related studies comprising this program of research 
 
34 
5.0 Study 1: Wearable sensor use for assessing standing balance and walking stability in 
people with Parkinson’s disease: A systematic review 
With the introduction of more affordable and sensitive measuring devices, such as 
wearable sensors, it is now becoming feasible for clinicians to conduct more objective 
assessments of postural stability within the clinical environment. However, to date, there has 
been little consensus amongst researchers regarding the most effective methods to adopt and 
the most sensitive outcomes to consider to improve the chances of correctly identifying ‘at risk’ 
patients. As such, the following chapter presents a systematic review of the literature 
concerning the use of wearable sensors for the assessment of postural stability under both static 
(standing balance) and dynamic (walking) conditions for people with PD. 
 
NOTE: The following chapter presents the findings of the following peer-reviewed 
manuscript, which has been reformatted for the purposes of this dissertation:  
 
Hubble, R. P., Naughton, G. A., Silburn, P. A., & Cole, M. H. (2015). Wearable sensor use 
for assessing standing balance and walking stability in people with Parkinson’s disease: 
A systematic review. PLoS One, 10(4), e0123705 
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5.1 Abstract 
Background: Postural instability and gait disability threaten the independence and well-being 
of people with Parkinson’s disease and increase the risk of falls and fall-related injuries. 
Prospective research has shown that commonly-used clinical assessments of balance and 
walking lack the sensitivity to accurately and consistently identify those people with 
Parkinson’s disease (PD) who are at a higher risk of falling. Wearable sensors provide a 
portable and affordable alternative for researchers and clinicians who are seeking to objectively 
assess movements and falls risk in the clinical setting. However, there is currently no consensus 
regarding the optimal placements for sensors and the best outcome measures to use for 
assessing standing balance and walking stability in PD patients. Hence, this systematic review 
aimed to examine the available literature to establish the best sensor types, locations and 
outcomes to assess standing balance and walking stability in this population. 
 
Methods: Papers listed in three electronic databases were searched by title and abstract to 
identify articles measuring standing balance or walking stability with any kind of wearable 
sensor among adults diagnosed with PD. To be eligible for inclusion, papers were required to 
be full-text articles published in English between January 1994 and December 2014 that 
assessed measures of standing balance or walking stability with wearable sensors in people 
with PD. Articles were excluded if they; i) did not use any form of wearable sensor to measure 
variables associated with standing balance or walking stability; ii) did not include a control 
group or control condition; iii) were an abstract and/or included in the proceedings of a 
conference; or iv) were a review article or case study. The targeted search of the three electronic 
databases identified 340 articles that were potentially eligible for inclusion, but following title, 
abstract and full-text review only 26 articles were deemed to meet the inclusion criteria. 
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Included articles were assessed for methodological quality and relevant data from the papers 
were extracted and synthesized. 
 
Results: Quality assessment of these included articles indicated that 31% were of low 
methodological quality, while 58% were of moderate methodological quality and 11% were of 
high methodological quality. All studies adopted a cross-sectional design and used a variety of 
sensor types and outcome measures to assess standing balance or walking stability in people 
with PD. Despite the typically low to moderate methodological quality, 81% of the studies 
reported differences in sensor-based measures of standing balance or walking stability between 
different groups of PD patients and/or healthy controls. 
 
Conclusion: These data support the use of wearable sensors for detecting differences in 
standing balance and walking stability between people with PD and controls. Further high-
quality research is needed to better understand the utility of wearable sensors for the early 
identification of PD symptoms and for assessing falls risk in this population. 
 
PROSPERO Registration: CRD42014010838 
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5.2 Introduction 
Parkinson’s disease (PD) is an age-related neurodegenerative disorder that results from 
the loss of neurons within the basal ganglia that produce dopamine, an important 
neurotransmitter involved in the regulation of movement. As medical advances have extended 
the life expectancy of the average person, clinical and experimental methods need to progress 
as well in order to improve the management of the symptoms associated with the disease. It is 
well understood that deficits in balance and gait are common and disabling features of PD that 
significantly increase an individual’s risk of falling [218], hence many clinical assessments 
have been developed to evaluate these symptoms in this population. The most common 
assessments include the Berg Balance Scale [119, 127], the Tinetti Gait and Balance 
assessment [119], the Timed up and Go test [119, 147] and the postural instability and gait 
disability score derived from the Unified Parkinson’s Disease Rating Scale (UPDRS) [119, 
139]. These assessments are suited to clinical settings because they require little equipment to 
conduct and provide almost immediate outcomes that can be reported to the patient. However, 
prospective research shows these tests have poor sensitivity and specificity for identifying 
prospective fallers in the PD population [119] and may not be sufficiently sensitive to detect 
changes in balance and walking in individuals with mild to moderate disease severity [2, 6, 84, 
134]. 
Given the inherent short-comings of the aforementioned clinical tests, previous 
research has sought to improve the objectivity of these measures to enhance their ability to 
track symptom progression and evaluate patient risk. Camera-based three-dimensional motion 
analysis systems have been commonly used in laboratory settings to examine the walking 
patterns of people with PD [42, 43, 255]. However, the methods associated with these 
assessments are often time-consuming and require specific expertise and expensive motion 
capture systems that are not suited to smaller clinical spaces. Wearable sensors, such as 
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accelerometers or inertial measurement units, offer a more portable, flexible and moderately-
priced alternative to camera-based motion analysis systems. Moreover, they do not require 
excessive space for normal operation and outcome measures can be output almost immediately 
without the need for significant post-processing procedures. Given these strengths, research 
has recently sought to improve the sensitivity of clinical assessments, such as the Timed Up 
and Go test, by incorporating accelerometers or inertial measurement units to provide 
continuous measures of walking [95, 152, 187, 207, 252]. The results of this research 
demonstrated that by instrumenting the Timed Up and Go test with a wearable sensor, it was 
possible to detect differences in the performances of people with PD compared with controls 
[95, 152, 187, 207, 252]. 
Wearable sensors have recently been shown to have good test-retest reliability for 
assessing individuals with PD, particularly for acceleration-based measures calculated in the 
time domain (e.g. Jerk; the first time derivative of acceleration) [152]. Furthermore, there is a 
growing body of literature supporting the use of wearable sensors to assess standing balance 
or walking for; i) people with PD and controls [12, 67, 138, 150-152, 187, 208, 213, 214, 240, 
253, 261, 263]; ii) PD fallers and non-fallers [129, 251]; iii) people with different PD sub-types 
[75, 95, 205, 215, 250]; iv) carriers and non-carriers of the Leucine-Rich Repeat Kinase 2 gene 
[163]; and v) people at high risk of developing PD (HRPD) [93, 144]. Results from these 
studies demonstrated that outcomes derived from wearable sensors were capable of detecting 
differences in standing balance between HRPD patients, people with PD and controls [144] 
and could discriminate HRPD patients from controls when combined with the functional reach 
test in a logistic regression model [93]. In addition to these findings, three-dimensional 
accelerometers positioned on the head, trunk or pelvis, have highlighted less rhythmic walking 
patterns for people with PD who retrospectively reported falling compared with patients who 
did not fall [129, 251]. Collectively, these results suggest that wearable sensors may not only 
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be useful for evaluating changes in a patient’s balance or gait patterns, but may also offer a 
means of screening individuals for various risk factors associated with PD or falls. 
Nevertheless, it is clear that scientifically-rigorous prospective research is needed before clear 
recommendations can be provided regarding the use of these devices as predictive instruments 
for clinical populations. 
Despite the expanding body of evidence to support the use of wearable sensors for 
assessing function in people with PD, it is important to recognise that this area of science is 
still developing. Furthermore, the adoption of such varying methodological approaches in the 
existing literature makes it difficult to determine which sensor types are the best to use and 
which placements and outcome measures are optimal to maximise the utility of these devices. 
As such, it was the purpose of this systematic review to examine the available literature that 
utilised wearable sensors to measure standing and walking balance in people with PD and 
provide a summary of the best sensor types, locations and outcomes based on a consensus of 
the literature. 
 
5.3 Methods 
This review was registered with the International Prospective Register of Systematic 
Reviews on September 3, 2014 (PROSPERO Registration: CRD42014010838). The search 
strategy and research protocol are included in Appendix A and outline the specific search terms 
and the systematic procedures adhered to for this study.  
 
5.3.1 Search Strategy 
An electronic database search of titles and abstracts was performed in January 2015 
using PubMed, EMBASE and the Cochrane Library to identify articles measuring standing 
balance and walking stability with any kind of wearable sensor among adults diagnosed with 
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PD. The following terms were used for the literature search: ‘Parkinson’, ‘Parkinson’s’, ‘walk’, 
‘gait’, ‘balance’, ‘stability’, ‘sensor’, ‘gyroscope’, ‘inertial’, ‘acceleration’ and 
‘accelerometer’. Specifically, papers that were included in this review were required to have 
the term ‘Parkinson or Parkinson’s’ AND (‘walk’ OR ‘gait’ OR ‘balance’ OR ‘stability’) AND 
(‘sensor’ OR ‘gyroscope’ OR ‘inertial’ OR ‘accelerometer’ OR ‘acceleration’) located within 
the title and/or abstract. In addition to the systematic electronic database search, a targeted 
search of the bibliographies of relevant articles was also performed to identify any additional 
studies for inclusion.  
 
5.3.2 Selection Criteria 
Only original, full-text articles published in English between January 1994 and 
December 2014 that assessed standing balance or walking stability with wearable sensors in 
people with PD were included in this review. Articles were excluded if they; i) did not use any 
form of wearable sensor to measure variables associated with standing balance or walking 
stability; ii) did not include a control group or control condition; iii) were an abstract and/or 
included in the proceedings of a conference; or iv) were a review article or case study. All 
studies that met the inclusion criteria were considered for review, irrespective of their research 
design (cross-sectional, randomised controlled trial, etc). After the initial literature search was 
completed, two assessors (RPH, MHC) independently screened each of the papers based on 
their title and abstract and made a decision on the suitability of the paper for inclusion in the 
review. Once both reviewers had completed this process, any and all discrepancies between the 
two assessments were discussed until a consensus was reached regarding each paper. Full-text 
articles were retrieved for all of the papers selected for inclusion based on the title and abstract 
review process and the full-text of these articles was reviewed for suitability by one assessor 
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(RPH). A flow diagram illustrating the study selection and exclusion process is provided in 
Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Flow diagram illustrating the systematic review process 
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5.3.3 Data Extraction and Quality Assessment 
Upon selection of the articles for inclusion, one assessor (RPH) extracted and collated 
information concerning the type and number of participants, their mean age, disease duration 
and symptom severity, as well as the type and location of the wearable sensor(s) used and the 
major findings of each study (Table 1). The included studies presented a range of outcomes 
that sought to gain a better insight into the deficits of standing balance and walking stability 
evident in people with PD and these included; i) the root mean square (RMS) of segmental 
accelerations; ii) the harmonic ratio; iii) Jerk (the first derivative of acceleration); iv) step or 
stride variability; v) step or stride regularity/symmetry; and vi) other less commonly-used 
measures of stability. 
In addition to extracting and compiling these data, a quality assessment was performed 
by one assessor (RPH) using a modified version of a previously-developed 27-item quality 
checklist, designed to accommodate both randomised and non-randomised studies [14]. To 
evaluate the overall methodological quality of each paper, 25 of the criteria on the quality 
assessment tool were assigned a score of one point if the criterion was met or a zero if the 
criterion was not met (Appendix B). If it was not possible or unreasonably difficult for the 
assessor to determine whether the information required for a particular criterion had been 
provided by the authors, a score of zero was given for that criterion. Of the remaining two 
questions on the quality checklist, one question evaluating whether potentially confounding 
variables had been reported by the authors was assessed on a 2-point scale, where the study 
was given 2 points if confounders were clearly described, 1 point if they were partially 
described or 0 points if they were not described. The final methodological aspect of the studies 
that was evaluated was statistical power, which was more heavily weighted than the other 
criteria and assessed on a 5-point scale. Studies that achieved a statistical power of ≤70% for 
the standing balance or walking stability measures were given a score of zero, while those that 
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achieved powers of 80, 85, 90, 95 or 99% were assigned scores of 1 to 5, respectively. Where 
an appropriate statistical power calculation was not provided by the authors, it was necessary 
to evaluate the statistical power of each study based on the data presented by the authors. If a 
statistical power calculation was not reported and the raw data were not presented, the paper 
was given a score of zero for this criterion. After each paper was assessed against these criteria, 
the scores were summed and divided by the maximum total points to yield a final score that 
represented the percentage of total possible points earned. This percentage score was used to 
evaluate the overall quality of the study using quartiles to classify the methodological quality 
of the article as either very low (≤25%), low (>25%, but ≤50%), moderate (>50%, but ≤75%) 
or high (>75%).  
 
5.4 Results 
The initial database search identified 335 articles that were potentially eligible for 
inclusion in this review. Of the 335 studies identified, 98 were excluded as duplicates, 114 
were conference abstracts, 6 were review articles and 6 were written in a language other than 
English. The remaining 115 papers were screened by title and abstract, which resulted in 34 
being excluded, based on title and 38 being excluded based on abstract. A manual search was 
conducted of the bibliographies of those papers that were considered appropriate for full-text 
review, which identified 5 additional papers for consideration. Following full-text review of 
the remaining 44 studies, a further 18 studies were excluded, including 1 that was unattainable, 
3 that had no control group or condition and 14 that had no sensor-based measure of standing 
balance or walking stability. The remaining 26 articles were selected for inclusion in this 
systematic review. 
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5.4.1 Study Design and Methodological Quality 
All 26 studies included within this review had a cross-sectional research design with a 
broad aim of using different types of wearable sensors to observe or identify differences in 
standing balance or walking stability for Parkinson’s disease compared with controls or a 
control condition (e.g. on medication vs. off medication, PD subtypes). Given their cross-
sectional nature, ten items were excluded from the methodological quality checklist, as they 
specifically targeted qualities that are unique to intervention studies. The decision to exclude 
these criteria was made to ensure that the overall quality of the studies included in this review 
was not unfairly biased by these items that were not relevant to their chosen design. 
Based on the appraisal of methodology quality, 8 papers were identified as being of low 
methodological quality (range = 31.8% to 50.0%), 15 papers were of moderate methodological 
quality (range = 54.5% to 72.7%) and three papers were of high methodological quality (range 
= 77.3% to 90.9%). In general, the reviewed papers performed poorly on those criteria that 
addressed external validity (e.g. representativeness of the sample), internal validity (e.g. 
identification of and adjustment for potential confounders) and statistical power (e.g. no power 
calculation and insufficient details to make an informed appraisal). A full scoring of the 
methodological quality of each study included within this review can be seen in Table 1. 
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Table 1: Methodological quality assessment of articles included in systematic review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quality Assessment Criterion 
Article 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 1
6 
1
7 
1
8 
1
9 
2
0 
2
1 
2
2 
2
3 
2
4 
2
5 
26 27 Total % 
Baston 2014 [12] 1 1 1  0 0 1   0 0 0 0   1  1  1 1 0   0  0 9 40.9 
Fazio 2013 [67] 1 1 1  0 1 1   0 0 0 0   1  1  1 0 0   0  5 13 59.1 
Gago 2014 [75] 1 1 1  2 1 1   1 0 0 0   1  1  1 1 0   1  0 13 59.1 
Hasmann 2014 [93] 1 0 1  1 1 1   1 0 0 0   1  1  1 0 1   0  3 13 59.1 
Herman 2014 [95] 1 1 1  1 1 1   1 0 0 0   1  1  1 0 0   1  5 16 72.7 
Latt 2009 [129] 1 1 1  2 1 1   0 0 0 0   1  1  1 1 0   1  5 17 77.3 
Lowry 2010 [137] 1 1 1  1 1 1   1 0 0 0   0  1  1 0 0   1  0 10 45.5 
Lowry 2009 [138] 1 1 1  2 1 1   1 0 0 0   1  1  1 0 0   1  3 15 68.2 
Maetzler 2012 [144] 1 1 1  2 1 1   1 0 0 0   1  1  1 0 0   1  0 12 54.5 
Mancini 2011 [151] 1 1 1  1 1 1   1 0 0 0   1  1  1 0 0   1  5 16 72.7 
Mancini 2012 [152] 1 1 1  0 1 1   1 0 0 0   1  1  1 0 0   0  3 12 54.5 
Mancini 2012 [150] 1 1 1  0 1 1   1 0 0 0   0  1  1 0 0   0  3 11 50.0 
Mirelman 2013 [163] 1 1 1  2 1 1   1 1 0 1   1  1  1 1 0   1  5 20 90.9 
Palmerini 2011 [188] 1 1 0  2 0 1   0 0 0 0   1  1  1 0 0   1  0 9 40.9 
Palmerini 2013 [187] 1 1 1  1 1 1   1 0 0 0   1  1  1 0 0   0  5 15 68.2 
Rocchi 2014 [205] 1 1 1  0 0 1   0 0 0 0   1  1  1 0 0   0  0 7 31.8 
Sant’Anna 2011 [208] 1 1 1  2 1 1   1 0 0 0   1  1  1 0 0   1  3 15 68.2 
Sejdic 2014 [213] 1 1 0  0 1 1   0 0 0 0   1  1  1 0 0   0  3 10 45.5 
Sekine 2004 [215] 1 1 0  1 1 1   0 0 0 0   1  1  1 0 0   0  5 13 59.1 
Sekine 2004 [214] 1 1 0  2 1 1   0 0 0 0   1  1  1 0 0   0  3 12 54.5 
Van Emmerik 1999 
[240] 
1 1 1  2 0 1   1 0 0 0   1  1  1 0 0   1  0 11 50.0 
Weiss 2011 [253] 1 1 1  1 1 1   1 0 0 0   1  1  1 1 0   1  5 17 77.3 
Weiss 2014 [250] 1 1 1  1 1 1   1 0 0 0   1  1  1 0 0   1  5 16 72.7 
Weiss 2014 [251] 1 1 1  1 1 1   1 0 0 0   1  1  1 0 0   1  5 16 72.7 
Yang 2011 [261] 1 1 0  0 0 1   1 0 0 0   1  0  1 0 0   0  3 9 40.9 
Zampieri 2009 [263] 1 1 1  2 1 1   1 0 0 0   1  1  1 0 0   1  0 12 54.5 
46 
5.4.2 Sensor Type and Placement 
Multiple wearable sensor types were used within the included articles to assess 
measures of standing balance and walking stability. Of these studies, 69% reported using three-
dimensional accelerometers [67, 75, 93, 95, 129, 137, 138, 163, 187, 188, 205, 213-215, 250, 
251, 253, 261], 27% used inertial sensors [12, 144, 150-152, 208, 263], and 4% used other 
types of sensors [240, 263]. Similarly, there were multiple protocols described with respect to 
the placement of the wearable sensors on the human body. Of the 26 included studies, 85% 
reported placing a wearable sensor on either the lumbar or sacral region of the trunk [12, 67, 
75, 93, 95, 137, 138, 144, 150-152, 163, 187, 188, 205, 208, 213-215, 250, 251, 253] and 15% 
reported placing devices on other body landmarks (e.g. head, shank, wrist) [129, 240, 261, 
263]. Details regarding the studies included in this review that reported using each specific type 
and placement of sensors are summarised in Table 2. 
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Table 2: Details of studies included within the systematic review 
Article 
Experimental Groups  
N (Mean Age ± SD) 
Disease Severity 
Disease 
Duration 
(Years) 
Sensor Type 
(Placement) 
Postural Stability 
Measures 
Modality Findings 
Baston  
2014 [12] 
PD  = 5 (62.0±6.0) 
PSP = 7 (68.0±5.0) 
Control  = 7 (68.0±7.0) 
UPDRS III 
PD   = 34.0±14.0 
Not Reported 
Inertial Sensor  
Freq: 128 Hz 
- L5 
- Shank 
RMS acceleration 
- Anterior-posterior (AP) 
Dynamic 
Posturography 
 
No significant difference between 
PD and controls for AP acceleration 
during all conditions of the Sensory 
Organisation Test (SOT). PD had 
reduced AP accelerations for 
conditions 4 and 5 of the SOT 
compared with the PSP group.  
Fazio  
2012 [67] 
PD  = 17 (60-85) 
Ataxia = 24 (20-85) 
Control  = 24 (20-85) 
UPDRS III 
PD   = 22.5±3.6 
Not Reported 
3D 
Accelerometer 
Freq: 20 Hz 
- Sternum 
- Front 
pelvis 
- Back pelvis 
RMS acceleration 
- For sum of sternum 
accelerations 
- For sum of front pelvis 
accelerations 
- For sum of back pelvis 
accelerations 
RMS Jerk 
- For sum of sternum 
accelerations 
Gait 
 
PD patients had lower Jerk scores 
compared with controls, but were not 
significantly different to ataxic 
patients. PD had significantly lower 
RMS accelerations for the sternum 
and two pelvis locations compared 
with the ataxic and control 
participants.  
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Gago  
2014 [75] 
IPD = 10 (73 [61-79]) 
VPD = 5 (77 [63-84]) 
MDS-UPDRS III 
IPD   = 30 [15-53] 
VPD   = 44 [33-57] 
IPD 
6.0 [5.0-10.0] 
 
VPD 
5.0 [3.0-9.0] 
3D 
Accelerometer 
Freq: 113 Hz 
- Lower back 
Length of sway  
Maximum sway distance 
Mean sway distance 
Maximum linear velocity 
Quiet Stance 
 
Idiopathic PD (IPD) patients had 
significantly increased length and 
maximum distance of sway during 
normal stance while on medication. 
Sway length and maximum distance 
was also greater for the IPD group 
when eyes were closed compared 
with open during the Romberg test 
off medication. Compared with the 
IPD patients, vascular PD patients 
had increased mean distance of sway 
during normal stance and greater 
maximal distance of sway compared 
with the IDP patients during the 
Romberg test with eyes closed off 
medication. 
Hasmann  
2014 [93] 
PD  = 13 (65.0±9.4) 
HRPD  = 31 (62.6±5.0) 
Control  = 13 (63.9±7.3) 
UPDRS III 
PD   = 26.8±11.0 
HRPD = 3.0±3.0 
Control = 0.2±0.6 
   
PD 
4.5±2.8 
3D 
Accelerometer 
Freq: Not 
reported 
- Lower back 
Mean acceleration 
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
Jerk 
- Anterior-posterior (AP) 
- Medial-lateral (ML 
Functional 
Reach 
 
Compared with controls, PD had 
increased mean acceleration in the 
AP and ML directions, but the 
groups did not differ significantly 
with respect to AP or ML Jerk scores. 
Herman 
2014 [95] 
PD PIGD  = 31 (65.0±7.7) 
PD TD  = 32 (64.6±11.6)  
UPDRS III - OFF 
PIGD = 38.7±10.5 
TD  = 39.5±12.5       
 
UPDRS III – ON 
PIGD = 33.3±10.0 
TD  = 33.4±11.6  
PIGD 
5.7±3.7 
 
TD 
5.4±3.2 
3D 
Accelerometer 
Freq: 100 Hz 
- Lower back 
Harmonic ratio (HR) 
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
- Vertical (VT) 
Stride regularity 
Stride timing variability 
Gait 
 
For usual walking, PIGD patients 
had reduced stride regularity and 
reduced vertical HRs compared with 
the TD group while off medication. 
Accelerometer-derived measures 
from a 3-day period of in-home 
activity monitoring revealed that the 
PIGD group had reduced stride 
regularity and lower harmonic ratios 
in both the AP and VT directions 
compared with the TD group.  
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Latt  
2009 [129] 
PD Fallers vs. Non-
Fallers: 
Non-Faller =  33  
 (63.0±4.0) 
Faller  =  33 
  (67.0±2.0) 
Control  =  33 
  (67.0±4.0) 
Hoehn & Yahr  
Non-faller =  
1 (1-1) 
Faller =  
3 (3-4) 
 
UPDRS III 
Non-faller = 
12.0±3.0 
 
Faller = 
21.0±3.0 
PD NF 
7.0±2.0 
 
PD F 
9.0±2.0 
3D 
Accelerometer 
Freq: 200 Hz 
- Head 
- Sacrum 
Harmonic Ratio (HR) 
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
- Vertical (VT) 
RMS Acceleration 
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
- Vertical (VT) 
Step timing variability 
Gait 
 
Compared with controls and PD non-
fallers, fallers had increased step 
timing variability. With the 
exception of AP head accelerations, 
PD fallers had significantly reduced 
head and pelvis accelerations 
compared with non-fallers and 
controls. Controls had higher AP 
head accelerations compared with 
PD fallers, and PD non-fallers had 
lower ML accelerations for the pelvis 
than controls.  
 
PD fallers had lower AP and VT HRs 
for the head and lower AP, ML and 
VT HRs for the pelvis compared with 
non-fallers and controls. PD non-
fallers had lower VT HRs for the 
head and pelvis and lower AP HRs 
for the head compared with controls. 
Non-fallers also had greater ML HRs 
for the head compared with fallers. 
Lowry 
2010 [137] 
PD  = 7 (70.3±8.5) 
Hoehn & Yahr  
PD   = 2.4±0.5 
PD 
6.2±4.7 
3D 
Accelerometer 
Freq: 200 Hz 
- L3 
Harmonic Ratio (HR) 
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
- Vertical (VT) 
Gait 
 
Cognitive cueing (thinking “big 
step” during the swing phase) and 
verbal cueing (assessor saying “big 
step” during the swing phase) both 
improved AP HR compared with 
preferred gait (without cues). 
Lowry 
2009 [138] 
PD  = 11 (68.0±7.7) 
Control = 11 (69.0±8.8) 
Hoehn & Yahr  
PD  = 1.9±0.8 
PD 
5.2±4.0 
3D 
Accelerometer 
Freq: 200 Hz 
L2 
Harmonic Ratio (HR) 
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
- Vertical (VT) 
Stride timing variability 
Stride length variability 
Gait 
PD and controls did not differ 
significantly with respect to stride 
length variability, stride timing 
variability or AP, ML and VT HRs. 
After normalising these data to 
walking speed, PD patients had 
lower AP and ML HRs compared 
with controls. 
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Maetzler  
2012 [144] 
PD = 12 (61.5±2.2) 
HRPD  = 20 (61.9±1.5) 
Control = 14 (63.9±1.9) 
Hoehn & Yahr 
PD  = 2.0±0.0 
 
UPDRS III - OFF 
PD = 26.5±10.9 
HRPD  = 3.3±2.4 
Control = 1.1±1.7 
PD 
4.3±2.6 
Inertial Sensor 
Freq: 100 Hz 
L3/L4 
RMS acceleration 
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
Jerk 
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
Frequency with 95% of 
signal (F95) 
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
Mean sway velocity  
Quiet Stance 
 
The PD and control groups did not 
differ significantly for AP or ML 
RMS accelerations or Jerk scores, 
even when vision was occluded 
and/or somatosensory feedback was 
reduced. However, the high risk of 
PD (HRPD) group had greater AP 
and ML RMS accelerations than PD 
patients and controls while standing 
on a foam surface with eyes closed 
and greater scores than PD when 
standing on a firm surface with eyes 
closed. The HRPD group also had 
greater AP and ML Jerk scores than 
the PD and controls group during the 
foam eyes closed task. Groups did 
not differ with respect to F95 or 
mean sway velocity. 
Mancini  
2011 [151] 
PD  = 13 (60.4±8.5) 
Control  = 12 (60.2±8.2) 
Hoehn & Yahr 
PD = 1.8±0.6 
 
UPDRS III 
PD = 28.2±11.2 
PD 
14.3±6.9 
Inertial Sensor 
Freq: 50 Hz 
L5 
RMS Acceleration 
- Resultant of AP and 
ML 
Jerk 
- Resultant of AP and 
ML 
Frequency with 95% of 
signal (F95) 
- Resultant of AP and 
ML 
Mean sway velocity  
Quiet Stance 
 
Compared with controls, the PD 
group had significantly greater RMS 
accelerations, Jerk scores and mean 
sway velocity measures while 
standing on a firm surface with eyes 
open, but not with eyes closed. 
Groups did not differ with respect to 
the F95 measure.  
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Mancini  
2012 [152] 
Study 1 
PD  = 13 (60.4±8.5) 
Control  = 12 (60.2±8.2) 
 
Study 2 
PD  = 17 (67.1±7.3) 
Control  = 17 (67.9±6.1) 
Study 1 
UPDRS III 
PD  = 28.1±11.2 
 
Study 2 
UPDRS III 
PD  = 28.3±10.4 
Not Reported 
Inertial Sensor 
Freq: 50 Hz 
L5 
RMS Acceleration 
- Resultant of AP and 
ML 
Jerk 
- Resultant of AP and 
ML 
Frequency with 95% of 
signal (F95) 
- Resultant of AP and 
ML 
Mean sway velocity 
Length of sway 
Mean sway distance 
Sway area 
Quiet Stance 
 
Compared with controls, the PD 
group had significantly higher RMS 
accelerations, Jerk scores, sway 
distances and sway areas, but the 
groups did not differ with respect to 
the F95 measure, mean sway 
velocities or length of sway. 
Mancini  
2012 [150] 
PD  = 13 (60.4±8.5) 
Control  = 12 (60.2±8.2) 
Hoehn & Yahr 
PD = 1.8±0.2 
 
UPDRS III  
PD  = 26.6±3.5 
Not Reported 
Inertial Sensor 
Freq: 50 Hz 
L5 
RMS acceleration 
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
Jerk 
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
Frequency with 95% of 
signal (F95) 
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
Mean sway velocity  
- Anterior-posterior (AP) 
Medial-lateral (ML) 
Quiet Stance 
 
For RMS accelerations, a significant 
main effect for group showed that PD 
participants had greater ML 
accelerations than controls, while the 
AP axis fell marginally short of 
statistical significance. PD 
participants also had higher AP and 
ML Jerk scores at baseline, but ML 
Jerk was also larger for the PD 
patients at the 3-6 and 12-month 
follow-up time points. There were 
also significant main effects for 
group for ML F95 values and mean 
sway velocity along the ML axis, 
indicating that the PD group had 
larger values for both of these 
measures compared with control. 
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Mirelman  
2013 [163] 
PD LRRK2 Gene: 
Carrier  =  50 
  (62.6±9.6) 
 
Non-Carrier = 50 
  (60.2±11.3) 
Hoehn & Yahr 
Carrier = 2-3 
 
Non-Carrier = 2-3 
 
UPDRS Total  
Carrier = 
27.9±14.2 
 
Non-Carrier = 
26.9±13.3 
 
Carrier 
4.4±3.3 
 
Non-Carrier 
6.1±6.1 
3D 
Accelerometer 
Freq: Not 
reported 
Lower back 
Preferred vs. Fast speed 
vs. Dual-task: 
Stride timing variability 
Step regularity (step-to-
step consistency) 
Width of dominant 
frequency 
Anterior-posterior (AP)  
Gait 
Carriers of the LRRK2 gene had 
greater stride timing variability and 
less step regularity than non-carriers 
during preferred speed, fast speed 
and dual-task (serially subtracting 
3s) walking. Carriers also had a 
greater gait variability during 
preferred and fast walking, as 
evidenced by the greater width of the 
dominant frequency. Significant 
group by condition interactions 
suggested that the carriers had a 
greater increase in stride timing 
variability and a greater width of the 
dominant frequency with increased 
task complexity (i.e. dual tasking) 
compared with non-carriers. 
Palmerini  
2013 [187] 
PD  = 20 (62.0±7.0) 
Control = 20 (64.0±6.0) 
Hoehn & Yahr 
PD = 2.4±0.2 
PD 
5.2±4.1 
3D 
Accelerometer 
Freq: 100 Hz 
L5 
RMS acceleration 
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
- Vertical (VT) 
Normalised Jerk 
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
- Vertical (VT) 
Harmonic ratio (HR) 
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
- Vertical (VT) 
Phase coordination index 
Timed Up and 
Go 
During the gait and turning portions 
of the Timed Up and Go test, PD 
patients had significantly lower AP 
and ML normalised Jerk scores than 
control participants. Similarly, 
during the gait component of the test, 
PD participants also had lower AP 
and VT HRs compared with controls. 
The two groups did not differ 
significantly for any of the other 
accelerometer-based measures.  
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Palmerini, 
2011 [188] 
PD = 20 (62.0±7.0) 
Control = 20 (64.0±6.0) 
Hoehn & Yahr 
PD = ≤2.5 
 
UPDRS-III 
PD = 26.6±7.1 
Not Reported 
3D 
Accelerometer 
Freq: 100 Hz 
- L5 
 
High Frequency Power 
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
Frequency Dispersion 
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
Sway Range 
- Anterior-posterior (AP) 
Medial-lateral (ML) 
Quiet Stance 
Compared with controls, the PD 
group had significantly higher high 
frequency power in the ML direction 
during the dual task condition and 
significantly lower AP frequency 
dispersion scores while standing on a 
foam surface. AP sway range was not 
significantly different between 
groups. A wrapper feature selection 
approach determined that ML high 
frequency power on a firm surface 
with eyes open, AP frequency 
dispersion on a foam surface with 
eyes open and AP sway range on 
foam surface with eyes closed 
represented the best candidate subset 
to distinguish PD from controls. 
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Rocchi,  
2014 [205] 
PD PIGD = 40 (64.5±6.9) 
PD TD  = 26 (67.6±9.9) 
Control  = 15 (78.2±3.9) 
UPDRS III 
PD PIGD =  
38.3±10.9 
 
PD TD  = 
43.3±13.4 
PD PIGD 
5.1±3.6 
 
PD TD 
5.7±2.8 
3D 
Accelerometer 
Freq: 100 Hz 
Lower back 
Feet together vs. Semi-
tandem: 
Centroidal frequency (CF) 
- Anterior-posterior (AP) 
Length of sway 
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
- 2-dimensional (2D)  
Mean sway velocity 
- Anterior-posterior (AP) 
Medial-lateral (ML) 
Quiet Stance 
The TD group had significantly 
lower CF values than controls for all 
experimental tasks and the PIGD 
group also had lower CF values than 
controls for all conditions except 
semi-tandem stance with eyes 
closed. The TD and PIGD groups did 
not differ with respect to CF during 
any of the experimental tasks. CF 
values were influenced by foot 
position for the two PD groups 
(PIGD and TD) with greater values 
recorded during semi-tandem stance. 
Results were similar for sway 
velocity and length of sway, with all 
groups typically showing higher 
values with eyes closed compared 
with eyes open. The groups did not 
differ for sway velocity or length of 
sway for the feet together or semi-
tandem stance trials with eyes open, 
but the PIGD and TD groups had 
lower values compared with controls 
during the EC conditions. 
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Sant’Anna  
2011 [208] 
PD  = 11 (60.0±8.6) 
Control  = 11 (61.0±7.8) 
Hoehn & Yahr 
PD = 1.6±0.6 
 
UPDRS-PIGD 
PD = 0.7±1.1 
 
PD 
1.1±1.1 
1D 
Gyroscopes 
Freq: 200 Hz 
- Anterior 
shank 
 
2D 
Gyroscopes 
Freq: 200 Hz 
Wrist 
Symbolic symmetry index 
(SIsymb) 
Symmetry index (SIindex) 
Gait asymmetry (SIGA) 
Symmetry angle (SIangle) 
Maximum angular 
velocity ratio (SIratio) 
Trend symmetry (SItrend) 
LCEA symmetry 
magnitude (SILCEA) 
Gait 
Of the symmetry measures derived 
from the gyroscopes placed on the 
shanks and wrists, only the SIindex, 
SIGA, SIratio and SIsymb values for the 
wrist sensors were significantly 
higher for PD participants. 
Evaluation of the area under the 
Receiver Operating Characteristic 
(ROC) curves for these four 
outcomes showed that only SIratio and 
SIsymb were able to differentiate PD 
from controls, but the higher Intra-
class Correlation Coefficients for 
SIsymb indicated that this outcome 
was more robust for differentiating 
between the two cohorts. 
Sejdić  
2014 [213]  
PD =  10 
  (≥65 years) 
 
Neuropathy = 11  
  (≥65 years) 
 
Control  =  14 
  (≥65 years) 
Hoehn & Yahr 
PD = 2-3 
Not Reported 
3D 
Accelerometer 
Freq: 100 Hz 
L3 
Lyapunov exponent (LE) 
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
- Vertical (VT) 
Harmonic ratio (HR) 
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
- Vertical (VT) 
Entropy rate  
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
- Vertical (VT) 
Cross entropy rate  
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
- Vertical (VT) 
Gait 
There were no significant differences 
between the groups for AP, ML or 
VT Lyapunov exponents, but PD 
patients had less gait rhythmicity in 
the vertical direction (decreased VT 
HRs) compared with healthy 
controls. With respect to the entropy 
measure, the PD and peripheral 
neuropathy groups both had 
significantly greater ML values than 
controls, but there were no group 
differences for cross entropy rate. 
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Sekine  
2004 [215] 
PD  = 11 (66±9.6) 
Control = 10 (66.3±5.3) 
Hoehn & Yahr 
PD = 1-2 
Not Reported 
3D 
Accelerometer 
Freq: 1024 Hz 
L5/S1 region 
Fractal Brownian Motion  
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
Vertical (VT) 
Gait 
The fractal values for the AP, ML 
and VT directions were significantly 
higher for the individuals with PD 
compared with controls. Also, the 
AP, ML and VT fractal dimensions 
were all significantly negatively 
correlated with walking speed for the 
PD group, but not controls. 
Sekine  
2004 [214] 
Mild PD  = 11 (66.0±9.6) 
Severe PD = 5 (57.4±19.1) 
Control  = 10 (66.3±5.3) 
Hoehn & Yahr 
Mild PD = 1-2 
Severe PD = 3-4 
Not Reported 
3D 
Accelerometer 
Freq: 1024 Hz 
L5/S1 region 
Vertical patterns  
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
- Vertical (VT) 
Circular patterns  
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
- Vertical (VT) 
Horizontal patterns  
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
- Vertical (VT) 
Gait 
Controls did not differ significantly 
from the mild or severe PD groups 
for AP, ML or VT vertical patterns. 
Circular patterns were different 
between the groups, with both mild 
and severe PD participants having 
larger values than controls in the AP 
and VT directions, while severe PD 
patients also had higher AP circular 
patterns than mild PD patients.  
Severe PD patients had greater short 
horizontal patterns than controls in 
all three directions and lower long 
horizontal patterns in the AP and VT 
than controls. Severe PD patients 
also had greater short horizontal 
patterns in the AP, ML, VT than mild 
PD patients and mild PD patients had 
lower values than controls for long 
horizontal patterns in the AP and VT 
directions. 
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van 
Emmerik 
1999 [240] 
PD  = 27  
  (53.7±10.6) 
Control = 11 
  (not reported) 
Hoehn & Yahr 
PD = 1.5 ±0.6 
 
UPDRS III  
PD = 16.7±6.2 
PD 
2.3±1.4 
 
1D 
Accelerometer 
Freq: 104 Hz 
Shank 
Stride timing variability 
Relative phase analysis     
Gait 
Stride timing variability was not 
significantly different between PD 
and controls, but variability 
significantly decreased for both 
groups as walking velocity 
increased. Continuous relative phase 
was also larger for controls 
compared with PD patients between 
walking speeds of 0.2 and 1.4 m/s. 
Weiss  
2011 [253] 
PD  = 22 (65.9±5.9) 
Control  = 17 (69.9±8.8) 
Hoehn & Yahr 
PD = 2.5±0.4 
 
UPDRS III  
PD = 23.6±9.4 
PD 
4.8±3.8 
3D 
Accelerometer 
Freq: 256 Hz 
Lower back 
Stride timing variability  
Width of the dominant 
harmonic 
Gait 
Stride timing variability was 
significantly higher for PD patients 
compared with healthy controls. 
Similarly, the width of the dominant 
harmonic of the power spectral 
density of the locomotor band of the 
acceleration signal was significantly 
greater for PD patients, both on and 
off medication, compared with 
controls. Furthermore, the width of 
the dominant harmonic was greater 
for patients when off medication 
compared with on medication. 
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Weiss  
2014 [250] 
PD Freezer vs.  
Non-Freezer: 
 
Non-Freezer = 44 
  (66.5±8.8) 
 
Freezer   = 28  
   (64.4±8.7) 
Hoehn & Yahr 
Non-Freezer = 
2.4±0.5 
 
Freezer  =  
3.2±0.8 
 
UPDRS III - OFF 
Non-Freezer = 
42.3±12.9 
 
Freezer = 
46.2±12.2 
 
UPDRS III - ON 
Non-Freezer = 
35.6±12.8 
 
Freezer  = 
36.3±11.7 
 
Non-Freezer 
6.7±2.2 
 
Freezer 
7.5±4.5 
3D 
Accelerometer 
Freq: Not 
reported 
Lower back 
Harmonic ratio (HR) 
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
- Vertical (VT) 
Stride regularity  
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
- Vertical (VT) 
Width of dominant 
frequency  
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
- Vertical (VT) 
Gait 
Freezers had decreased AP, ML and 
VT harmonic ratios and stride 
regularity compared with non-
freezers. PD freezers also had a 
significantly greater width of the 
dominant frequency in the VT and 
AP directions. Harmonic ratios and 
stride regularity were significantly 
correlated with the new freezing of 
gait questionnaire and the width of 
the dominant frequency in the VT 
and AP direction were also 
significantly correlated with this 
clinical test.  
Weiss  
2014 [251] 
PD Fallers vs.  
Non-Fallers: 
 
Non-Faller =  67  
  (64.0±9.8) 
 
Faller  =  40  
  (66.5±8.2) 
Hoehn & Yahr 
Non-Faller = 
2.4±0.5 
 
Faller = 
2.9±0.8 
Non-Faller 
5.2±3.1 
 
Faller 
6.1±4.0 
3D 
Accelerometer 
Freq: 100 Hz 
Lower back 
Harmonic ratio (HR) 
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
- Vertical (VT) 
Stride regularity  
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
- Vertical (VT) 
Width of dominant 
frequency  
- Anterior-posterior (AP) 
- Medial-lateral (ML) 
Vertical (VT) 
Gait 
During a 3-day assessment of gait 
and mobility, fallers exhibited 
reduced HRs in both the AP and VT 
directions. PD fallers also had less 
VT stride regularity than non-fallers 
and a greater width of the dominant 
frequency for the AP and VT 
directions. 
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Yang  
2011 [261] 
PD  = 5 (78.0±9.8) 
Control  = 5 (26.0±3.1) 
Hoehn & Yahr 
PD  = 2-3 
Not Reported 
3D 
Accelerometer 
Freq: 50 Hz 
Lateral pelvis 
Step regularity 
Stride regularity 
Step symmetry 
 
Gait 
There were no significant differences 
observed in step regularity, stride 
regularity or step symmetry between 
PD patients and controls. 
Zampieri  
2009 [263] 
PD  = 12 (60.4±8.5) 
Control  = 12 (60.2±8.2) 
Hoehn & Yahr 
PD  = 1.6±0.5 
 
UPDRS III  
PD  = 20.0±9.4 
PD 
1.1±1.1 
1D 
Gyroscopes 
Freq: 200 Hz 
- Anterior 
shank 
 
2D 
Gyroscopes 
Freq: 200 Hz 
- Wrist 
 
Inertial Sensor 
Freq: 200 Hz 
- Sternum 
Stride length variability 
Stride timing variability 
Timed Up and 
Go 
PD and control groups did not differ 
with respect to stride length 
variability or stride time variability. 
 
PD: Parkinson’s disease; PSP: Progressive supranuclear palsy; IPD: Idiopathic Parkinson’s disease; VPD: Vascular Parkinson’s disease; HRPD: People at high-risk of 
Parkinson’s disease; UPDRS: Unified Parkinson’s Disease Rating Scale; MDS-UPDRS: Movement Disorders Society’s revision of the Unified Parkinson’s Disease Rating 
Scale; Freq: Sampling frequency of wearable sensor; LRRK2: Leucine-Rich Repeated Kinase 2; PIGD: Postural Instability and Gait Disability 
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5.4.3 Assessment of standing balance and walking stability 
Of the 26 included studies, 65% used wearable sensors to assess walking during clinical 
tests, such as the Timed up and Go Test [187, 263] or during assessments of straight-line 
walking at a self-selected speed [67, 95, 129, 137, 138, 163, 208, 213-215, 240, 250, 251, 253, 
261]. A wide range of sampling frequencies were used to assess walking stability in the 
reviewed studies, with authors reporting sampling frequencies that ranged from 20 to 1024 Hz. 
The remaining 9 studies (35%) assessed standing balance using an instrumented functional 
reach test [93], dynamic posturography [12] or one of many pre-existing clinical tests 
conducted during quiet stance (i.e. the Romberg test, tandem stance, semi-tandem stance, 
standing with eyes open and eyes closed) [75, 144, 150-152, 188, 205]. Understandably, the 
wearable sensors used in these studies were generally set to collect data at a slower rate to those 
used for assessing the dynamic tasks, with reported sampling frequencies ranging from 50 to 
128 Hz. 
The included studies reported multiple outcomes of standing balance and walking 
stability, which were calculated from the signals provided by the wearable sensors (e.g. 
accelerations). Of these outcomes, the most commonly-reported measures of standing balance 
included postural sway velocity (23% of studies) [75, 144, 150-152, 205], RMS accelerations 
(19% of studies) [12, 144, 150-152] and Jerk (19% of studies) [93, 144, 150-152]. The most 
commonly-reported measures of walking stability included, the harmonic ratio (31% of 
studies) [95, 129, 137, 138, 187, 213, 250, 253] and stride timing variability (27% of studies) 
[95, 129, 138, 163, 240, 253, 263]. A definition of each of the outcome measures of standing 
balance and walking stability that were used in the studies is provided in Table 3. 
 
  
6
1
 
Table 3: Definition of the sensor-based measures of standing and walking stability. 
Outcome Measure Definition of Measure  
Standing Balance or Walking Stability Articles 
Mean acceleration 
The average of the Anterior-posterior (AP), Medial-lateral (ML) or vertical (VT) accelerations during a specific 
phase of the movement. Provides an indication of the rate of change in the velocity of the body during this phase. 
Under static conditions, larger values would represent poorer control. 
[93] 
   
Root mean square (RMS) acceleration 
Taking the RMS of the accelerations makes all values of the time series positive, to yield an average positive 
amplitude for AP, ML or VT accelerations. Like mean accelerations, RMS accelerations provides an indication 
of the rate of change in velocity, but is more robust for data that has both positive and negative values. 
[12, 67, 129, 
144, 150-152, 
187] 
   
Jerk 
Time series of the first derivative of acceleration (third derivative of displacement), representing the rate of 
change of acceleration. It is calculated from the raw AP, ML or VT accelerations. During steady movements, the 
body should be neither accelerating nor decelerating rapidly, hence Jerk scores should be smaller for more stable 
people. 
[93, 144, 150-
152] 
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Root mean square (RMS) Jerk Similar to RMS accelerations, RMS Jerk mathematically converts all values to a positive number and provides 
an average value for the AP, ML and VT Jerk time series. In lay terms, the RMS Jerk provides a single value 
that describes the jerkiness of the movement. 
[67] 
   
Normalised Jerk RMS Jerk score divided by overall movement time. Provides similar information to RMS Jerk, but takes into 
account differences in task duration for different populations. 
[187] 
   
Standing Balance   
Maximum sway distance 
The resultant of AP and ML displacement is calculated for an inertial measurement unit placed at the height of 
the centre of mass (COM; 55% of height). Maximum sway distance is the single largest value recorded 
throughout the trial. Provides insight into the extremes of postural sway. 
[75] 
   
Mean sway distance 
The resultant of AP and ML displacement is calculated for an inertial measurement unit placed at the height of 
the COM (55% of height). Mean sway distance is the average of all resultant values recorded throughout the 
trial. Larger values represent poorer postural control. 
[75, 152] 
   
Sway Range 
The overall range of displacement of the centre of mass (COM; estimated from an inertial measurement unit 
positioned on the trunk) in the Anterior-posterior (AP) and Medial-lateral (ML) directions. Larger values 
represent an increased amount of postural sway. 
[188] 
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Length of sway 
The total distance travelled by the COM on the transverse plane. Increased length of sway indicates more sway 
per unit of time and, hence, reduced postural control. 
[75, 152, 205] 
   
Mean sway velocity 
The first integral of the AP, ML or VT acceleration signals. Higher sway velocities represent more erratic postural 
adjustments and, hence, poorer postural control. 
[144, 150-152, 
205] 
   
Sway area 
The elliptical area that encapsulates the sway path derived from the AP and ML accelerations. Larger sway areas 
represent an increased volume of sway, which may suggest poorer balance. 
[152] 
   
F95 
The frequency below which 95% of the acceleration signals power is present. Higher frequencies would represent 
a larger number of postural adjustments to maintain balance during the trial. 
[144, 150-152] 
   
Centroidal frequency 
The frequency at which the power of the signal above and below is exactly balanced (i.e. the centre point). The 
centroidal frequency can be calculated for the AP, ML and VT axes separately. Lower frequencies represent 
poorer postural control. 
[205] 
   
High frequency power 
Percentage of the acceleration signal that is present between 4 and 7 Hz. A greater proportion of data in this high 
frequency band represents increased postural adjustment and postural sway. 
[188] 
   
  
6
4
 
Frequency dispersion 
A unitless frequency-based measure of variability. Values closer to zero would represent more regular patterns 
of sway, while values closer 1 represent a greater degree of variability. 
[188] 
   
Walking Stability   
Harmonic Ratio 
A measure of the stability of gait-related accelerations by evaluating the stride-to-stride regularity of the 
harmonics within the acceleration signal. Walking patterns that produce higher ratios have more regular 
acceleration profiles over successive gait cycles (i.e. less stride-to-stride variability); hence, the gait pattern is 
deemed to be more stable. 
[95, 129, 137, 
138, 187, 213, 
250, 251] 
   
Step and stride regularity 
The regularity of the AP, ML or VT acceleration profiles from step-to-step or stride-to-stride. Higher regularity 
scores represent a more rhythmic and consistent walking pattern and is often said to reflect a more stable gait 
pattern. 
[95, 163, 250, 
251, 261] 
   
Step symmetry 
Ratio of step regularity to stride regularity. A ratio closer to 1 represents greater symmetry between the left and 
right steps, while values closer to 0 indicate poorer symmetry. 
[261] 
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Step and stride timing variability 
The standard deviation (SD) or the coefficient of variation ((SD/mean)*100) of all step or stride times collected 
during a trial. Greater variability represents a less rhythmic walking pattern that is often said o reflect a less stable 
gait pattern. 
[95, 129, 138, 
163, 240, 253, 
263] 
   
Stride length variability 
The standard deviation (SD) or the coefficient of variation ((SD/mean)*100) of all stride lengths collected for 
the left and right leg collected throughout a trial. Greater variability represents a less predictable and, hence, less 
stable walking pattern. 
[138] 
   
Lyapunov exponent 
A non-linear measure that assesses the sensitivity of the system to perturbations in the AP, ML or VT directions. 
The Lyapunov exponent provides an indication of the local dynamic stability of the gait pattern, with lower 
values representing increased local stability during gait. 
[213] 
   
Entropy rate 
Assesses the regularity of the AP, ML and VT accelerations. Values range from 0, which represents no regularity 
(maximum randomness) to 1, which represents maximum regularity. 
[213] 
   
Cross entropy rate 
Non-linear measure of asynchrony between two related time series. Used to assess how well the pattern of AP 
acceleration (for example) can predict ML accelerations. Higher values indicate more synchronisation between 
the acceleration patterns and, hence, a more stable gait pattern. 
[213] 
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Width of the dominant frequency 
The width of the dominant harmonic of the power spectral density of the acceleration signal. Greater widths, 
represent greater dispersion and greater variability of the gait pattern. 
[163, 250, 251, 
253] 
   
Relative phase analysis 
A graphic-based analysis that plots the angular position of a segment against the angular velocity of the same 
segment. Relative phase analysis provides a measure of the coordination between two adjoining segments (e.g. 
pelvic and trunk) and the overall stability of this pattern. 
[240] 
   
Phase coordination index (PCI) 
Stable walking has step times that are approximately half the length of the gait cycle (i.e. 180° of a 360° cycle). 
Deviation from this expectation is considered an inaccuracy. The PCI is a summary measure that combines this 
value representing the accuracy with the coefficient of variation, representing consistency; hence the PCI is 
considered a measure of gait coordination. 
[187] 
   
Symmetry index (SIindex) 
The SIindex compares movements from one side (e.g. injured) to the other side (e.g. uninjured). Perfect symmetry 
is represented by zero and larger numbers represent more asymmetry. 
[208] 
   
Gait asymmetry (SIGA) 
Mean swing time is calculated for both left and right legs. Gait asymmetry is the natural log (ln) of the swing 
time of the leg with the shortest swing time divided by the swing time of the leg with the longer swing time. 
Values closer to zero represent a symmetrical movement pattern. 
[208] 
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Symmetry angle (SIangle) Measures the relationship between discrete values obtained from the left and right side and is derived when the 
right-side value is plotted against the left-side value to create a line that forms an angle with the x-axis. Angles 
that deviate from 45° represent some degree of asymmetry. 
[208] 
   
Maximum angular velocity ratio (SIratio) Ratio of the maximum angular velocity of the left leg (averaged over all gait cycles) to maximum angular velocity 
of the right leg (averaged over all gait cycles). Values that are closer to zero represent better symmetry between 
the left and right sides of the body. 
[208] 
   
Trend symmetry (SItrend) Translated data from the left and right sides of the body are used to derive eigenvectors. Trend symmetry assesses 
the ratio of the variability about the eigenvector (y-axis) to the variability along the eigenvector (x-axis). A value 
of zero represents perfect symmetry. 
[208] 
   
LCEA symmetry magnitude (SILCEA) 
Applies a latency corrected ensemble average (LCEA) to assess the correlation between the magnitudes of the 
signals collected from the left and right sides of the body using a cross-correlation approach. Larger values 
represent a greater degree of symmetry. 
[208] 
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Fractal Brownian Motion 
Fractal measures provide an indication of the complexity of the AP, ML, VT accelerations during walking. 
Higher values represent more complex walking patterns, hence walking patterns that are more difficult to 
coordinate and control effectively. 
[214] 
   
Vertical Patterns 
A time-frequency pattern of the energy of the acceleration signal for AP, ML and VT directions. Vertical patterns 
represent impulse type activities during the walking cycle. 
[215] 
   
Circular Patterns 
A time-frequency pattern of the energy of the acceleration signal for AP, ML and VT directions. Circular patterns 
characterise irregular burst like patterns during the walking cycle. 
[215] 
   
Horizontal Patterns 
A time-frequency pattern of the energy of the acceleration signal for AP, ML and VT directions. Horizontal 
patterns represent long-term smooth and regular activities. 
[215] 
   
   AP = anterior-posterior; ML = medial-lateral; VT = Vertical; RMS = root mean square; COM = centre of mass; SD = standard deviation; LCEA = latency corrected ensemble 
average 
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5.5 Discussion 
The purpose of this systematic review was to examine the existing literature to 
determine the best types of wearable sensors and the most appropriate anatomical placements 
and outcome measures to assess deficits in balance and gait between people with PD and 
controls. Using the methodological quality assessment tool adapted from Downs and Black 
[60], it was determined that the overall quality of scientific reporting in this area is largely of 
low to moderate quality. In general, the reviewed papers were lacking details concerning the 
representativeness of the study population (external validity), the approaches adopted to 
identify and account for confounding variables (internal validity) and an appropriate 
justification for the chosen sample size. Interestingly, 62% of the included studies received a 
score of zero for all of the criteria related to at least two of these three areas, while one study 
(4%) received a score of zero for all three of these areas. The heavier weighting attributed to 
the sample size criterion is indicative of the importance of ensuring that a study has sufficient 
statistical power to identify a difference where one exists and, hence, minimise the likelihood 
of incorrectly accepting the null hypothesis (i.e. Type II error) [177]. Of the 26 studies included 
in this review, not one reported the results of a sample size calculation, but 13 (50%) had fewer 
than 15 participants in each of their groups [12, 75, 137, 138, 150-152, 208, 213-215, 261, 263] 
and 3 others (12%) had at least one group with fewer than this number [93, 144, 240]. While it 
is important to emphasise that a large sample size is not always required to address a specific 
research question, reporting the outcome of an appropriate a-priori statistical power calculation 
is beneficial for determining the overall rigor of the reported findings. 
Of the other methodological aspects that were poorly reported, the lack of appropriate 
detail regarding the influence of confounding variables is quite significant, as failure to account 
for these factors may result in a study observing a significant change that is simply the 
manifestation of another variable that has not been adequately controlled for [219]. For 
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example, it is widely recognised that gait and balance variables are influenced by walking speed 
[1, 64, 94, 98, 130] and age [80, 90, 226], hence if groups differ for either or both of these 
variables, appropriate adjustments should be made to account for this. Of the reviewed studies, 
15 (58%) described the principal confounder(s) of their research and reported having made 
adjustments to their outcomes to account for these variable(s) [75, 95, 129, 137, 138, 144, 151, 
163, 188, 208, 240, 250, 251, 253, 263]. Of the remaining studies, 4 (15%) provided a 
description of the potential confounders, but did not clearly describe how they were accounted 
for in their analyses [93, 187, 214, 215], while 7 (27%) neither reported nor accounted for their 
potential confounders [12, 67, 150, 152, 205, 213, 261]. In the study by Fazio et al [67], it was 
reported that people with PD had significantly lower accelerations and Jerk scores than ataxic 
patients and healthy controls. However, the age of the patients in the PD group (n=17) ranged 
from 60-85 years, while the ataxic patients (n=24) and controls (n=24) were aged between 20 
and 85 years, with more than 60% of these participants aged less than 60 years. Furthermore, 
the authors reported that the PD and ataxic patients walked significantly slower than the control 
participants. Given the differences in age and walking speed between the cohorts, it is difficult 
to determine whether the reported differences in acceleration profiles were indicative of 
disease-related changes or whether they were simply representative of age-related and/or 
speed-related factors. Identifying all potential confounders in this type of research and 
reporting how they have been accounted for in the analyses is critical to ensuring that any 
changes in outcome can be confidently attributed to the treatment or disease of interest. 
Collectively, the results of the methodological quality assessment identified that issues related 
to internal and external validity and statistical power are typically poorly reported in the 
literature. However, it should be emphasised that this does not suggest that the authors did not 
consider some or all of these factors, but rather suggests that these areas should be given more 
attention in the reporting of future research. To improve the overall methodological quality of 
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research in this area, it is recommended that scientists use existing research reporting guidelines 
(e.g. CONSORT, STROBE) when designing their studies. 
Despite the outlined shortcomings in the reporting of the methods, 81% of the studies 
described differences between different PD groups and/or a healthy control group for one or 
more of their sensor-based measures of standing balance or walking stability [67, 75, 93, 95, 
129, 137, 138, 150-152, 163, 187, 188, 205, 208, 213-215, 240, 250, 251, 253]. However, 
contradictory findings reported in separate studies suggest that some of the reported outcomes 
may be more robust than others. For example, 2 studies that compared PD patients with controls 
using a standing balance assessment reported no significant differences between the groups for 
Jerk scores [93, 144], while 3 others reported significantly greater Jerk scores for PD patients 
[150-152]. Similarly, 2 studies reported no differences between people with PD and controls 
for RMS accelerations [12, 144], while 3 studies reported significantly greater RMS 
accelerations for PD patients [150-152]. Sway velocity was another common measure used to 
evaluate standing balance, but similarly only 3 studies [150, 151, 205] reported differences 
between people with PD and controls, while the remaining 3 did not [75, 144, 152]. It is 
interesting to note, however, that contradictory findings were presented by the 3 studies that 
did report differences between patients and controls for sway velocity, as one study reporting 
reduced values for PD patients while standing with eyes closed [205], while the others reported 
greater values for people with PD while standing with eyes open [150, 151], but not eyes closed 
[151]. While each of the studies that assessed standing balance derived their outcomes from a 
wearable sensor positioned on the trunk [12, 75, 93, 144, 150-152, 205], there were some 
methodological differences that may explain the discrepancies observed between the studies’ 
reported outcomes. The studies that reported no significant differences in Jerk scores, RMS 
accelerations and sway velocities assessed standing balance using a semi-tandem stance test 
[144], the Sensory Organisation Test [12], the Romberg test [75] or an instrumented version of 
 72 
the functional reach test [93]. In contrast, the studies that reported significant differences for 
Jerk, RMS accelerations and sway velocities assessed participants during quiet standing with 
the heels separated by 10 cm [150-152] or while they stood with their feet together or in a semi-
tandem stance with their eyes open and closed [205]. Given the available evidence, it seems 
that the best recommendation for clinicians seeking to assess standing balance using wearable 
sensors would be to calculate RMS accelerations or Jerk scores from trunk accelerations 
collected while patients are standing with their eyes open and their heels 10 cm apart. However, 
a degree of caution may be required when considering this recommendation, as three of the 
four studies that reported differences in standing balance for people with PD appear to have 
used the same patient cohort, as the reported demographics are the same for each study [150-
152]. As such, it is possible that the overall interpretation of the existing literature in this area 
may be biased and the transferability of the findings may be more limited than they appear. 
In addition to the 9 studies that used wearable sensors to assess standing balance, the 
remaining 65% used these devices to assess walking stability. These studies reported numerous 
outcome measures derived from the acceleration signals, but the Harmonic Ratio (HR) was the 
most commonly-reported measure and was calculated for the head [129] and lumbosacral 
region [95, 129, 137, 138, 187, 213, 250, 251]. The HR seems to be a sensitive and versatile 
measure of walking stability, as the reviewed literature reports differences between people with 
PD and controls [129, 138, 187, 213], PD freezers and non-freezers [250], PD fallers and non-
fallers [129, 251], PD patients with different dominant symptoms [95] and different methods 
of cueing for people with PD [137]. Stride timing variability was the second most common 
outcome measure for the studies that assessed walking stability, but careful review of the 
included studies suggested that it may not be a dependable measure for discriminating between 
different populations. Of the 7 studies that reported this outcome, 3 studies described 
differences in stride timing variability between PD fallers and non-fallers [129], PD patients 
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and controls [129, 253] or carriers and non-carriers of the Leucine-Rich Repeat Kinase 2 gene 
mutation [163]. In contrast, 4 studies reported no differences between PD patients and controls 
[138, 240, 263] or patients with different sub-types of PD [95]. A common characteristic of 
those studies that did report differences for the HR and stride timing variability was that they 
each assessed walking stability during straight line walking. As such, it is recommended that 
clinicians who wish to assess walking stability using wearable sensors calculate the HR from 
trunk accelerations collected while patients are walking in a straight line at a self-selected 
speed. While there is some evidence to support the use of stride timing variability to assess 
walking stability, it would be recommended as a secondary measure due to the inconsistencies 
evident within the current literature. 
While it was not the primary focus of this review to evaluate the effects of anti-
parkinsonian medications, such as levodopa, on measures of standing balance and walking 
stability, it is an important factor that warrants consideration. It is widely recognised that 
levodopa improves symptoms of PD (based on the UPDRS) [75, 95], spatiotemporal gait 
characteristics (e.g. stride length) [185, 210] and performance on clinical tests of balance, such 
as the Berg Balance scale [184]. Of the studies included in this review, 5 (19%) reported 
assessing standing balance or walking stability while patients were not medicated [12, 144, 
187, 188, 205], 9 (35%) assessed patients on-medication [67, 129, 137, 138, 163, 213, 214, 
250, 251] and 3 (12%) assessed patients in both on and off states [75, 95, 253]. Of the remaining 
studies, 6 (22%) assessed patients who were not yet being medicated for PD [150-152, 208, 
240, 263], while 3 (12%) did not report whether their participants were on or off medication at 
the time of testing [93, 215, 261]. Interestingly, of those studies that did not report differences 
in standing balance or walking stability between different groups of PD patients and/or healthy 
controls, 2 assessed patients while they were off medication [12, 144], while the other did not 
report whether patients were assessed on or off medication [261]. Of the three studies that 
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assessed patients on and off medication, only two statistically compared their presented 
outcomes for the two conditions [75, 253]. For a group of idiopathic PD patients, it was 
reported that the length and maximal distance of postural sway was significantly increased 
during normal stance when patients were assessed on medication [75], which would typically 
be interpreted as a greater amount of sway during the medicated state. During walking, Weiss 
et al. [253] reported a significant reduction in the width of the dominant harmonic in the 
acceleration signal when patients were tested on medication, which represented less variability 
in the gait patterns of medicated patients. While there is a clear need for further research in this 
area, the presented findings suggest that wearable sensors can be effectively used to evaluate 
changes in standing balance and walking stability for different patients who are assessed with 
or without anti-parkinsonian medication. 
Considering that 66% of individuals with PD fall at least once in a given year [43, 259] 
and that nearly 50% of these falls occur during locomotion [7, 17], assessing walking stability 
and falls risk is critical to ensure that high-risk patients can be easily identified by clinicians. 
However, to date, there is a paucity of research evaluating the capacity for wearable sensors to 
identify people with PD who are at a higher risk of prospectively falling. Two of the studies 
included in this review compared people with PD who retrospectively reported having no falls 
(non-fallers) to those who reported falling at least once (fallers) in the previous 12 months [129, 
251]. Both of these studies reported that PD fallers had less symmetrical movements for the 
pelvis or lower trunk (as assessed using the HR) in both the anterior-posterior (forward-
backward) and vertical directions compared with PD non-fallers [129, 251] and controls [129]. 
While their retrospective nature makes it difficult to determine whether these deficits were 
contributory to the patients falling or whether they are perhaps a consequence of an increased 
fear of future falls, the results of these studies provide some support for the use of wearable 
sensors for screening patients for falls risk. Nevertheless, further prospective research is needed 
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to confirm whether sensor-based measures of standing balance or walking stability are suitable 
for the assessing falls risk and predicting future falls in this population. 
As with any review of this nature, there are a number of limitations that should be 
considered when reviewing this research. Firstly, the results of the methodological quality 
assessment included in this systematic review are based on the assessor’s (RPH) interpretation 
of each of the studies. The results reflect the quality of the reporting of the research and, hence, 
should not be seen as a critique of the significance of the research and its outcomes. Secondly, 
given the relatively small number of studies that have been published in this area and the wide 
variety of research questions addressed using wearable sensors, it is difficult to make strong 
recommendations regarding the most appropriate equipment, placements and outcomes for 
assessing standing balance and walking stability in people with PD.  For example, there may 
be other anatomical sites for sensor placement that offer superior sensitivity to those identified 
in this review. Furthermore, other more complex measures of stability, such as the Lyapunov 
exponent, may be more appropriate for assessing stability than those outcomes that have 
traditionally been used in Parkinson’s disease research.  While the maximum Lyapunov 
exponent has not been used to assess walking stability in people with PD, it has been used to 
examine healthy younger and older adults and is known to have excellent construct validity 
[27]. In light of these limitations, the results presented in this systematic review should be 
considered preliminary and additional work will be required as this field of science continues 
to evolve 
In conclusion, wearable sensors provide a light-weight, portable and affordable 
alternative to more expensive three-dimensional motion analysis systems and are effective for 
detecting changes in standing balance and walking stability in people with PD. However, it 
appears that some outcome measures may be more useful than others for discriminating patient 
cohorts from controls. Specifically, measures of Jerk and RMS acceleration for the trunk seem 
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to be the best sensor-based measures of standing balance, even under less challenging 
conditions (i.e. feet apart on a firm surface with eyes open). For assessments of walking 
stability, a trunk-mounted wearable sensor can be used to assess the symmetry of dynamic gait 
patterns using the HR calculated for the three axes of motion. While some studies have 
provided support for other more complex frequency-based measures of postural stability, 
additional research is essential to objectively assess the utility of these measures for the PD 
population. Future research should give careful consideration to the internal and external 
validity of their methods and provide an appropriate sample size calculation to support their 
study, as these aspects have typically been poorly reported in the existing literature. 
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6.0 General Methods for the Experimental Studies 
The results of the systematic review (Study 1) answered a number of questions that 
were considered pertinent to the design of the subsequent experimental studies (i.e. Studies 2 
to 4). Specifically, it was established that accelerometers placed on the axial skeleton, 
specifically the head and/or trunk, have been the most commonly used wearable sensor for 
assessing aspects of static and dynamic postural stability in people with PD. Furthermore, 
measures of Jerk and RMS acceleration derived from trunk-based accelerometers seem to be 
the best sensor-based measures of standing balance, while the rhythmicity (or symmetry) of 
head and/or trunk accelerations are best suited to the assessment of dynamic tasks. The 
following section, which outlines the general methods of the experimental studies, was 
developed with the outcomes of the systematic review in mind. It should be noted that this 
chapter only presents the methods that were common across all of the experimental studies, 
while additional detail concerning the specific methods employed for each investigation is 
included in the following chapters. 
 
NOTE: The protocol for the randomised controlled trial portion of this research was published 
in the following peer-reviewed manuscript:  
 
Hubble, R. P., Naughton, G. A., Silburn, P. A., & Cole, M. H. (2014). Trunk muscle exercises 
as a means of improving postural stability in people with Parkinson's disease: a protocol 
for a randomised controlled trial. BMJ open, 4(12), e006095.  
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6.1 Participant Recruitment 
For the purposes of this research, 683 individuals diagnosed with idiopathic PD, based 
on the UK Brain Bank Criteria [106] were invited to participate via; i) neurology clinics; ii) 
community support groups; and iii) a pre-existing database of individuals who had expressed 
an interest in participating in research. Prospective participants were sent an information letter 
outlining the details of the research and inviting them to contact a member of the research team 
if they were interested in volunteering for the research (Appendix C). Of these patients, 571 
did not respond to the invitation and 19 declined to participate, and initial phone screening 
revealed another 63 patients who did not meet the inclusion criteria. Participants were excluded 
if they: i) were unable to stand and walk independently without the use of a walking aid, ii) had 
uncontrolled hypertension, iii) were taking psychotropic medications, iv) had any significant 
limitations due to osteoporosis, v) had any orthopaedic surgery within the previous year, vi) 
had any serious neck, shoulder or back injuries; including spinal fusions, or vii) had received 
deep brain stimulation surgery to manage their symptoms. 
Following the phone screening process, 30 patients were scheduled for baseline 
assessments at the university. At the baseline assessment, clinical tests used as screening tools 
were performed before laboratory tests were performed. Participants were excluded if they had 
any significant visual (Bailey-Lovie high contrast visual acuity > 0.30 logMAR [9]) or 
cognitive impairment (Addenbrooke’s Cognition Examination Revised (ACE-R) [162] total 
score <82). One additional participant was excluded with an ACE-R score < 82, leaving 29 
individuals eligible for Study 2. 
Following the completion of the baseline assessments (see Section 6.2), participants 
who had reported experiencing at least 1 fall or 2 or more near misses in the previous 12 months 
(n=24) were invited to participate in a 12-week randomised controlled trial, which formed the 
basis of Studies 3 and 4. Of the 24 patients invited to participate in the randomised controlled 
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trial, 22 accepted the invitation and were randomised to one of the two intervention groups. 
For the purpose of this research, a fall was defined as “any coming to the ground or lower level 
not as the result of a major intrinsic event or overwhelming hazard” and a near-miss was 
defined as “an event during which an individual felt that he/she was going to fall but did not 
actually do so” [6]. 
The recruitment and assessment of all participants was completed between February 
2014 and November 2015 and all data collection was conducted at the Brisbane campus of the 
Australian Catholic University. Prior to their involvement in this research, all volunteers were 
asked to provide written informed consent in accordance with the Declaration of Helsinki 
(Appendix D). The experimental procedures for this research were approved by the Australian 
Catholic University Human Research Ethics Committee (Appendix E; approval number 2013-
223Q). The processes of recruitment and data collection are summarised in Figure 5. 
 
6.2 Data Collection 
6.2.1 Cognition and Visual Function Screening 
Those individuals who were deemed eligible to participate based on telephone 
screening and who provided written informed consent were asked to attend a Baseline testing 
session at the Australian Catholic University (Brisbane). During this session, participants were 
screened for any significant deficits in cognitive function and/or visual acuity using the ACE-
R and Bailey-Lovie high contrast visual acuity assessments, respectively. The ACE-R is a 
clinical test that assesses five aspects of cognitive function, including attention and orientation, 
memory, fluency, language and visuospatial ability. The assessment has been shown to have 
excellent reliability [156, 162] and has established validity for assessing and classifying 
dementia [156, 202]. The ACE-R is scored out of a maximum of 100 points, with higher scores 
representing better overall performance and it has been used previously used to assess various 
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aspects of cognition in people with PD [201, 202]. Furthermore, research shows that a cut-off 
score of 82 out of 100 yields a high sensitivity (82%) and specificity (100%) for detecting 
dementia in ageing populations [162]. 
 
Figure 5: Summarises the recruitment, screening and data collection processes of this research. 
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The standardized Bailey-Lovie high contrast visual acuity chart is a common assessment 
of visual function that presents 11 lines, each comprising 5 letters. As the individual being 
assessed progresses downward after reading each line of the chart, the size of letters on each line 
progressively gets smaller and, hence, become more difficult to read [9]. For the purposes of this 
study, participants were positioned 3.0 meters away from the chart wearing any lenses that they 
may have been prescribed to wear for distance vision. Starting on the top line (representing 6/30 
vision), the participants were asked to read each letter aloud before progressing to the next line. 
This process was repeated until the participant was unable to determine the letter presented on 
the chart. The Bailey-Lovie high contrast visual acuity chart has been deemed a reliable and valid 
tool for assessing visual acuity [136] and similar charts are routinely used in standard optometry 
clinics. Participants with significant visual (Bailey-Lovie high contrast visual acuity >0.30 
logMAR) and/or cognitive (ACE score <82) impairment were excluded prior to completing any 
further baseline testing (Table 4).  
 
6.2.2 Clinical Assessments 
Following the assessments of cognitive and visual function, eligible participants were 
asked to provide details of any prescription medications that they routinely consumed to manage 
their parkinsonian symptoms and/or any other medical conditions. Each participant then 
completed a battery of tests that included clinical assessments of; i) symptom severity (the 
UPDRS [71]); ii) disease stage (the modified H&Y stage score [100]; the Schwab & England 
Activities of Daily Living Scale [212]); iii) gait impairment (the PD Gait and Falls Questionnaire 
[77]); iv) balance confidence (the ABC scale [198]); v) mobility (Timed Up and Go [197] test); 
and vi) quality of life (39-item Parkinson’s Disease Questionnaire (PDQ-39) [195]). The UPDRS 
is the most widely used clinical tool for assessing symptom severity in people with PD [71] and 
comprises four distinct parts; each addressing a different aspect of the disease. The first part 
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assesses changes in mentation, behaviour and mood, while the second evaluates the patient’s 
perceived difficulties with completing common activities of daily living. The third section of the 
UPDRS assesses the severity of the patient’s motor symptoms, while the fourth sub-scale 
evaluates the nature and impact of any complications that are commonly related to the therapeutic 
management of the condition [66]. Given this research was concerned with assessing static and 
dynamic postural stability in people with PD, only the motor sub-section of the UPDRS (UPDRS 
III) was completed for each participant. The motor subscale has been shown to have excellent 
internal reliability [223, 224, 241], good test-retest [225] and is capable of strong inter-rater [225] 
reliability and moderate to excellent construct validity based on correlations with multiple 
clinical assessments [28, 77, 183, 223, 224]. 
The Hoehn and Yahr scale is a five point assessment scale used to rate the severity or 
stage of Parkinson’s disease based on the severity and distribution of a patient’s symptoms [100]. 
Although developed over 30 years ago, it has not been formally assessed for reliability, however, 
it is the second most widely used tool (after the UPDRS) to assess disease severity in people with 
PD [82]. Nevertheless, the Hoehn and Yahr scale is considered to be a reliable tool as it is 
moderately correlated with other valid and reliable tests of disease and symptom severity for PD 
[77, 153, 223, 224]. 
Functional independence in daily living is important to individuals with PD. The Schwab 
and England Activities of Daily living scale is used to evaluate a patient’s ability to independently 
and efficiently perform daily tasks. This assessment rates the individual’s overall independence 
on a scale of 0 to 100%, with a score of 100% representing complete independence when 
performing common activities of daily living [212]. Once again, clinometric data are limited for 
this measure; however, it has moderate test-retest reliability [49], adequate inter and intra-rater 
reliability [158] and has is known to be well correlated with other well established and trialled 
assessments of disease severity of PD [153, 223] (Table 4). 
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The PD Gait and Falls Questionnaire comprises 16 questions that assess the severity of 
common symptoms of PD and other Parkinsonian syndromes that affect walking ability and 
promote falls [77]. Each item on this questionnaire is scored on a Likert scale of 0-4, with higher 
scores reflecting a greater perceived impairment due to the described symptoms. The scores of 
six questions included in this questionnaire are summed to provide the Freezing of Gait score, 
which assesses symptoms specifically associated with the inability to initiate and/or continue 
walking (i.e. freezing of gait). The PD Gait and Falls Questionnaire lacks inter and intra rater 
reliability due to the subjective nature of this self-reported measure, However, it has high internal 
consistency and reliability, good test-retest reliability, and is deemed valid as it has been 
correlated with a number of other similar measures of symptom severity (Table 4). It also has 
low to moderate concurrent and predictive validity with a number of clinical tests.  
 
6.2.3 Fear of Falling 
The Activities-specific Balance Confidence scale is a 16-item questionnaire that asks 
participants to rate how confident they are that they will not overbalance or become unsteady 
while performing a number of normal everyday tasks. Balance confidence is self-reported on 
a scale from 0 to 100%, with lower scores representing less confidence and, hence, a greater 
fear of falling while performing the activity. As another self-reported and subjective score, it 
lacks an inter-rater reliability, but internal and test-retest reliability are acceptable (Table 4). 
More recently it has been able to independently predict future recurrent fallers in PD [41]. 
 
6.2.4 Mobility 
A frequently used, inexpensive and convenient assessment of basic movement ability 
is the Timed Up and Go test. It measures the time taken for an individual to rise from a standard 
armchair, walk three meters until both feet cross a line, turn around, and then walk back to the 
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chair and sit back down (Figure 6). For this study, participants were seated in a 42 cm high 
chair with their feet flat on the floor, their back flat against the backrest and their arms resting 
on the armrests, which were situated 20 cm above the seat. Upon the word ‘GO,’ participants 
were required to stand from the chair and walk at a brisk, but comfortable pace to a line on the 
floor three meters away, turn around and return to the chair to sit down. The time taken to 
complete the test was recorded by the assessor using a stopwatch. For all of the experimental 
studies included in this thesis, participants completed five barefoot trials of the Timed Up and 
Go test, which has been shown to have moderate to strong test-retest, intra-rater and inter-rater 
reliability (Table 4). 
 
6.2.5 Quality of Life 
Although there are a number of quality of life inventories, few address the specific 
issues that affect the quality of life for patients with PD. The PDQ-39 is a short PD-specific 
assessment of quality of life comprising 39 questions scored on a 5 point Likert scale. The 
survey includes questions relating to difficulties experienced with mobility, activities of daily 
living, emotional well-being, stigma, social support, cognition, communication, and bodily 
discomfort. It has high internal consistency, moderate to high test-retest reliability, and 
moderate to strong correlations with clinical tests of disease severity (Table 4).  
Figure 6: Diagrammatical representation of the Timed Up and Go test. 
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Table 4: Reliability and validity of the clinometric instruments used for patient evaluation. 
 Reliability Validity 
Test Internal consistency 
median[range] 
Test-Retest 
median[range] 
Inter/Intra-rater 
median[range] 
Internal Construct 
(Convergent/Discriminant) 
Criterion 
(Predictive/Concurrent) 
Balance Confidence      
Activity-
specific 
Balance 
Confidence 
Scale [198] 
α = 0.95 [0.91-0.96]  
[135, 167, 193, 225] 
ICC = 0.79 [0.77-0.94] [49, 
121, 225] 
Inter-rater 
Self-Reported, not 
applicable 
Self-Reported, not 
applicable 
 
Intra-rater 
Not Available 
Not 
Available 
General Construct 
FES-I 
r = -0.68 [167] 
mSAFEE 
r = -0.68 [167] 
CoF 
r = -0.56 [167] 
Gait Speed 
rs = 0.56 [175] 
Posturography 
rs = 0.37-0.61 [175] 
 
Convergent 
Not Available 
 
Discriminant 
Differences in FOF in PD 
vs. Controls 
58% sensitivity, 96% 
specificity [193] 
Differences in FOF in 
HLGDs vs controls 
96% sensitivity, 96% 
specificity [193] 
Differences in FOF in PD vs 
HLGDs 
97% sensitivity, 32% 
specificity [193] 
Reduced falls risk in PD for 
ABC score > 80 
OR = 0.06 [147] 
General Criterion 
Not Available 
 
Predictive 
Future falls 
ROC = 0.82 
69 (93% sensitivity, 67% 
specificity [149] 
 
Concurrent 
ABC-6 
r = 0.96-0.97 [135] 
ABC-5 
r = 0.95 [135] 
Berg Balance Scale 
rs = 0.50 [135] 
FR 
r = 0.184 [135] 
1-Leg Stance 
r = 0.26 [135] 
Tandem Stance 
r = 0.357 [135] 
Timed Up and Go Test 
r = -0.372 [135] 
6MW 
r = 0.458 [135] 
PIGD 
rs = -0.38 [135] 
UPDRS Motor 
rs = -0.22 [135] 
Knee muscle strength 
rs = 0.301 [148] 
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No Reduced falls risk in PD 
with moderate ABC score 
OR = 0.10 [147] 
UPDRS-PG 
rs = -0.661 [148] 
Cognition       
Revised 
Addenbrooke’s 
Cognitive 
Examination 
[162] 
 
α = 0.79 [0.78-0.80] 
[156, 162] 
Not Available Inter-rater 
Not Available 
 
Intra-rater 
Not Available 
Not 
Available 
General Construct 
DSM-IV 
k = 0.59-0.62 [156] 
 
Convergent 
CDR 
rs = -0.321 [162] 
 
Discriminant 
Not Available 
 
General Criterion 
Not Available 
 
Predictive 
Not Available 
 
Concurrent 
CDR 
rs = -0.321 [162] 
DSIM-IV 
ROC = 0.91 [156] 
Visual Function      
Bailey-Lovie 
high contrast 
visual acuity 
[9] 
 
Reliable [136] Not Available Inter-rater 
Not Available 
 
Intra-rater 
Not Available 
Valid 
[136] 
General Construct 
Not Available 
 
Convergent 
Not Available 
 
Discriminant 
Not Available 
General Criterion 
Not Available 
 
Predictive 
Not Available 
 
Concurrent 
Not Available 
Quality of Life      
Parkinson’s 
disease 
questionnaire 
39 [195] 
Total scale 
α = 0.85 [0.84-0.96] 
[26, 50, 111, 140, 141] 
 
Sub-scales: 
Mobility 
α = 0.94 [0.69-0.96] 
[26, 33, 50, 69, 89, 
124, 140-142, 168, 
195] 
 
Activities of Daily 
Living (ADL) 
Total Scale 
ICC = 0.82 [0.79-0.86] 
[121, 140] 
 
Sub-scales: 
Mobility 
ICC =0. 85 [0.74-0.95] [33, 
89, 140-142, 195] 
 
Activities of Daily Living 
(ADL) 
ICC = 0.87 [0.71-0.96] [33, 
89, 140-142, 195] 
 
Inter-Rater 
Total Scale 
ICC = 0.55 [70] 
Sub-scales: 
Mobility 
ICC = 0.66 [70] 
Activities of Daily Living 
ICC = 0.67 [70] 
Emotional Well-Being 
ICC = 0.47 [70] 
Stigma 
ICC = 0.35 [70] 
Social Support 
ICC = 0.40 [70] 
rs = 0.09-
0.70 [153] 
General Construct 
Age at diagnosis 
r = -0.27 [168] 
Disease duration 
r = 0.27 [168] 
 
Convergent 
PDQ-39 Mobility to SF-36 
Physical Functioning 
r = -0.88 [33] 
PDQ-39 ADL to SF-36 Role 
limitations due to physical 
problems 
r = -0.59 [33] 
General Criterion 
Not Available 
 
Predictive 
Not Available 
 
Concurrent 
Not Available 
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α = 0.89[0.85-0.90] 
[26, 33, 50, 69, 89, 
124, 140-142, 168, 
195] 
 
Emotional Well-Being 
α = 0.87 [0.79-0.90] 
[26, 33, 50, 69, 89, 
124, 140-142, 168, 
195] 
 
Stigma 
α = 0.86 [0.78-0.88] 
[26, 33, 50, 69, 89, 
124, 140-142, 168, 
195] 
 
Social Support 
α = 0.69 [0.51-0.87] 
[26, 33, 50, 69, 89, 
124, 140-142, 168, 
195] 
 
Cognition 
α = 0.70 [0.63-087] 
[26, 33, 50, 69, 89, 
124, 140-142, 168, 
195] 
 
Communication 
α = 0.80 [0.74-0.87] 
[26, 33, 50, 69, 89, 
124, 140-142, 168, 
195] 
 
Bodily Discomfort 
α = 0.72[0.59-
0.87][26, 33, 50, 69, 
Emotional Well-Being 
ICC = 0.87 [0.62-0.95] [33, 
89, 140-142, 195] 
 
Stigma 
ICC = 0.86 [0.67-0.90] [33, 
89, 140-142, 195] 
 
Social Support 
ICC = 0.75 [0.56-0.95] [33, 
89, 140-142, 195] 
 
Cognition 
ICC = 0.83 [0.71-0.93] [33, 
89, 140-142, 195] 
 
Communication 
ICC = 0.81 [0.70-0.86] [33, 
89, 140-142, 195] 
 
Bodily Discomfort 
ICC = 0.81 [0.68-0.88] [33, 
89, 140-142, 195] 
Cognition 
ICC = 0.38 [70] 
Communication 
ICC = 0.38 [70] 
Bodily Discomfort 
ICC = 0.56 [70] 
 
Intra-Rater 
Not Available 
PDQ-39 Emotional Well-
Being to SF-36 mental 
health 
r = -0.78 [33] 
PDQ-39 Bodily Discomfort 
to SF-36 Bodily pain 
r = -0.73 [33] 
PDQ-39 Social Support to 
SF-36 Social Functioning 
r = -0.22 [33] 
H&Y 
rs = 0.58 [153] 
SES 
rs = -0.60 [153] 
UPDRS I-III 
rs = 0.49-0.69 [153] 
PDQL 
rs = -0.91 [153] 
 
Discriminant 
PDQ-39 Subscales: 
Mobility to Tremor 
r = 0.21 [33] 
Mobility to Stiffness 
r = 0.54 
Mobility to Slowness 
r = 0.74 [33] 
Mobility to Freezing 
r = 0.64 [33] 
Mobility to Jerking 
r = 0.41 [33] 
  
8
8
 
89, 124, 140-142, 168, 
195] 
 
      Symptom Severity and Disease Stage      
Unified 
Parkinson’s 
Disease Rating 
Scale Part III - 
Motor Sub-
scale [66] 
α = 0.90 [0.88-0.95] 
[223, 224, 241] 
ICC = 0.89 [225] Inter-rater 
ICC = 0.82 [204] 
 
Intra-rater 
Not Available 
Not 
Available 
General Construct 
H&Y 
Eta = 0.58[0.55-0.61][223, 
224] 
Freezing of Gait 
Questionnaire 
r = 0.40 [77] 
PDQ-39 
rs = 0.49-0.69 [153] 
SES 
Eta = 0.65 [223] 
Webster Scale 
rs = 0.94 [183] 
 
Convergent 
Not Available 
 
Discriminant 
Not Available 
General Criterion 
Not Available 
 
Predictive 
Not Available 
 
Concurrent 
H&Y 
rs = 0.75 [241] 
Berg Balance Scale 
rs = -0.69 [28] 
Timed Up and Go Test 
rs = 0.58 [28] 
 
 
Modified 
Hoehn & Yahr 
Scale [110] 
Single score, not 
applicable 
Not Available Inter-rater 
Not Available 
 
Intra-rater 
Not Available 
Not 
Available 
General Construct 
UPDRS III 
Eta = 0.61 [223] 
Eta = 0.55 [224] 
PDQ-39 
rs = 0.58 [153] 
 
Convergent 
Freezing of Gait 
Questionnaire 
r = 0.66 [77] 
 
Discriminant 
Not Available 
General Criterion 
Not Available 
 
Predictive 
Not Available 
 
Concurrent 
UPDRS III 
rs = 0.75 [241] 
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Schwab & 
England 
Activities of 
Daily Living 
Scale [212] 
 
Not Applicable ICC = 0.70 CI 0.43-0.86 
[49] 
Inter-rater 
ICC = 0.60 [158] 
 
Intra-rater 
ICC = 0.65 [158] 
Not 
Available 
General construct 
UPDRS III 
Eta = 0.65 [223] 
PDQ-39 
rs = -0.60 [153] 
 
Convergent 
Not Available 
 
Discriminant 
Not Available 
General Criterion 
Not Available 
 
Predictive 
Not Available 
 
Concurrent 
Not Available 
PD Gait and 
Falls 
Questionnaire 
[77] 
α = 0.90 [0.89-0.96] 
[77, 78] 
ICC = 0.83 [0.83-0.84] 
[78] 
Inter-rater 
Self-Reported not 
applicable 
Intra-rater 
Not Available 
 General Construct 
Not Available 
 
Convergent 
UPDRS I 
r = 0.20 [78] 
UPDRS II 
ON-Phase 
r = 0.40 [78] 
OFF-Phase 
r = 0.34 [78] 
UPDRS III 
ON-Phase 
r = 0.34 [0.28-0.40] [77, 78] 
OFF-Phase 
r = 0.49 [78] 
UPDRS Item: Freezing 
when Walking 
ON-Phase 
r = 0.43 [78] 
OFF-Phase 
r = 0.74 [78] 
UPDRS Item: Walking 
ON-Phase 
r = 0.23 [78] 
OFF-Phase 
r = 0.34 [78] 
UPDRS Item: Depression 
General Criterion 
Not Available 
 
Predictive 
Predict PDQ-39 score 
R2 change = 0.23 [65] 
 
Concurrent 
UPDRS Total: 
r = 0.48 [77] 
UPDRS I 
r = 0.08 [77] 
rs = 0.41 [0.35-0.48] [180, 
230] 
UPDRS II 
r = 0.43 [77] 
rs = 0.66 [180] 
UPDRS III 
r = 0.40 [77] 
rs = 0.59 [180] 
UPDRS Part IV 
rs = 0.62 [180] 
H&Y 
ON-Phase 
r = 0.66 [77] 
rs = 0.46 [180] 
OFF-Phase 
rs = 0.65 [180] 
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r = 0.16 [78] 
UPDRS Item: Intellectual 
Impairment 
r = 0.11 [78] 
UPDRS Item: Tremor 
ON-Phase 
r = 0.07 [78] 
PDQ-39 Subscale 
Mobility 
r = 0.55 [78] 
Activities of Daily Living 
r = 0.33 [78] 
Emotional Well-being 
r = 0.30 [78] 
Bodily Discomfort 
r = 0.28 [78] 
Communication 
r = 0.23 [78] 
Social support 
r = 0.17 [78] 
Stigma 
r = 0.14 [78] 
Cognition 
r = 0.12 [78] 
H&Y 
r = 0.66 [77] 
 
Discriminant 
Not Available 
Phonological verbal 
fluency 
rs = -0.464 [4] 
Frontal assessment battery 
rs = 0.501 [4] 
Timed Up and Go Test 
rs = 0.40 [180] 
PD Duration 
rs = 0.42 [180] 
Fall-Efficacy Scale 
rs = -0.59 [180] 
Age 
rs = 0.05 [180] 
Physical Functioning scale 
of 36-item short-form 
health survey 
rs = -0.48 [180] 
Comfortable/Fast gait 
speed 
rs = -0.32 [180] 
UPDRS Item 13: Falling 
unrelated to freezing 
rs = 0.55 [180] 
UPDRS Item 15: Walking 
rs = 0.56 [180] 
UPDRS Item 29: Gait 
rs = 0.54 [180] 
SES 
rs = -0.048 [230] 
PDQ-39 
r = 0.57 [65] 
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Clinical Mobility      
Timed Up and 
Go [197] 
Not Available ICC = 0.83 [0.69-0.99] 
[28, 49, 102, 173, 225] 
 
 
Inter-rater 
ICC = 0.99 [0.83-0.99] 
[16, 133, 173, 197, 243] 
 
Intra-rater 
ICC = 0.98 [0.93-0.99] 
[16, 133, 197, 243] 
 
 
 General Construct 
Not Available 
 
Convergent 
Not Available 
 
Discriminant 
Not Available 
 
General Criterion 
Not available 
 
Predictive 
Not available 
 
Concurrent 
UPDRS III 
rs = 0.58 [28] 
ABC 
r = -0.37 [135] 
PD Gait and Falls 
rs = 0.40 [180] 
       
α = Cronbach’s alpha , CDR = Clinical Dementia Rating , CGS = Comfortable gait speed, CI = Confidence Interval, CoF = Consequences of Falling scale, DSIM-IV = Diagnostic 
and statistical manual of mental disorders, fourth edition, Eta = Eta correlation coefficient, FES-I = Fall-efficacy Scale International, H&Y = Hoehn and Yahr, ICC = Intraclass 
correlation coefficient, k = kappa score,       OR = Odds ratio, PDQ-39 = 39-item Parkinson’s Disease Questionnaire, PDQL = Parkinson’s Disease Quality of Life Questionnaire, 
PIGD = Postural Instability and Gait Disability, r = Pearson’s correlation coefficient, rs = Spearman’s Rank Correlation Coefficient, ROC = receiver operating characteristics, SES = 
Schwab and England Scale, T = time, UPDRS = Unified Parkinson’s Disease Rating Scale, UPDRS I = UPDRS sub-scale I: Mentation, Behaviour and Mood, UPDRS II = UPDRS 
sub-scale II: Activities of Daily Living, UPDRS III = UPDRS sub-scale III: Motor Examination, UPDRS IV = UPDRS sub-scale IV: Complications of Therapy 
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Of the participants included in this research, 27 out of 29 (93%) were prescribed anti-
parkinsonian medications as a means of managing their symptoms. To ensure that the data 
collected were representative of the real-world setting, all participants were assessed on 
medication, as research has shown that anti-parkinsonian medications, such as Levodopa, can 
improve motor symptoms severity based on the UPDRS motor sub-scale [87, 184, 210] and 
the Hoehn and Yahr stage score [87, 184, 185, 210]. In addition to symptom severity, Levodopa 
has also been shown to improve mobility, by increasing walking speed and step length in 
people with PD [30, 185]. 
 
6.3 Statistical Analysis 
To assess for any significant differences between groups for Studies 2, 3, and 4, 
continuous demographic variables (e.g. age, height, mass) were contrasted using a one-way 
analysis of variance (ANOVA), while the Chi-square tests were used to identify any differences 
in the frequency of categorical data (e.g. gender, Hoehn and Yahr stage score). If the 
assumptions of normal distribution (Shapiro-Wilks test) and/or homogeneity of variance 
(Levene’s test) were violated, the equivalent non-parametric Kruskal-Wallis test was used for 
the continuous measures [244]. The specific statistical analyses used to examine the 
relationship(s) between outcomes and/or changes in the primary outcomes following the 
intervention are described in the subsequent chapters of this thesis. 
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7.0 Study 2: Assessing stability in mild and moderate Parkinson’s disease: Can clinical 
measures provide insight? 
Traditionally, the efficacy of exercise-based interventions seeking to improve postural 
stability and/or reduce falls has been evaluated using a collection of widely-accepted clinical 
assessments. However, research shows that these types of assessments are not well-suited to 
identifying patients at risk of falling [119], which seems to suggest that the somewhat 
subjective nature of these assessments may render them inadequate for objectively appraising 
changes in postural stability following an intervention. As outlined in Study 1, accelerometers 
are becoming widely adopted by clinicians and researchers for the assessment of postural 
stability in people with PD. Accelerometers were primarily placed on the head and trunk and 
the harmonic ratio was the most common measure for detect differences in gait symmetry 
between people with PD and other populations. Using these findings as guidance, Study 2 was 
designed to determine whether accelerometer-based measures of postural stability were related 
to clinical measures of mobility, balance, balance confidence and/or gait difficulty in a cohort 
of PD patients. 
 
NOTE: this chapter presents the findings of the following peer-reviewed manuscript, which 
has been reformatted for the purposes of this dissertation: 
 
Hubble, R. P., Naughton, G. A., Silburn, P. A., & Cole, M. H. (2016). Assessing stability in 
mild and moderate Parkinson’s disease: Can clinical measures provide insight? Gait & 
Posture, 49(1), 7-13. 
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7.1 Abstract 
Background: In the clinic, the mobility of people with Parkinson’s disease (PD) is often 
assessed using timed tests, such as the 6-meter walk and Timed up and Go tests.  Given their 
wide-spread acceptance, these tests have also been used to assess the efficacy of exercise-based 
falls prevention interventions for this population.  However, it is currently unclear whether 
these mobility assessments provide insight into changes in walking; hence research is needed 
to determine their suitability for assessing postural control in PD patients. This cross-sectional 
study aimed to investigate the relationship between accelerometer-derived measures of 
movement rhythmicity and clinical measures of mobility, balance confidence and gait 
difficulty in people with Parkinson’s disease (PD). 
 
Methods: Twenty-nine independently-living PD patients (Hoehn & Yahr stages 1-3) with no 
history of significant injury or orthopaedic/deep brain stimulation surgery were recruited from 
a database of patients who had expressed an interest to participate in research. Participants 
completed clinical assessments of mobility, postural stability, balance confidence and symptom 
severity, while head and trunk symmetry was evaluated during gait using accelerometers. 
Following data collection, patients were stratified based on disease stage into either a Mild 
(Hoehn & Yahr Stage 1) or Moderate (Hoehn & Yahr Stages 2 to 3) PD group.  
 
Results: The results highlighted that the Moderate PD group had poorer quality of life, reduced 
balance confidence and increased gait and falls difficulty. Furthermore, for these patients, gait 
disability and the number of previous falls were both negatively correlated with multiple 
components of head and trunk rhythmicity. For the Mild PD group, six-meter walk time was 
positively correlated with ML head rhythmicity and linear regression highlighted a significant 
predictive relationship between these outcomes. For the Mild and Moderate PD groups, balance 
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confidence respectively predicted anterior-posterior trunk rhythmicity and vertical head 
rhythmicity.  
 
Conclusion: While these findings demonstrate that falls history and the Gait and Falls 
questionnaire provide moderate insight into head and trunk symmetry in Moderate PD patients, 
objective and clinically-feasible measures of postural instability would assist with the 
management of these symptoms. 
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7.2 Introduction 
Postural instability is one of the most disabling symptoms of Parkinson’s disease (PD) 
and significantly increases the risk of falling [248]. The costs of falls and falls-related injuries 
are not well established for many countries [247], but Australian estimates indicate that 
approximately AUD$27.5 million was spent on injuries associated with falls and falls-related 
injuries in 2010 [189]. Given the significant physical and financial burden associated with falls 
in PD, a clear need exists to develop an improved capacity to assess symptoms of postural 
instability to assist with early identification and treatment. For people with PD, symptoms of 
postural instability are often accompanied by a decline in the patient’s mobility [225]. 
Traditionally, clinical tests like the Timed up and Go [249] and 10-meter [225] (or 6-meter 
[21]) walk tests have been used to assess changes in mobility for a range of healthy [21]  and 
pathological [225] populations. Given the ease with which the clinical tests can be administered 
and their widespread use in hospitals and other clinical settings, it is not surprising that such 
tests are often used to assess the efficacy of exercise interventions aimed at improving mobility 
and/or preventing falls in people with PD [61]. Despite their widespread use for the assessment 
of people with PD [264], research suggests that some of these clinical tests are not always able 
to identify differences in mobility between people with PD and age-matched controls [207, 
252]. Therefore, while the Timed Up and Go and 6-meter walk tests are widely acceptable as 
clinical tests of mobility, a need exists for further investigations to determine whether such 
clinical tests have the capacity to identify changes in postural stability in people with PD. 
The improved availability and affordability of wearable sensors have now made it 
feasible to develop and/or enhance clinical assessments to incorporate more objective measures 
of walking stability. For example, the objectivity of the assessment can be significantly 
improved by placing a wearable sensor on a patient’s body during the performance of the 
Timed Up and Go test [252]. Specifically, research using this adaptation of the Timed Up and 
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Go test has reported differences in the amplitude, symmetry, and smoothness of segmental 
motion (as measured using RMS accelerations, harmonic ratios and jerk, respectively) for 
people with PD compared with age-matched controls [187]. Of the numerous accelerometer-
based outcomes reported in the literature, the harmonic ratio (HR) is the most commonly 
reported for people with PD [104] and provides a measure of gait symmetry by assessing the 
ratio of in-phase accelerations to out-of-phase accelerations within a given gait cycle [164]. 
Additionally, the HR has the capacity to discriminate PD patients with a history of falling from 
patients who have not previously fallen [129]. Despite its frequent use in the research setting, 
more traditional tests of mobility continue to be used in daily clinical practices. As such, this 
study aimed to determine whether the results of common clinical tests of mobility, balance 
confidence and gait difficulty correlate with laboratory-based measures of postural stability to 
determine whether these assessments offer insight into deficits in postural stability for people 
with PD. It was hypothesised that clinical measures of mobility, gait difficulty, postural 
stability, and balance confidence would not be related to movement symmetry and, therefore, 
offer limited insight into dynamic postural stability. 
 
7.3 Methods 
7.3.1 Participants 
Thirty participants diagnosed with idiopathic PD, based on the UK Brain Bank Criteria 
were recruited and screened for eligibility via the methods outlined in Section 6.1. Following 
the assessment of cognitive function, it was determined that one of the participants achieved a 
score of 68 out of 100 on the revised Addenbrooke’s Cognitive Examination. Given that scores 
of less than 82 are predictive of cognitive impairment [162], this participant was not required 
to complete the remaining assessments and was excluded from the experiment. Of the 
remaining 29 patients (Table 5), 5 reported no history of falls or near misses within the previous 
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12 months, while 24 reported experiencing at least one falls and/or two or more near misses in 
past year.  For the purposes of this study, a fall was defined as “any coming to the ground or 
other lower level not as the result of a major intrinsic event or overwhelming hazard” [6]. 
Similarly, a near miss was defined as “an event on which an individual felt that they were going 
to fall but did not actually do so” [6]. Experimental procedures were approved by the 
University’s Human Research Ethics Committee and all volunteers provided written informed 
consent to participate (Appendix D). An a-priori sample size calculation based on a p-value of 
0.05, a power of 80% and a large effect size (ρ=0.6) indicated that at least 13 participants were 
required per group to examine the relationships between the clinical tests and harmonic ratios. 
 
7.3.2 Clinical Assessments 
Individuals attending a single testing session during which they completed the battery 
of clinical tests outlined in Section 6.2, which included assessments of vision, cognition, 
disease stage and symptom severity (UPDRS III, H&Y stage score, Schwab and England 
Activities of Daily Living Scale; PD Gait and Falls Questionnaire); balance confidence (the 
ABC scale); and quality of life (PDQ-39). Using the data collected during the assessment of 
motor symptoms, a clinical measure of postural instability and gait disability was calculated 
for each participant by summing the scores for items 27 to 30 from the UPDRS III [181]. In 
addition to these clinical questionnaires, participants were also asked to perform 5 trials of the 
Timed Up and Go test while being timed by the experimenter. The preparation and procedures 
implemented for the Timed Up and Go test are outlined in Section 6.2.4 and illustrated 
diagrammatically in Figure 6.  
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Table 5: Demographics and results for the assessments of mobility, balance confidence, quality of life and symptom severity for the Mild and Moderate PD groups. 
 
All PD 
(n = 29) 
Mild PD 
(n = 13) 
Moderate PD  
(n = 16) 
Test p-value 
Demographics      
Male 21 (72.4%) 8 (61.5%) 13 (81.3%) 3 0.238 
Age (years) 64.7 ± 6.4 62.8 ± 7.1 66.3 ± 5.4 1 0.147 
Height (cm) 171.7 ± 8.0 170.6 ± 8.9 172.6 ± 7.3 1 0.504 
Mass (kg) 80.4 ± 20.1 78.8 ± 20.2 81.7 ± 20.7 1 0.709 
Body Mass Index (kg/m2) 27.0 ± 5.3 26.8 ± 5.1 27.2 ± 5.6 1 0.853 
      Cognition and Vision      
Addenbrooke’s Cognitive Exam 91.7 ± 6.1 92.5 ± 5.2 91.1 ± 6.8 1 0.527 
High Contrast Visual Acuity (LogMAR) 0.0 ± 0.1 0.0 ± 0.1 0.0 ± 0.1 2 0.475 
      
Balance Confidence and Quality of Life      
Previous Fallers 23 (79.3%) 11 (84.6%) 12 (75.0%) 3 0.525 
Previous Falls 1.4 ± 2.0 1.2 ± 1.5 1.6 ± 2.4 2 0.846 
Activities-specific Balance Confidence (%) 77.8 ± 24.8 93.2 ± 6.6 65.4 ± 27.4 2 <0.001 
39-Item Parkinson’s Disease Questionnaire 23.5 ± 15.3 14.9 ± 6.9 30.4 ± 16.9 2 0.001 
      
Mobility      
Timed Up and Go Total Time (s) 9.4 ± 1.5 9.0 ± 1.2 9.8 ± 1.7 1 0.202 
6-Meter Walk Test (s) 4.7 ± 0.6 4.8 ± 0.5 4.7 ± 0.7 1 0.647 
      Neurological Examination      
Disease Duration (years) 6.7 ± 5.3 4.9 ± 1.1 8.1 ± 6.8 2 0.288 
Unified Parkinson’s Disease Rating Scale (Part III) 14.4 ± 11.5 9.1 ± 2.3 18.8 ± 14.1 2 0.004 
Hoehn & Yahr Stage Score  1.7 ± 0.7 1.0 ± 0.0 2.2 ± 0.4 2 <0.001 
Schwab & England Activities of Daily Living Scale 86.6 ± 7.5 90.0 ± 4.1 83.8 ± 8.5 2 0.056 
Freezing of Gait Score 4.9 ± 5.2 2.7 ± 2.9 6.7 ± 6.0 2 0.040 
Postural Instability and Gait Disorder Score 1.9 ± 1.6 0.8 ± 1.0 2.7 ± 1.6 2 0.002 
Retropulsion Test 0.5 ± 0.7 0.2 ± 0.4 0.8 ± 0.9 2 0.083 
Levodopa (mg/day) 618.3 ± 432.1 545.2 ± 350.7 677.8 ± 491.7 1 0.421 
Dopamine Agonists 6 (20.7%) 2 (15.4%) 4 (25.0%) 3 0.468 
Catechol-O-Methyl Transferase Inhibitors 9 (31.0%) 4 (30.8%) 5 (31.3%) 3 0.885 
Monoamine Oxidase Inhibitors 10 (34.5%) 3 (23.1%) 7 (43.8%) 3 0.194 
Benzodiazepine  1 (3.4%) 1 (7.7%) 0 (0.0%) 3 0.274 
Note: Test 1 = One-way analysis of variance; Test 2 = Mann-Whitney U test; Test 3 = Chi-square test 
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7.3.3 Objective Gait Assessment 
Following the completion of the clinical assessments, the 29 participants completed 
four gait trials along a 10-meter walkway at a comfortable and self-selected pace. Participants 
were given a minimum of 30 seconds rest between trials to minimise the risk of fatigue. During 
this task, gait speed was measured with the Speedlight timing system (SWIFT Performance 
Equipment, Alstonville, Australia), which comprised two pairs of gates that were positioned 6 
meters apart (Figure 7). Gait speed has been shown to influence accelerometer-based measures, 
like the harmonic ratio [130], therefore, gait speed was collected to facilitate adjustments for  
Figure 7: Set-up of walkway for assessment of gait 
 
gait speed. Two microelectromechanical three-dimensional accelerometers sampling as a rate 
of 500 Hz (Noraxon Inc., Scottsdale, AZ) were used to assess gait symmetry. Prior to 
commencing data collection the two accelerometers were statically calibrated using methods 
that have been described previously [165]. Specifically, the calibration procedure involved 
aligning each sensing axis of the accelerometers perpendicular to a horizontal surface to 
determine a conversion factor describing the magnitude of gravitational acceleration (1 
gravitational unit or 1g). Accelerometers have been shown to have moderate to excellent 
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concurrent [34, 44, 92, 260] and construct validity [53] and moderate to excellent test-retest 
reliability [34, 81, 123] when placed on the trunk to assess gait in younger [44, 81, 260] and 
older adults [34, 44, 53, 81, 92], as well as people with knee osteoarthritis [123] and 
Parkinson’s disease [53]. 
Following static calibration, an accelerometer was firmly attached over the occipital 
protuberance of the skull via a sport headband, while another was attached directly to the skin 
over the spinous process of the 10th thoracic vertebra (T10) using double-sided tape and 
Micropore (Figure 8). It is well understood that movement of the soft-tissue beneath an 
accelerometer can contribute to the introduction of accelerations that are not specifically related 
to the movement of interest [155]. As both the occipital protuberance and the spinous processes 
are typically not masked by thick layers of soft tissue, these sites were considered optimal for 
minimising the risk of introducing this error. Furthermore, the results of Study 1 provided 
support for these placements for accelerometer-based assessments of postural stability [104].  
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Positioning of the head and trunk accelerometers 
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7.3.4 Data Analysis 
Following data collection, raw accelerations were transformed to a horizontal-vertical 
orthogonal coordinate system [164]. Transformation of the data was necessary because 
accelerometers measurements occur relative to a local rather than global coordinate system. The 
sensor may deviate from the horizontal plane due to inaccurate placement or curvature of the 
spine or the bony landmark to which it is attached. This tilt in the sensor not only detects the 
dynamic movement acceleration, but also registers the effects of gravity, which must be corrected 
for in acquiring a true estimate of the movement accelerations [164]. After transforming the data 
to a horizontal-vertical orthogonal coordinate system (Figure 9A), accelerations were low-pass 
filtered using a bi-directional fourth order Butterworth filter, with a cut-off frequency of 30 Hz 
as used in previous research [116, 117]. Given that 99% of accelerations during walking occur 
below 15 Hz [155], a cut-off frequency of 30 Hz was considered adequate to capture walking 
related activity and limit higher frequencies not related to movement. Filtered and transformed 
accelerations for the anterior-posterior, medial-lateral, and vertical axes were then used to derive 
the accelerometer-based outcomes for the head and trunk segments, separately. Specifically, the 
accelerometer-based measures included: i) the harmonic ratio and ii) root mean square (RMS) 
accelerations, both of which were shown to be suitable for assessing postural stability during 
dynamic tasks in Study 1 [104]. 
 
 
 
 
 
 
 
Figure 9: Example of the A) vertical trunk acceleration; and B) first 20 harmonics of the signal.  
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In order to calculate the harmonic ratio, the time-series data were divided into 
individual gait cycles by identifying the positive peaks in the vertical trunk accelerations, which 
coincided with heel contact [129, 137, 138, 160]. Using a custom Matlab program (version 
R2015), anterior-posterior, medial-lateral and vertical harmonic ratios were calculated for four 
consecutive gait cycles identified within the central portion of each walking trial. To facilitate 
this, the transformed anterior-posterior, medial-lateral and vertical accelerations were 
converted from the time domain to the frequency domain using a Finite Fourier 
Transformation. Following this transformation, the harmonics of the fundamental frequencies 
of the signals are plotted to show the in-phase (or even) harmonics and the out-of-phase (or 
odd) harmonics (Figure 9B).  
As the harmonic ratio is calculated over the course of a gait cycle, two subsequent heel 
strikes with the same foot (e.g. right foot) are separated by an inter-mediate step with the alternate 
foot (e.g. left foot). Given each gait cycle includes two steps, the harmonics of the anterior-
posterior and vertical accelerations occur in multiples of two, which would normally contribute 
to much higher values for the even harmonics in healthy gait. Given this point, calculation of the 
anterior-posterior and vertical harmonic ratios involves dividing the sum of the first 10 even 
harmonics by the sum of the first 10 odd harmonics [160]. This yields a ratio of the in-phase to 
out-of-phase harmonics and provides insight into the degree of symmetry within the three-
dimensional head and trunk acceleration profiles. Given the nature of this calculation, larger 
numbers  are representative of more symmetrical movements, while lower numbers indicate less 
symmetrical movements [13]. In contrast to anterior-posterior and vertical accelerations, medial-
lateral accelerations during a gait cycle are characterised by a change in direction approximately 
mid-stride, as the body’s weight is shifted from the left to right foot (or vice versa). As such, the 
odd harmonics represent the in-phase accelerations and are generally of higher amplitude than 
the even harmonics for the medial-lateral accelerations of healthy walking. To derive the ML 
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harmonic ratio, it was necessary to divide the sum of the first 10 odd harmonics by the sum of 
the first 10 even harmonics within the chosen stride [160].  
 
𝑅𝑀𝑆 𝐴𝑐𝑐𝑒𝑙𝑒𝑟𝑎𝑡𝑖𝑜𝑛𝑗 =  
√
∑ 𝑎𝑐𝑐𝑒𝑙𝑒𝑟𝑎𝑡𝑖𝑜𝑛𝑖𝑛𝑑𝑒𝑥(𝑖)
2𝑗+𝑤
𝑖=𝑗−𝑤
2𝑤 + 1
 
Where: j = the output index 
  w = the window size 
  index(i) = i if first_index ≤ i ≤ last_index 
  index(i) = first_index if i < first_index 
  index(i) = last_index if i > first_index 
Equation 1 
 
In addition to the harmonic ratio, root mean square (RMS) accelerations were also calculated 
as a secondary outcome measure for the head and the trunk (Equation 1). The results of Study 
1 indicated that there was a need for further research to determine the utility of RMS 
accelerations for the assessment of postural stability in people with PD [104]. 
 
7.3.5 Statistical Analysis 
Data were sub-divided based on each patient’s H&Y stage score. Patients with mild 
symptoms affecting one side of the body only (H&Y Stage 1) were combined to form a Mild 
PD group, while data for patients presenting with Mild (H&Y Stage 2) to Moderate (H&Y 
Stage 3) bilateral symptoms were combined to form a Moderate PD group. The outcome 
measures for each group were assessed for normality and homogeneity of variance and the 
groups were statistically contrasted using the procedures outlined in Section 6.3. 
Bivariate correlations were used to establish the degree of association between the 
clinical tests of mobility and stability and the laboratory-based measures of gait symmetry. To 
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determine the appropriateness of the parametric Pearson’s correlation coefficient, the normality 
of the continuous measures was assessed using the Shapiro-Wilk test and where a p-value of 
less than 0.05 was returned, the non-parametric Spearman’s Rho test was used. Linear 
regression analyses examined whether clinical measures of mobility, postural stability, balance 
confidence and gait difficulty were capable of explaining a significant proportion of the 
variance in head and trunk rhythmicity during walking. Statistical analyses were performed in 
Statistical Package for the Social Sciences (SPSS v.22, New York, USA) and the level of 
statistical significance was set at p<0.05. 
 
7.4 Results 
In accordance with the strict inclusion and exclusion criteria adhered to throughout the 
participant recruitment phase, all participants were free of any significant medical conditions 
(other than PD) that may have influence their balance and/or gait and presented with no 
significant physical, psychological or visual disabilities at the time of testing. Based on the 
neurological assessment, the 29 patients included in this study had mild to moderate symptoms 
of PD, were independently living and most (90%) were taking anti-parkinsonian medication. 
Patients comprising the Moderate PD group were shown to have more severe motor symptoms 
(p=0.004) and reported poorer balance confidence (p<0.001), poorer quality of life (p<0.001), 
a greater incidence of freezing of gait (p=0.040) and increased postural instability and gait 
difficulty (p=0.002) compared with the Mild PD group (Table 5). 
 
7.4.1 Correlation Analyses 
Tests of normality indicated a number of the continuous outcome measures were not 
normally distributed; hence the non-parametric Spearman’s Rho test was used to assess the 
relationships between the clinical tests and the accelerometer-based measures of gait symmetry 
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(Table 6). For the whole PD sample, previous falls were positively correlated with the gait and 
falls questionnaire (ρ=0.508, p=0.005) and negatively correlated with the 6-meter walk time 
(ρ=-0.466, p=0.011), as well as all harmonic ratios for the head (ρ=-0.448 to -0.513, p≤0.02) 
and trunk (ρ=-0.437 to -0.623, p≤0.02). The sub-group analyses indicated these relationships 
were further strengthened for the Moderate PD patients, when patients with milder symptoms 
were considered separately. Specifically, the bivariate correlations revealed that previous falls 
were moderately and positively correlated with gait and falls difficulty (ρ=0.600, p=0.014) and 
moderately and negatively correlated with 6-meter walk time (ρ=-0.531, p=0.034) in addition 
to all head (ρ=-0.537 to -0.693, p≤0.05) and most trunk (ρ=-0.595 to -0.766, p≤0.015) harmonic 
ratios. In contrast, the number of previous falls was moderately and positively correlated with 
balance confidence (ρ=0.555, p=0.049) and moderately and negatively correlated with AP 
trunk rhythmicity (ρ=-0.611, p=0.027) for the Mild PD patients.  
Analysis of the two mobility assessments demonstrated that the 6-meter walk time was 
negatively correlated with gait speed (ρ=-1.000, p<0.001) and positively correlated with the 
Timed Up and Go total time (ρ=0.519, p=0.004) and medial-lateral head HR (ρ=0.416, 
p=0.025). The sub-group analyses showed that the 6-meter walk time was moderately and 
positively correlated with Timed Up and Go total time (ρ=0.624, p=0.010) for the Moderate 
PD group, while ML head rhythmicity was moderately and positively correlated with the 6-
meter walk time (ρ=0.573, p=0.041) for the Mild PD group. For the whole PD cohort, the 
Timed Up and Go total time was negatively correlated with gait speed (ρ=-0.519, p=0.004) and 
balance confidence (ρ=-0.565, p=0.001), but the sub-group analyses revealed that these 
relationships only remained significant for the Moderate PD group (gait speed: ρ=-0.624, 
p=0.010; ABC: ρ=-0.708, p=0.002).  
Similar to clinical tests of mobility, the retropulsion test was negatively correlated with 
balance confidence (ρ=-0.595, p=0.001) and positively associated with the Gait and Falls 
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questionnaire (ρ=0.434, p=0.019). Additionally, the Gait and Falls questionnaire was 
moderately and negatively correlated with balance confidence (ρ=-0.555, p=0.002) and AP 
trunk movement symmetry (ρ=-0.425, p=0.022). The sub-group analyses indicated that the 
retropulsion test was moderately and negatively correlated with balance confidence (ρ=-0.652, 
p=0.006) and AP head movement symmetry (ρ=-0.499, p=0.049) for the Moderate PD group. 
Furthermore, for the Moderate PD group, the gait and falls questionnaire was moderately and 
negatively correlated with balance confidence (ρ=-0.521, p=0.038) and most head (ρ=-0.526 
to -0.538, p<0.05) and all trunk (ρ=-0.510 to -0.642, p<0.05) HRs. No other relationships were 
observed between the questionnaires and the objective measures of walking stability (Table 6). 
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Table 6: Correlation between the harmonic ratios and clinical assessments of balance and mobility for the entire PD cohort and the Mild and Moderate sub-groups 
   All PD  Mild PD Moderate PD 
   
Spearman’s 
Rho 
p-value 
 Spearman’s 
Rho 
p-value 
Spearman’s 
Rho 
p-value 
Retrospective Falls 6-Meter Walk Time  -0.466 0.011*  -0.344 0.250 -0.531 0.034* 
 Timed Up and Go Total Time  -0.169 0.381  -0.194 0.526 -0.193 0.474 
 Retropulsion Test  0.008 0.965  0.077 0.802 0.055 0.839 
 Gait & Falls Questionnaire  0.508 0.005*  0.274 0.365 0.600 0.014* 
 Activities-Specific Balance Confidence Scale  0.039 0.839  0.555 0.049* 0.038 0.889 
  AP -0.465 0.011*  -0.521 0.068 -0.537 0.032* 
 Harmonic Ratio (Head) ML -0.448 0.015*  -0.320 0.286 -0.579 0.019* 
  VT -0.513 0.004*  -0.436 0.137 -0.693 0.003* 
  AP -0.524 0.004*  -0.611 0.027* -0.430 0.097 
 Harmonic Ratio (Trunk) ML -0.437 0.018*  -0.272 0.369 -0.595 0.015* 
  VT -0.623 <0.001*  -0.436 0.137 -0.766 0.001* 
          
6-Meter Walk Time Gait Speed  -1.000 <0.001*  -1.000 <0.001
* 
-1.000 <0.001* 
 Timed up and Go Total Time  0.519 0.004*  0.287 0.343 0.624 0.010* 
 Retropulsion Test  0.082 0.672  -0.286 0.344 0.268 0.315 
 Gait & Falls Questionnaire  -0.134 0.487  -0.034 0.913 -0.158 0.560 
 Activities-Specific Balance Confidence Scale  -0.197 0.307  -0.228 0.453 -0.474 0.064 
  AP 0.163 0.397  0.571 0.571 0.174 0.520 
 Harmonic Ratio (Head) ML 0.416 0.025*  0.573 0.041* 0.365 0.165 
  VT 0.035 0.857  0.174 0.571 -0.026 0.922 
  AP 0.020 0.918  0.025 0.936 0.038 0.888 
 Harmonic Ratio (Trunk) ML 0.313 0.099  0.446 0.126 0.194 0.471 
  VT 0.003 0.988  0.209 0.492 -0.091 0.737 
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Timed Up and Go Total Gait Speed  -0.519 0.004*  -0.287 0.343 -0.624 0.010* 
 Retropulsion Test  0.320 0.091  -0.171 0.577 0.413 0.112 
 Gait & Falls Questionnaire  0.352 0.061  0.539 0.058 0.257 0.336 
 Activities-Specific Balance Confidence Scale  -0.565 0.001*  -0.472 0.104 -0.708 0.002* 
  AP 0.358 0.057  0.440 0.133 0.035 0.897 
 Harmonic Ratio (Head) ML 0.326 0.084  0.225 0.459 0.169 0.531 
  VT 0.297 0.118  0.324 0.280 0.107 0.692 
  AP 0.053 0.783  0.280 0.354 -0.187 0.488 
 Harmonic Ratio (Trunk) ML 0.278 0.145  0.473 0.103 -0.075 0.782 
  VT 0.110 0.570  0.110 0.721 -0.097 0.720 
          
Retropulsion Test Gait Speed  -0.082 0.672  0.286 0.344 -0.268 0.315 
 Gait & Falls Questionnaire  0.434 0.019*  0.087 0.777 0.349 0.185 
 Activities-Specific Balance Confidence Scale  -0.595 0.001*  -0.143 0.641 -0.652 0.006* 
  AP -0.297 0.118  -0.285 0.345 -0.499 0.049* 
 Harmonic Ratio (Head) ML -0.143 0.458  -0.513 0.073 -0.422 0.104 
  VT 0.119 0.540  -0.057 0.853 -0.051 0.851 
  AP -0.102 0.597  0.342 0.253 -0.275 0.303 
 Harmonic Ratio (Trunk) ML 0.089 0.645  0.228 0.454 -0.173 0.523 
  VT 0.116 0.550  0.114 0.711 -0.064 0.814 
          
Gait & Falls 
Questionnaire 
Gait Speed  0.134 0.487  0.034 0.913 0.158 0.560 
 Activities-Specific Balance Confidence Scale  -0.555 0.002*  0.007 0.982 -0.521 0.038* 
  AP -0.176 0.360  0.067 0.827 -0.526 0.036* 
 Harmonic Ratio (Head) ML -0.107 0.579  0.079 0.799 -0.538 0.032* 
  VT -0.042 0.828  0.163 0.595 -0.496 0.051 
  AP -0.425 0.022*  -0.115 0.708 -0.642 0.007* 
 Harmonic Ratio (Trunk) ML -0.201 0.296  0.129 0.674 -0.510 0.044* 
  VT -0.267 0.162  0.022 0.942 -0.638 0.008* 
          
  
  
1
1
0
 
Activities-Specific 
Balance 
Gait Speed  0.197 0.307  0.228 0.453 0.474 0.064 
Confidence Scale  AP -0.119 0.540  0.025 0.936 -0.032 0.905 
 Harmonic Ratio (Head) ML -0.256 0.181  0.014 0.964 0.159 0.557 
  VT -0.322 0.088  0.061 0.844 -0.291 0.274 
  AP -0.014 0.944  -0.505 0.078 0.126 0.641 
 Harmonic Ratio (Trunk) ML -0.209 0.277  -0.356 0.233 -0.153 0.572 
  VT -0.158 0.414  0.168 0.583 -0.112 0.680 
AP = Anterior-posterior, ML = Medial-lateral, VT = Vertical, * = Significant correlation 
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7.4.2 Regression Analysis 
 The linear regression analyses performed for the entire PD cohort indicated that, of all 
of the clinical assessments conducted, the 6MWT and ABC scale were the only tests able to 
predict any component of head or trunk movement symmetry. Specifically, the 6MWT 
predicted medial-lateral head HRs (p=0.041) and the ABC scale predicted vertical head HRs 
(p=0.032). Similar results were found for the regression analyses that was conducted for the 
two sub-groups; with the 6MWT predicting medial-lateral head HRs (p=0.036) for the Mild 
PD group and the Activities-specific Balance Confidence scale predicted anterior-posterior 
trunk HRs (p=0.012) and vertical head HRs (p=0.047) for the Mild and Moderate PD groups, 
respectively (Table 7). 
  
  
1
1
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Table 7: Linear regressions for the harmonic ratios and clinical assessments of balance and mobility for the entire PD cohort and the Mild and Moderate sub-groups 
   All PD Mild PD Moderate PD 
   
Unstandardized 
beta (B) 
Standardised 
Beta (β) 
p-value 
Unstandardized 
beta (B) 
Standardised 
Beta (β) 
p-value 
Unstandardized 
beta (B) 
Standardised 
Beta (β) 
p-value 
Retrospective Falls           
  AP -0.499 -0.179 0.354 -0.668 -0.316 0.293 -0.491 -0.153 0.572 
 Harmonic Ratio (Head) ML -0.478 -0.164 0.395 -0.301 -0.125 0.683 -0.787 -0.236 0.379 
  VT -0.671 -0.271 0.155 -0.469 -0.287 0.342 -1.074 -0.331 0.211 
  AP -0.755 -0.238 0.214 -0.868 -0.352 0.239 -0.671 -0.191 0.479 
 Harmonic Ratio (Trunk) ML -0.437 -0.135 0.486 -0.218 -0.100 0.746 -0.729 -0.181 0.502 
  VT -0.683 -0.321 0.089 -0.506 -0.319 0.288 -0.934 -0.374 0.154 
            
6-Meter Walk Time           
  AP 0.121 0.154 0.424 0.148 0.222 0.465 0.142 0.160 0.553 
 Harmonic Ratio (Head) ML 0.348 0.382 0.041* 0.500 0.585 0.036* 0.423 0.398 0.127 
  VT 0.064 0.086 0.657 0.160 0.299 0.322 -0.003 -0.003 0.993 
  AP 0.036 0.183 0.846 0.030 0.040 0.897 0.040 0.037 0.892 
 Harmonic Ratio (Trunk) ML 0.237 0.238 0.214 0.296 0.404 0.171 0.224 0.180 0.504 
  VT 0.005 0.008 0.966 0.177 0.330 0.270 -0.076 -0.110 0.684 
            
Timed Up and Go Total           
  AP 0.663 0.363 0.053 0.676 0.459 0.115 0.535 0.265 0.321 
 Harmonic Ratio (Head) ML 0.577 0.272 0.153 0.263 0.139 0.651 0.547 0.226 0.400 
  VT 0.516 0.301 0.113 0.255 0.215 0.482 0.664 0.291 0.274 
  AP 0.036 0.016 0.933 0.413 0.246 0.418 -0.256 -0.104 0.701 
 Harmonic Ratio (Trunk) ML 0.713 0.309 0.103 0.817 0.503 0.080 0.423 0.149 0.581 
  VT 0.302 0.214 0.265 0.138 0.116 0.705 0.273 0.174 0.519 
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Retropulsion Test           
   AP -0.243 -0.271 0.155 -0.128 -0.267 0.378 -0.491 -0.483 0.058 
 Harmonic Ratio (Head) ML -0.124 -0.199 0.538 -0.259 -0.419 0.154 -0.402 -0.330 0.212 
  VT 0.085 0.101 0.603 0.028 -0.072 0.815 -0.007 -0.006 0.982 
  AP -0.107 -0.098 0.612 0.153 0.280 0.354 -0.308 -0.249 0.352 
 Harmonic Ratio (Trunk) ML 0.059 0.052 0.790 0.044 0.084 0.785 -0.109 -0.077 0.778 
  VT 0.051 0.074 0.703 0.020 0.053 0.864 -0.069 -0.087 0.748 
            
Gait & Falls Questionnaire           
  AP -3.309 -0.207 0.282 0.238 0.052 0.866 -8.161 -0.449 0.081 
 Harmonic Ratio (Head) ML -2.575 -0.154 0.425 0.765 0.147 0.631 -8.745 -0.465 0.070 
  VT -0.774 -0.055 0.779 0.557 0.158 0.607 -5.408 -0.295 0.268 
  AP -6.204 -0.341 0.071 -0.096 -0.018 0.954 -9.312 -0.469 0.067 
 Harmonic Ratio (Trunk) ML -3.315 -0.178 0.355 0.180 0.038 0.902 -8.699 -0.383 0.143 
  VT -2.140 -0.175 0.363 -0.402 -0.117 0.703 -5.602 -0.397 0.127 
            
Activities-Specific Balance Confidence Scale 
  AP -6.767 -0.199 0.300 -3.088 -0.329 0.272 -3.881 -0.108 0.691 
 Harmonic Ratio (Head) ML -9.947 -0.281 0.140 -4.230 -0.397 0.180 -4.687 -0.126 0.642 
  VT -12.013 -0.399 0.032* -0.922 -0.127 0.679 -18.297 -0.504 0.047
*   AP -6.616 -0.171 0.374 -7.332 -0.669 0.012* -7.555 -0.192 0.475 
 Harmonic Ratio (Trunk) ML -6.457 -0.164 0.395 -4.123 -0.424 0.149 -4.191 -0.093 0.731 
  VT -8.144 -0.315 0.096 -0.745 -0.106 0.731 -8.898 -0.319 0.229 
AP = Anterior-posterior, ML = Medial-lateral, VT = Vertical, * = Significant linear predictor 
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7.5 Discussion 
The purpose of this study was to examine whether common clinical tests of mobility, 
postural stability, balance confidence and gait difficulty were capable of providing insight into 
walking stability in people with PD. Overall, the results indicated that individuals with 
moderate disease severity reported experiencing poorer balance confidence, greater postural 
instability and gait difficulty and poorer quality of life than patients with milder symptoms. 
However, the Moderate and Mild PD groups showed similar results from ANOVA tests for 
between-group differences for the clinically-administered assessments, including the 
retropulsion test, Timed Up and Go and 6MWT. Similar findings were evident for the 
correlation analyses, which indicated that the outcomes of the clinically-administered tests 
were not correlated with the measures of head and trunk movement symmetry. However, 
patients in the Moderate PD group who reported a greater number of previous falls and/or 
greater difficulties with gait and falls did record poorer head and trunk movement symmetry 
than patients with milder symptoms. These findings were similar to previous research showing 
PD fallers with moderate symptoms had poorer head and pelvis rhythmicity during gait than 
patients with milder symptoms who had not previously fallen [129].  
Collectively, these findings suggest that clinical measures of balance, mobility, gait 
difficulty and balance confidence may not provide the most thorough insight into the walking 
rhythmicity of individuals with milder symptoms. However, for patients with more advanced 
symptoms, assessments relying more on a patient’s self-reported difficulties may offer better 
insight into the gait rhythmicity of these patients. These findings appear to have important 
clinical implications and suggest that objectively evaluating patients’ mobility without 
considering their perceived difficulties may inadvertently result in important information 
regarding falls risk being overlooked. Nevertheless, it is widely recognised that self-report 
assessments can be limited by the potential bias associated with patients over- or under-
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reporting their difficulties. Hence more objective tests would greatly benefit the clinical 
assessment of postural stability in people with mild symptom severity of PD.  
The retropulsion test is among the most commonly used clinical assessment of postural 
stability for people with PD and is incorporated into the motor sub-section of the UPDRS [71]. 
Despite widespread use and an apparent capacity to assess a patient’s stability under static 
conditions, a major limitation lies in the inability to discriminate PD fallers from non-fallers 
[251] or single fallers from recurrent fallers in cohorts with and without PD [20]. While the 
findings largely agreed with these studies, it is important to highlight that the retropulsion test 
was significantly correlated with anterior-posterior head rhythmicity in individuals with 
moderate symptom severity. Given the retropulsion test examines a patient’s postural response 
to a firm backward pull on their shoulders, it is perhaps not surprising that individuals scoring 
more poorly on the retropulsion test also demonstrated poorer anterior-posterior head control 
during gait (i.e. lower anterior-posterior head HRs).  
The poor relationship between the retropulsion test and the continuous measures of 
head and trunk symmetry may be explained, at least in part, by a number of factors. First, the 
retropulsion test is somewhat limited by its use of a Likert scale that ranges from zero (normal 
response) to four (unable to stand without assistance). Specifically, for a patient’s score to 
change from a zero to a one for the retropulsion test, he/she must demonstrate a retropulsive 
gait pattern and recover without assistance. Given the marked heterogeneity of PD symptoms, 
it is very likely that some patients will develop difficulties that affect their gait and balance, 
but do not manifest in the form of a retropulsive gait pattern during this test. A second factor 
potentially influencing the applicability of the retropulsion test to dynamic situations could be 
that quiet stance rather than under dynamic conditions is used assesses postural stability. Given 
that only 32% of falls occur during standing [7], it is possible that the retropulsion test may be 
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limited in its capacity to explain the factors contributing to the 66% of falls that occur during 
ambulation and transfer events [7]. 
Another major finding of this study was that the number of previous falls experienced 
by patients in the Mild PD group was significantly and positively correlated with balance 
confidence; suggesting that individuals who fell more had greater balance confidence. This 
finding is in contrast with a growing body of literature that supports the use of the Activities-
specific Balance Confidence scale for assessing balance confidence in people with PD and for 
identifying patients at an increased risk of future recurrent falls [147, 149]. While the 
uncharacteristically high balance confidence reported for individuals in the Mild PD group may 
have been influenced by their higher level of motor functioning (i.e. lower UPDRS III scores) 
and the improved quality of life reported for these patients, it remains unclear what attributes 
of the disease most influence individuals’ perceived risk of falling. As such, a future need exists 
to examine how self-reported balance confidence changes with disease progression and to 
establish what symptoms are most likely to influence a fear of falling. 
As with any study, our results should be considered in the context of a number of 
limitations. First, our sample size, particularly once stratified based on disease severity, may 
be considered quite small from a statistical perspective. While the two groups were at least the 
size of the minimum group size determined in our a-priori sample size calculation, further 
research involving larger cohorts would be warranted. Second, the patients involved in this 
study were typically of mild to moderate disease severity (Hoehn & Yahr stages 1 to 3), hence 
the transferability of our findings may be limited to similar patient cohorts. The potential biases 
in self-reported recall is also acknowledged but were justified within the need to more closely 
examine typical clinical assessments. Longitudinal or cohort studies of changing risks and 
symptoms would better improve the information available from the tests used in this study 
using a cross-sectional design. Third, this study presents the results of a relatively large number 
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of correlations and linear regressions, which may increase the risk of identifying a statistically 
significant relationship where one does not truly exist (i.e. Type 1 error). Nevertheless, all p-
values have been reported within the tables and these should be considered when interpreting 
the clinical meaningfulness of the reported outcomes. Finally, it should be acknowledged that 
there are a number of other stability measures that can be derived from accelerometer data, 
which have not been examined as part of this research. As these alternate measures would not 
be expected to share the same relationships with the clinical measures presented in this study, 
the reported findings should be considered specific to the harmonic ratio. 
Nevertheless, the findings of this study suggest that existing clinical tests of mobility, 
postural stability, balance confidence and gait difficulty typically provide little insight into 
movement symmetry in individuals with mild symptom severity. In contrast, the Gait and Falls 
questionnaire and knowledge of the patient’s falls history may provide additional insight into 
head and trunk symmetry in individuals with moderate symptom severity. However, given that 
these measures rely on accurate patient recall, the development and implementation of 
objective and clinically-feasible measures of postural instability and gait disability would help 
to improve the monitoring and management of postural instability and gait disability in people 
with PD. 
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8.0 Study 3: Exercise improves postural sway in Parkinson disease: A blind phase II 
randomised-controlled trial 
As hypothesized, the results of Study 2 suggested that a large number of common 
clinical assessments of balance, mobility, balance confidence and gait disability may not be 
capable of providing significant insight into changes in postural stability during dynamic tasks. 
Building on these findings, Study 3 adopted a randomised controlled trial design to investigate 
whether a 12-week exercise-based intervention that targeted enhanced mobility and endurance 
of the trunk was effective at improving a patient’s postural stability during static tasks. Given 
the outcomes of Study 2, this study was designed to incorporate both clinical assessments of 
postural stability and more continuous measures of postural control to ensure that any small, 
yet clinically-relevant changes in a patient’s function could be identified.   
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8.1 Abstract 
Background: The trunk is important in maintaining postural stability during static and 
dynamic situations. People with Parkinson’s disease (PD) have reported deficits in trunk 
control that may contribute to poor postural stability in this population. Furthermore, symptoms 
of postural instability are relatively unresponsive to anti-parkinsonian medication and 
neurological surgery. Considering the deficits in control trunk control and its importance in 
maintaining stability, the objective of this study was to investigate the effects of a 12-week 
trunk-specific exercise program on postural sway in people with PD.  
 
Methods: Twenty-four PD patients with a history of falls completed baseline assessments of 
symptom severity, fear of falling, mobility and quality of life. Postural sway was analysed with 
a portable force platform. Following baseline testing, participants were randomised to receive 
either 12-weeks of exercise or education. Baseline tests were repeated 12 and 24-weeks 
following baseline. This trial is listed with the Australian New Zealand Clinical Trials Registry 
(ACTRN12613001175763). 
 
Results: Linear mixed model analyses showed no significant changes in clinical variables. The 
Exercise group reduced postural sway on a foam surface without vision at the 12 and 24-week 
time points (p<0.003) compared with baseline values. The education group saw a significant 
increase in postural sway on the foam surface without vision (p=0.02) and a decrease in sway 
length with vision (p=0.03) at the 12-week follow-up compared with baseline values. The 
exercise group reduced the standard deviation of medial-lateral (p=0.006) and anterior-
posterior (p=0.04) centre of pressure postural sway variability 12-weeks following baseline, 
and the standard deviation of medial-lateral sway variability 24-weeks (p=0.005) post baseline, 
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and the exercise group maintained improvements in the standard deviation of anterior-posterior 
postural sway variability at the 24-week follow-up (p=0.04).  
 
Conclusion: Scores on clinical assessment of symptom severity, balance, mobility and balance 
confidence did not significantly change following the 12-week exercise-based intervention, 
suggesting that they may lack the sensitivity to detect small, but clinically meaningful changes 
in function. In contrast, standard posturography assessment demonstrated that those patients 
who received the 12-week trunk-specific exercise program had significantly less postural sway 
following the intervention when conditions were most challenging (i.e. when vision and 
proprioception were impaired). 
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8.2 Introduction  
While the maintenance of postural stability relies on the effective regulation and 
coordination of all body segments, the combined mass of the head and trunk (approximately 
60% of the body’s mass [257]) highlights the importance of these segments to the maintenance 
of equilibrium. While 33% of adults aged 60 years or over experience a fall in a calendar year 
[1, 125, 134], up to 68% of people with Parkinson’s disease (PD) report as least one fall a year, 
with 50% of fallers reporting recurrent falls [43, 259]. Approximately 66% of falls occur during 
ambulation or transfers, while 32% of falls occur during standing [7]. While there is a growing 
body of research seeking to better understand the mechanism(s) surrounding the falls that occur 
during ambulation and transfer events, the 32% of falls that occur during static or standing 
situations are also a common focus of research in this area. 
Levodopa replacement therapy and stereotactic neurosurgery are two of the most 
common medical treatments for the management of motor symptoms in PD, but symptoms of 
postural instability are known to be largely unresponsive to these treatments [19]. Due to the 
shortcomings of traditional therapies, researchers have sought to determine whether exercise 
or physical therapy may offer benefits to patients who experience these symptoms. In recent 
years, exercise has been shown to have a series of short-term benefits for people with PD, 
including improvements in clinical measures of mobility [2, 128, 139, 236, 237], balance [2, 
128, 139, 236, 237], quality of life [186], cognitive function [174, 186] and symptom severity 
[236, 237]. There have also been a small number of studies that have investigated the efficacy 
of different non-invasive methods for improving balance and reducing falls risk in this high-
risk population [2, 6, 63, 169, 170].  
Despite their significant contribution to this area of research, the majority of these 
studies have relied upon clinical rating scales to assess the efficacy of their interventions, rather 
than more quantitative and continuous measures. Many of these clinical scales adopt Likert 
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scales to assess different aspects of physiological function and, hence, may be limited in their 
capacity to identify small, yet meaningful improvements in a patient’s condition. The possible 
shortcomings of such assessments has been highlighted in prospective falls research, which 
demonstrated that many common clinical assessments are not capable of independently 
predicting future fallers in a PD population. Posturography is a technique that measures 
changes in the centre of pressure to provide insight into an individual’s postural sway. 
Furthermore, research suggests that the outcomes derived from a posturographic analysis may 
be useful for predicting falls in people with PD [119]. Due to the apparent limitation of using 
only clinical assessments to evaluate changes in patient function following an intervention, this 
randomised-controlled trial sought to determine whether outcome measures derived via 
posturography could provide greater insight into the potential benefits of an exercise-based 
intervention. Specifically, it was the aim of this phase II randomised-controlled trial to establish 
whether a 12-week trunk-specific exercise program was more effective than education at 
improving objective measures of postural sway and clinical measures of symptom severity, 
balance, gait difficulty and balance confidence in people with PD. It was hypothesized that the 
patients who received the 12-weeks of exercise would show greater improvements in postural 
sway than the education group immediately following the 12-week intervention. 
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8.3 Methods 
8.3.1 Participants 
This study protocol was developed in accordance with the Consolidated Standards of 
Reporting Trials (CONSORT) guidelines [211]. Of the 29 participants involved in Study 2, the 
24 who had a history of at least 1 fall in the previous 12 months or 2 or more near misses were 
invited to participate in this randomised controlled trial (Table 8). For the purposes of this 
study, a fall was defined as “any coming to the ground or other lower level not as the result of 
a major intrinsic event or overwhelming hazard” [6]. Similarly, a near miss was defined as “an 
event on which an individual felt that they were going to fall but did not actually do so” [6]. 
The processes involved with the recruitment and screening of the participants and the specific 
inclusion and exclusion criteria involved in this research are outlined in Section 6.1.  
On the basis of an a-priori power calculation completed using the maximum excursion 
of the sway path presented in a previous study comparing PD fallers and PD non-fallers [206], 
it was determined that a minimum of 11 participants per group would be required to confidently 
report any significant changes in postural stability during challenging tasks (Cohen’s d = 1.10, 
Power = 80%, p = 0.05). Given the primary outcome measures of this study were based on an 
assessment of the patients’ postural sway patterns via posturography and that the study 
population was comprised of PD fallers, the study was deemed appropriate to determine an 
estimate of sample size. The experimental procedures for this study were approved by the 
Australian Catholic University Human Research Ethics Committee and all volunteers provided 
written informed consent in accordance with the Declaration of Helsinki to participate in the 
study. 
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Table 8: Demographics and scores for the clinical baseline assessments completed by the entire PD cohort and the Exercise and Education sub-groups. 
 All (n = 22) Education (n = 11) Exercise (n = 11)   
 Mean ± SD / N (%) Mean ± SD / N (%) Mean ± SD / N (%) Test Sig. (p) 
Demographics      
Gender (Male) 15 (68.2%) 8 (72.7%) 7 (63.6%) 3 0.65 
Age (years) 65.4 ± 5.7 67.5 ± 5.8 63.3 ± 4.9 2 0.08 
Height (cm) 170.6 ± 7.7 171.6 ± 7.7 169.7 ± 8.0 1 0.58 
Mass (kg) 80.0 ± 20.3 78.6 ± 23.9 81.4 ± 17.0 1 0.76 
Body Mass Index (kg/m2) 27.2 ± 5.5 26.3 ± 5.9 28.2 ± 5.1 1 0.42 
      
Cognition & Vision      
Addenbrooke’s Cognitive Exam 91.5 ± 6.8 92.3 ± 5.4 90.6 ± 8.1 1 0.58 
High Contrast Visual Acuity (LogMAR) 0.01 ± 0.1 0.04 ± 0.1 -0.02 ± 0.1 1 0.09 
      
Mobility, Balance Confidence & Quality of Life      
Timed Up and Go (s) 9.3 ± 1.6 9.87 ± 1.7 8.85 ± 1.9 1 0.31 
Activities-specific Balance Confidence (%) 80.8 ± 20.4 78.4 ± 26.0 83.3 ± 13.8 1 0.77 
39-Item Parkinson’s Disease Questionnaire 22.7 ± 11.6 24.1 ± 11.2 21.3 ± 12.2 1 0.49 
      
Neurological Examination      
Disease Duration (years) 6.7 ± 5.0 7.0 ± 5.0 6.5 ± 5.2 2 0.84 
Unified Parkinson’s Disease Rating Scale (Part III) 19.4 ± 13.0 21.5 ± 11.7 17.3 ± 14.4 2 0.31 
Hoehn & Yahr Stage Score 1.9 ± 0.6 2.0 ± 0.7 1.8 ± 0.6 3 0.50 
Schwab & England Activities of Daily Living Scale 82.5 ± 8.8 81.0 ± 10.0 84.1 ± 7.7 2 0.34 
Gait and Falls Questionnaire 10.7 ± 11.6 12.8 ± 13.5 8.6 ± 9.4 1 0.60 
Freezing of Gait Score 5.3 ± 5.5 6.0 ± 5.9 4.6 ± 5.2 1 0.78 
Retropulsion Test 0.4 ± 0.7 0.6 ± 0.7 0.6 ± 0.7 1 0.27 
Levodopa Daily Equivalent Dose (mg) 716.5 ± 427.7 868.2 ± 475.7 564.8 ± 327.6 1 0.10 
Dopamine Agonists 5 (22.7%) 3 (27.3%) 2 (18.2%) 3 0.61 
Catechol-O-Methyl Transferase Inhibitors 8 (36.4%) 3 (27.3%) 5 (45.5%) 3 0.38 
Monoamine Oxidase Inhibitors 8 (36.4%) 6 (54.5%) 2 (18.2%) 3 0.08 
Benzodiazepines 1 (4.5%) 1 (9.1%) 0 (0.0%) 3 0.31 
Note: Test 1 = One-way analysis of variance; Test 2 = Mann-Whitney U test; Test 3 = Chi-square test 
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8.3.2 Clinical Measures 
Individuals who were considered to be eligible following the telephone screening 
process and who provided consent to participate in this study were invited to attend a testing 
session at the University to facilitate the collection of baseline data. Baseline data collection 
included the battery of clinical assessments described Section 6.2 and all participants were 
assessed approximately 1-2 hours following a scheduled dose of their anti-parkinsonian 
medication to ensure that the results were representative of how they might perform similar 
tasks in the real world. 
 
8.3.3 Static Postural Sway 
In addition to the clinical assessments, postural sway was also assessed for each 
participant using standard posturography techniques. Specifically, participants were required to 
complete two 30-second trials that involved standing as still as possible for each of the following 
conditions: i) on a firm surface with eyes open, ii) on a firm surface with eyes closed, iii) on a 
foam surface with eyes open and iv) on a foam surface with eyes closed. The manipulation of 
surface from a firm platform to a foam platform was guided by previous research, which has 
shown that balance may become more difficult for some participants when somatosensory 
feedback is reduced or deprived [119, 145, 146, 190, 194, 201]. The use of foam surfaces has 
been used previously to detect differences in postural stability between people with PD and 
healthy controls [239] as well as detecting differences in balance when different textured insoles 
were used [201].  Similarly, it is well understood that visual feedback plays a significant role in 
one’s ability to orientate themselves relative to their environment, hence the eyes closed 
conditions were included to place a higher load on the other sensory systems involved in postural 
control. During each of the standing balance trials, postural sway was measured on a portable 
AccuGait force plate at an effective rate of 200 Hz (Advanced Mechanical Technology Inc., 
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USA).  While performing the balance task participants stood with their arms resting at their sides 
and their feet 10 cm apart looking at a cross that was placed at eye level 0.4 meters in front of 
them in front of them. These requirements were implemented as previous research has shown 
that standing balance can be improved when a near visual target is provided [227] and to ensure 
that assessments were standardised for each testing session. 
Ground reaction forces and moments were measured by the force platform in all three 
axes of motion (vertical, anterior-posterior, and medial-lateral) via multiple sensors embedded 
within its upper surface. While attempting to stand still, the participant’s centre of mass will 
oscillate, causing the fluctuations in the three-dimensional ground reaction forces and moments. 
These forces and moments are subsequently used to derive centre of pressure, which, in a 
relatively rigid system, reflects the movement patterns of the centre of mass (COM). To facilitate 
this process, the collected ground reaction forces and moments were passed to a laptop computer 
that was running the NetForce software (Advanced Mechanical Technology, Watertown MA, 
USA), where it was used to calculate the centre of pressure.   
Using the centre of pressure data, outcome measures that included the 95% elliptical sway 
area, sway velocity and the variability of anterior-posterior and medial-lateral sway patterns (as 
determined using the standard deviation) were calculated using the BioAnalysis software 
(Advanced Mechanical Technology, Watertown MA, USA). The selection of these outcomes 
was guided by previous research which has reported differences in these measures for people 
with PD relative to controls [18, 108, 201] and for PD fallers compared with non-fallers [119].  
 
8.3.4 Randomisation and Blinding 
This study was designed to be a parallel group phase II randomised controlled trial. 
After baseline assessment, participants were assigned to a 12-week education or exercise 
intervention (Figure 10) using a random allocation sequence (block size=2; 1:1 ratio). This 
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random allocation sequence was generated by a member of the research team who was not 
involved in participant recruitment, assessment or group allocation (GAN), who was not 
involved in participant allocation or assessment. Originally, a secondary aim of this thesis was 
to examine the dose response of exercise with a third intervention group exercising an 
additional two days a week at home. However, a slow rate of participant recruitment resulted 
in a relatively small number of patients (from a statistical perspective) coming into the program 
and the third arm of the intervention had to be abandoned. To minimise the possibility of 
biasing the clinical assessments, an experienced movement disorders scientist who was blinded 
to the assigned group of participants (MHC) conducted each of these assessments.  
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Figure 10: Flow diagram illustrating the recruitment and randomisation processes. 
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8.3.5 Intervention 
Participants randomised to the education group were encouraged to continue their day-
to-day lives, but received a weekly multi-disciplinary education pack that included health tips 
explaining how lifestyle (e.g. exercise) and/or condition-related issues (e.g. poor sleep quality) 
can influence their risk of falling and overall quality of life. The education brochures that were 
provided to the participants were created using scientific evidence drawn from pre-existing 
research and from freely-available information sheets produced by government and not-for-
profit organisations. 
Participants assigned to the exercise groups completed a low-level supervised, 12-week 
exercise program aimed at improving trunk mobility and endurance. The exercise group 
experienced one supervised session each week with a trained Exercise Scientist at the 
University. While it is possible that an exercise program completed on a more regular basis 
may offer greater benefits to less frequent programs, the once weekly face-to-face session was 
considered adequate based on similar programs leading to reduced falls risk in older adults 
[10]. The exercise program consisted primarily of exercises used previously in two different 
exercise-based interventions involving older adults [96] and people with PD [24]. The exercises 
focused on improving trunk muscle strength and endurance. Importantly, the program was 
designed to conform to the current recommendations for best clinical practice for the 
implementation of exercise-based interventions targeting improved postural stability [132, 216, 
221]. Specifically, the program included components that sought to improve trunk mobility, 
trunk muscle strength and endurance, balance under challenging situations (i.e. on an unstable 
surface) and ambulation over different real-world terrains. As described earlier (Section 2.5), 
the appropriate activation of the superficial and deep muscles of the trunk is critical to the 
overall control of this segment during locomotion and is known to be impaired in people with 
PD [40]. By specifically targeting the function of these muscles, it was anticipated that such 
 130 
  
impairments could be reversed and that this improved function may translate to improved static 
and dynamic stability. While the exercises incorporated into this program largely targeted the 
muscles of the trunk, it should be acknowledged that the muscles surrounding the shoulder, 
pelvis and neck were also likely to have been indirectly targeted, as they were required to 
stabilise their respective joints against gravity during the performance of the exercises. The 
program progressed in complexity to accommodate individuals with different physical 
capabilities (Table 9).  
 
Table 9: Summarises the structure of the progressive trunk-specific exercise program 
 
Each of the endurance exercises were repeated 10 times (i.e. 10 repetitions) and 
participants were asked to hold each static position for a duration of 5 (easy) to 20 (difficult) 
Task Movement Repetitions/Progression 
Trunk Mobility 
Warm-up 
Lateral bends 
10 to the left 
10 to the right 
Torso rotations 
10 to the left 
10 to the right 
Small arm circles 
10 forward 
10 backward 
Large arm circles 
10 forward 
10 backward 
Torso rotations with high and low 
reaching 
10 reaching up to left, down to right 
10 reaching up to right, down to left 
Trunk 
Endurance 
 
Abdominal hollowing Adjust difficulty of exercise by: 
 Increasing hold times 
 Increasing movement complexity 
 Introducing an unstable support surface 
Side bridging 
Front bridging 
Bird dog 
Mobility 
Circuit involving stair ascent / descent 
and walking over surfaces of varying 
incline / decline and density 
8-10 minutes of walking on an outdoor walking 
path 
Active Cool 
Down 
Hamstring stretch 2 sets of 20 second holds 
Quadriceps stretch 2 sets of 20 second holds 
Gastrocnemius / soleus stretch 2 sets of 20 second holds 
Triceps stretch 2 sets of 20 second holds 
Pectoral stretch 2 sets of 20 second holds 
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seconds, with the hold time manipulated to adjust the difficulty of each exercise (Table 10). In 
addition to lengthening the static hold times, the difficult of the exercises was also manipulated 
by incorporating a round and flat air filled disc to create an unstable surface that challenged the 
participants’ balance during the performance of the static holds. The walking portion of the 
program was completed on an outdoor walking path that specifically incorporated varying 
degrees of incline and decline, stairs and multiple surface types to simulate walking during 
activities of daily living. The various challenges offered by this walking course served to 
improve participants’ capacity to safely and effectively ambulate in both predictable and 
unstable real world environments. Immediately following the completion of the 12-week 
intervention, all participants were re-assessed using the same tests completed at baseline. In 
addition, a follow-up assessment occurred 12 weeks after the completion of the intervention to 
examine whether any changes were retained longer term. Compliance to the intervention 
protocol and any adverse events was also monitored and reported by the researchers. 
 
 
Table 10: Summarises the progressions and hold times for each of the trunk exercises 
 
Trunk 
Exercise 
Progression Exercise Details 
Hold time 
(seconds) 
 1 Supine 5 
 2 Seated 7 
Abdominal  3 Hands and knees 10 
Hollowing 4 Pelvic bridge 13 
 5 Pelvic bridge and single leg extension 15 
 6 Pelvic bridge and single leg extension (stability disc under foot) 17 
    
 1 On a wall 20 
Front Bridge 2 Forearms and knees  
 3 Forearms and feet  
 4 Forearms and feet (stability disc under feet)  
    
 1 On a wall  
Side  2 Forearms and knees  
Bridging 3 Forearms and feet  
 4 Forearms and feet (stability disc under feet)  
    
 1 Single arm raise  
Bird Dog 2 Single leg raise  
 3 Contralateral arm and leg raise  
 4 Contralateral arm and leg raise (stability disc under knee)  
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8.3.6 Statistical Analysis 
As there were a small number of participants who withdrew from the study prior to its 
completion, intention to treat analysis was not possible. Therefore, analyses of the clinical and 
biomechanical outcomes post-intervention were based on per protocol analysis. To assess for 
changes between groups at 12 and 24 weeks compared with baseline, linear mixed model 
analyses were used (Baseline vs. 12 weeks, Baseline vs. 24-weeks, 12 weeks vs. 24-weeks). 
These models included multiple repeated factors (Day, 3 levels; Vision, 2 levels; Surface, 2 
levels), one fixed factor (Group; 2 levels) and 2 covariates (daily levodopa equivalent dose and 
age). Levodopa daily equivalent dose was included as a covariate, as previous research has 
shown that levodopa improves motor symptoms [184], while age was included due to the 
knowledge that postural sway is influenced by age [80]. If a significant difference was found, 
the Tukey’s Least Significant Difference test was used to perform post-hoc comparisons 
between groups. Tukey’s honestly significant difference determined the minimum mean raw 
score difference that had be obtained to declare two groups significantly different. The test also 
controls for the overall significant level when performing pairwise comparisons to reduce the 
chance of obtaining a Type 1 error [244]. Lastly, to highlight the clinical importance of the 
presented outcomes, the minimal detectable change (MDC) value for each outcome measure 
was derived. All data analyses were conducted using SPSS v.22 (New York, USA) with 
significance set at p<0.05. 
 
8.4 Results 
8.4.1 Study Population 
Of the 24 participants who completed baseline assessments, 13 were assigned to the 
Exercise group and 11 were assigned to the Education group. Of the 13 allocated to the Exercise 
group, two withdrew from the study before completing the 12-week program citing their 
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inability to commit the time required for the exercise program. As such, these participants were 
not re-assessed at the 12- (post-intervention) or 24-week (retention) time points and their data 
were not included in the subsequent analyses. Statistical comparisons of the group indicated 
that, at baseline, the groups did not differ significantly with respect to demographics or their 
performance on the clinical assessments of cognition, vision, mobility, balance confidence, 
quality of life (Table 8). Among the 11 individuals completing the 12-week exercise-based 
intervention, compliance to the exercise program was 90%, on average, with the individual 
rates of compliance ranging from 67% to 100%. All participants included in this study were 
free of any significant medical conditions (other than PD) that may have influence their balance 
and/or gait and presented with no significant physical, psychological or visual disabilities at 
the time of testing. 
Over the 12-week intervention period, each participant in the exercise group 
demonstrated improvements in trunk muscle strength and endurance, as evidenced by their 
progression from simple to more complex exercises and their longer front bridge hold times at 
the 12-week time-point relative to their week 1 assessment (Table 11).  As the front bridge test 
was only conducted for the exercise group, it has not been included in subsequent statistical 
analysis, but it is interesting to note that, on average, participants recorded 141.66 ± 124.90% 
improvement in their static hold times following the program. 
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Table 11: Summary of each participant’s progression through the exercise intervention 
Participant 
Exercise Progression 
# / Hold time (s) 
Front Bridge Test 
Maximum Hold Time (s) 
 Trunk Exercise Week 1 Week 12 Week 1 Week 12 Change 
01 Abdominal Hollowing 2 (10) 6 (20) 34 62 +82% 
 Front Bridging 1 (5) 4 (20)    
 Side Bridging 1 (7) 4 (20)    
 Bird Dog 1 (5) 4 (20)    
       
02 Abdominal Hollowing 2 (5) 4 (15) 10 15 +50% 
 Front Bridging 1 (5) 2 (10)    
 Side Bridging 1 (5) 2 (10)    
 Bird Dog 1 (5) 2 (15)    
       
03 Abdominal Hollowing 2 (5) 6 (10) 38 42 +11% 
 Front Bridging 1 (5) 3 (10)    
 Side Bridging 2 (5) 3 (10)    
 Bird Dog 1 (5) 3 (20)    
       
04 Abdominal Hollowing 2 (5) 6 (10) 17 67 +294% 
 Front Bridging 1 (5) 4 (10)    
 Side Bridging 1 (5) 3 (10)    
 Bird Dog 1 (5) 4 (10)    
       
05 Abdominal Hollowing 2 (5) 6 (20) 42 72 +71% 
 Front Bridging 1 (10) 4 (15)    
 Side Bridging 1 (10) 4 (15)    
 Bird Dog 1 (10) 4 (15)    
       
06 Abdominal Hollowing 2 (7) 6 (15) 15 69 +360% 
 Front Bridging 2 (7) 3 (15)    
 Side Bridging 2 (7) 3 (15)    
 Bird Dog 2 (7) 4 (15)    
       
07 Abdominal Hollowing 2 (7) 6 (15) 12 40 +233% 
 Front Bridging 2 (7) 3 (10)    
 Side Bridging 2 (7) 3 (10)    
 Bird Dog 2 (7) 4 (15)    
       
08 Abdominal Hollowing 2 (7) 5 (15) 5 19 +282% 
 Front Bridging 1 (7) 3 (15)    
 Side Bridging 1 (7) 2 (15)    
 Bird Dog 2 (7) 3 (15)    
       
09 Abdominal Hollowing 4 (10) 6 (20) 41 59 +44% 
 Front Bridging 3 (10) 4 (20)    
 Side Bridging 3 (10) 4 (20)    
 Bird Dog 3 (10) 4 (20)    
       
10 Abdominal Hollowing 4 (10) 6 (20) 134 213 +59% 
 Front Bridging 3 (10) 4 (20)    
 Side Bridging 3 (10) 4 (20)    
 Bird Dog 3 (10) 4 (20)    
       
11 Abdominal Hollowing 2 (10) 6 (15) 61 98 +61% 
 Front Bridging 3 (7) 4 (15)    
 Side Bridging 2 (7) 4 (15)    
 Bird Dog 3 (7) 4 (15)    
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Between the 12- and 24-week assessments, an additional four participants were lost 
(two from the Exercise group and two from the Education group); two underwent deep brain 
stimulation surgery for their symptoms, one was unable to be contacted and one was unable to 
complete the 24-week assessment until 32-weeks after the baseline assessment. As such, the 
data presented for the 24-week follow-up assessment were derived from the 18 participants 
who completed all of the assessments at this time point.  
 
8.4.2 Clinical Assessments 
The results from the linear mixed model analyses for the clinical tests of mobility, 
balance confidence, quality of life and symptom severity revealed a number of significant 
group effects. Specifically, these highlighted that, in general, patients in the Education group 
reported poorer quality of life (PDQ-39, p=0.030), a greater severity of motor symptoms 
(UPDRS III, p=0.02) and larger daily doses of levodopa (p=0.02) than the Education group. 
Despite these findings, the statistical model identified no significant main effects for testing 
day or any significant Group*Day interactions for these clinical measures (Table 12).
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Table 12: Means (± SD) scores for the clinical assessments of symptom severity, disease stage, mobility, balance confidence and quality of life 
 Education Exercise Main Effects Interaction 
 Baseline 12-Week 24-Week Baseline 12-Week 24-Week Group Day Group*Day 
Mobility and Balance 
Confidence 
         
Timed Up and Go (s) 9.87 ± 1.66 9.96 ± 2.02 8.85 ± 1.90 8.78 ± 1.29 9.26 ± 1.80 8.72 ± 0.90 ns ns ns 
Activities-specific Balance 
Confidence (%) 
78.35 ± 25.96 78.70 ± 23.09 89.06 ± 5.34 83.30 ± 13.78 74.15 ± 30.82 76.39 ± 31.21 ns ns ns 
Quality of Life          
39-Item Parkinson’s 
Disease Questionnaire 
24.13 ± 11.24 22.84 ± 10.77 17.95 ± 7.78 21.33 ± 12.32 21.27 ± 14.38 16.60 ± 9.30 ‡ ns ns 
Neurological Examination         
Unified Parkinson Disease 
Rating Scale III 
21.45 ± 11.73 24.55 ± 10.15 19.50 ± 7.97 17.27 ± 14.40 16.45 ± 11.94 15.11 ± 5.80 ‡ ns ns 
Hoehn & Yahr Stage 
Score 
1.95 ± 0.69 2.14 ± 0.67 1.67 ± 0.41 1.77 ± 0.56 1.55 ± 0.69 1.56 ± 0.68 ns ns ns 
Schwab & England 
Activities of Daily Living 
80.91 ± 9.95 80.00 ± 7.07 85.00 ± 6.32 84.09 ± 7.69 84.55 ± 7.57 86.67 ± 8.29 ns ns ns 
Gait and Falls 
Questionnaire 
12.82 ± 13.50 10.36 ± 10.08 5.83 ± 4.88 8.64 ± 9.45 9.27 ± 12.19 5.44 ± 9.04 ns ns ns 
Freezing of Gait  6.00 ± 5.92 5.27 ± 5.24 3.17 ± 2.64 4.64 ± 5.20 5.00 ± 6.00 2.89 ± 4.62 ns ns ns 
Retropulsion Test 0.55 ± 0.69 0.55 ± 0.82 0.33 ± 0.52 0.27 ± 0.65 0.27 ± 0.65 0.11 ± 0.33 ns ns ns 
Levodopa Daily 
Equivalents (mg) 
868.23 ± 475.71 783.59 ± 530.36 794.00 ± 521.95 564.81 ± 327.58 569.55 ± 343.83 484.11 ± 338.37 ‡ ns ns 
ns = no significant differences; ‡ = Significant Group effect; ¥ = Significant Day effect; i = Significant difference between Baseline and 12-week; ii = Significant difference between 
Baseline and 24-week; iii = Significant difference between 12-week and 24-week; Ŧ = Significant Group*Day interaction; a = Significant difference between Baseline and 12-week 
for Education; b = Significant difference between Baseline and 24-week for Education; c = Significant difference between 12-week and 24-week for Education; d = Significant 
difference between Baseline and 12-week for Exercise; e = Significant difference between Baseline and 24-week for Exercise; f = Significant difference between 12-week and 24-
week for Exercise 
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8.4.3 Static Postural Stability 
Linear mixed model analyses reported no significant main effects for group or day for 
any of the outcome measures derived from the force platform (p>0.05). However, a significant 
main effect for surface was observed for all of the postural sway measures, with each outcome 
being greater during the trials completed on the foam surface (p<0.001). Similarly, significant 
main effects for vision were observed with each of the outcomes derived from the force 
platform, with the measures of postural sway being significantly greater during the eyes closed 
conditions (p<0.001).  
In addition to the significant main effects, significant Group*Day*Surface*Vision 
interactions were observed for 95% elliptical sway area (Figure 11), sway velocity (Figure 12) 
and sway variability in both the AP (Figure 13) and ML (Figure 14) directions (p<0.001). 
Pairwise comparisons revealed that, while standing on the foam surface without vision, 
participants in the Exercise group had a reduced 95% elliptical sway area at both the 12- 
(p=0.003) and 24-week (p=0.001) time points compared with the baseline values. Furthermore, 
under these conditions, the Exercise group had less variable medial-lateral postural sway 
patterns at the 12- (p=0.01) and 24-week (p=0.01) time points compared with baseline values. 
Interestingly, following the 12-week intervention, sway velocity was significantly reduced for 
the Education group during the standing balance tasks completed on the foam surface with eyes 
open.  However, despite these statistically significant reductions in sway area, sway velocity 
and sway variability, the reported MDC values suggest that these changes were insufficient to 
be considered clinically meaningful (Table 13). 
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Figure 11: Mean (+1 SEM) 95% elliptical sway area for the Exercise and Education groups. 
Figure 12: Mean (+1 SEM) sway velocity for the Exercise and Education groups. 
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Figure 13: Mean (+1 SEM) AP sway variability for the Exercise and Education groups. 
Figure 14: Mean (+1 SEM) ML sway variability for the Exercise and Education groups. 
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Table 13: Mean (and standard deviation) outcomes for the posturography assessments conducted at Baseline, 12-weeks and 24-weeks. 
  Exercise Education  Main Effects Interactions 
  Baseline 12-Week 24-Week Baseline 12-Week 24-Week Group Day MDC Surface Vision 
Group*Day* 
Surface*Vision 
95% Elliptical Area (cm2)             
Firm 
EO 2.09 ± 1.92 1.80 ± 1.21 3.11 ± 5.17 2.15 ± 2.57 2.06 ± 1.76 1.95 ± 1.26 ns ns 1.81 ‡ ¥ ns 
EC 2.66 ± 1.48 2.52 ± 1.34 2.77 ± 1.80 3.94 ± 4.63 3.06 ± 1.66 3.80 ± 3.82 ns ns 2.51   ns 
Foam 
EO 4.04 ± 2.63 4.05 ± 3.58 4.04 ± 2.13 6.84 ± 10.43 4.71 ± 3.44 3.58 ± 2.03 ns ns 5.37   ns 
EC 21.26 ± 20.45 13.18 ± 8.42 11.57 ± 8.41 17.02 ± 9.56 15.21 ± 9.59 20.15 ± 17.29 ns ns 11.86   Ŧ, c, d, e 
Sway Velocity (cm/s)             
Firm EO 3.32 ± 0.82 3.23 ± 0.49 3.31 ± 0.58 3.51 ± 1.34 3.68 ± 1.51 3.46 ± 1.38 ns ns 0.88 ‡ ¥ ns 
 EC 3.43 ± 0.46 3.46 ± 0.51 3.35 ± 0.53 3.82 ± 1.24 3.91 ± 1.58 3.89 ± 1.43 ns ns 0.69   ns 
Foam EO 3.50 ± 0.66 3.48 ± 0.65 3.39 ± 0.59 4.21 ± 1.75 3.74 ± 1.31 3.67 ± 1.34 ns ns 0.98   Ŧ, a 
 EC 4.83 ± 1.11 4.51 ± 1.01 4.29 ± 0.63 5.26 ± 1.86 5.10 ± 1.75 4.94 ± 1.79 ns ns 1.20   ns 
AP Sway SD (cm)             
Firm 
EO 0.44 ± 0.15 0.42 ± 0.14 0.46 ± 0.28 0.49 ± 0.35 0.44 ± 0.20 0.40 ± 0.14 ns ns 0.21 ‡ ¥ ns 
EC 0.56 ± 0.14 0.51 ± 0.13 0.49 ± 0.19 0.59 ± 0.28 0.59 ± 0.23 0.52 ± 0.21 ns ns 0.17   ns 
Foam 
EO 0.53 ± 0.19 0.57 ± 0.28 0.59 ± 0.14 0.56 ± 0.29 0.53 ± 0.19 0.48 ± 0.16 ns ns 0.19   ns 
EC 1.17 ± 0.48 1.03 ± 0.29 0.98 ± 0.28 1.04 ± 0.34 1.02 ± 0.39 1.12 ± 0.50 ns ns 0.33   Ŧ, e 
ML Sway SD (cm)             
Firm 
EO 0.22 ± 0.10 0.24 ± 0.13 0.27 ± 0.22 0.21 ± 0.11 0.25 ± 0.12 0.26 ± 0.12 ns ns 0.08 ‡ ¥ ns 
EC 0.26 ± 0.11 0.27 ± 0.10 0.30 ± 0.12 0.32 ± 0.21 0.29 ± 0.05 0.34 ± 0.21 ns ns 0.13   ns 
Foam 
EO 0.39 ± 0.13 0.37 ± 0.14 0.38 ± 0.15 0.58 ± 0.63 0.44 ± 0.16 0.40 ± 0.16 ns ns 0.31   ns 
EC 0.87 ± 0.53 0.63 ± 0.22 0.61 ± 0.25 0.83 ± 0.31 0.75 ± 0.29 0.82 ± 0.38 ns ns 0.33   Ŧ, d, e 
MDC = minimal detectable change, EO = Eyes open; EC = Eyes closed; SD = standard deviation; ML = medial-lateral; AP = anterior-posterior; ns = no significant differences; ‡ 
= Significant Surface effect; ¥ = Significant Vision effect; Ŧ = Significant Group*Day*Surface*Vision interaction; a = Significant difference between Baseline and 12-week for 
Education; b = Significant difference between Baseline and 24-week for Education; c = Significant difference between 12-week and 24-week for Education; d = Significant difference 
between Baseline and 12-week for Exercise; e = Significant difference between Baseline and 24-week for Exercise; f = Significant difference between 12-week and 24-week for 
Exercise. NOTE: An asterisk (*) after a symbol indicates that the statistically-significant difference can also be considered clinically important. 
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8.5 Discussion 
The purpose of this phase II randomised controlled trial was to evaluate whether a 12-
week trunk-specific exercise program could improve clinical measures of symptom severity 
and mobility and/or objective measures of static postural stability. The exercise intervention 
did not lead to significant improvements in typical clinical measures of mobility, symptom 
severity or balance confidence. These findings are commensurate with previous exercise-based 
interventions that have previously fallen short of demonstrating significant improvements in 
clinical measures of balance and mobility after an 8-week [6, 139] 10-week [84] or 6-month 
[2] exercise program. Additionally exercise intervention has also previously failed to reduce 
falls risk [2] and falls rates [6, 84] in PD. Collectively, these findings suggest that clinical 
assessments, used widely to assess and monitor changes in patient health, balance and/or 
mobility in people with PD, may lack the necessary specificity and/or sensitivity to detect 
change following intervention. Clinical rating scales may be limited by the experience of the 
individual administering the assessment, poor reliability [205] and/or their dependence on 
Likert scales that may be insensitive to subtle changes in function. This notion seems to be 
supported by previous research which reported only moderate sensitivities (65-69%), 
specificities (62-69%) and accuracies (53-68%) for the Tinetti Balance and Gait tests, Berg 
Balance Scale, Timed Up and Go test, Functional Reach test and Physiological Profile 
Assessment of Falls Risk with respect to the prediction of prospective falls in people with PD 
[119]. Furthermore, the results of Study 2 highlighted weak relationships between objective 
measures of gait symmetry and clinical measures of balance and mobility for patients with mild 
to moderate PD [105].  
In contrast to the clinical assessments, the objective assessment of postural stability 
during quiet stance revealed that the 12-week trunk-specific exercise program led to significant 
improvements in postural sway. Specifically, those who received the exercise intervention 
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demonstrated reductions in the 95% elliptical sway area and sway variability in the anterior-
posterior and medial-lateral directions when completing the most challenging condition (i.e. 
on a foam surface without vision). These findings appear to be in contrast to previous studies, 
which reported no significant improvement in sway area [45] or sway range on firm [2, 121] 
or compliant [2] surfaces. However, a possible explanation for this disparity is that these earlier 
studies only assessed balance while patients stood on a firm surface with their eyes open. The 
significant main effects for vision and surface that were reported in the current study indicated 
that, irrespective of group, all measures of postural sway increased when somatosensory and/or 
visual feedback were impaired. Similar findings have been reported in previous research, which 
has shown improvements in balance following exercise intervention during conditions five 
[262] and six [14, 262] on the Sensory Organisation Test, which involve the manipulation or 
absence of proprioceptive and/or visual feedback. On the basis of these findings, it seems 
apparent that subtle changes in postural stability may not be easily detected during assessments 
conducted under less-challenging conditions. 
In spite of the statistically significant changes observed in the Exercise group following 
the 12-week intervention, it is important to note that the minimal detectable change scores 
indicated that these improvements were not large enough to be considered clinically important. 
A possible means of enhancing such improvements in postural sway would be to increase the 
frequency of the exercise sessions and/or lengthen the duration of the overall program. Support 
for the potential benefits of increased exercise frequency may be provided by previous studies 
that have reported improvements in postural sway following a treadmill training intervention 
completed 3 to 4 times per week [14, 76]. As such, future research should seek to determine 
whether an increased frequency of trunk-specific exercises can yield both statistically 
significant and clinically important improvements in postural sway for people with PD. 
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The results of this study should be considered in light of a number of limitations. First, 
as a phase II randomised controlled trial, the sample size was relatively small, which may mean 
that the reporting of the secondary outcomes may be confounded by insufficient statistical 
power. Nevertheless, the a-priori sample size calculation indicated that data collected for the 
11 participants at baseline and immediately following the 12-week intervention was adequate 
to achieve a level of 80% statistical power for the comparisons made for the sway measures 
between these two time points. When considering the results presented for the 24-week time 
point, it is important to recognise that four participants did not return for their final follow-up 
visit, hence the results represent response from only the remaining 9 individuals in each group. 
As such, while the comparisons reported between the baseline and 12-week assessments are 
supported by the a-priori power calculation, the loss of 2 participants from each of the groups 
during the latter stages of the study, would likely mean that the comparisons that involved the 
24-week time point may be slightly underpowered. Second, given the longitudinal nature of 
this project, the potential impact of any changes in a patient’s anti-parkinsonian medication 
needs to be considered.  It is well recognised that anti-parkinsonian medications, such as 
levodopa, can significantly improve a patient’s symptoms [184]; hence any changes to the 
frequency, dose and/or type of medication was carefully monitored. On the basis of this 
process, it was noted that during the 24-week period that followed the baseline assessment, 
25% of those in the Education group and 36% of those in the Exercise group reported at least 
one change to their prescription medications. Nevertheless, statistical comparison of the 
patients’ levodopa daily equivalents at the three time points indicated no significant increase 
or decrease in the effective amount of levodopa being taken by groups. 
In conclusion, the findings of this study collectively provide evidence to suggest that 
regular trunk-specific exercises may lead to improvements in static postural stability under 
more challenging balancing conditions. However, these improvements do not appear to be 
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easily measured with existing clinical assessments and higher volumes of training may be 
necessary to achieve clinically meaningful improvements in postural control. Additional 
research is needed to determine whether a similar exercise-based intervention that is performed 
more frequently can be used to improve static postural stability in a larger cohort of PD patients 
and to ascertain whether similar improvements can be achieved during dynamic tasks. 
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9.0 Study 4 Exercise improves gait symmetry in Parkinson disease: A blind phase II 
randomised-controlled trial 
Study 3 of this thesis revealed that the trunk specific exercise intervention was more 
effective than the education program at improving postural sway under challenging conditions, 
with some improvements in postural sway under challenging conditions being maintained after 
the 12-week retention period. However, it remains unknown whether these improvements in 
static postural stability extend to dynamic situations, such as walking. To address this issue, 
Study 4 was designed to examine whether the trunk-specific exercise intervention described in 
Study 3 was capable of improving gait symmetry and muscle function in people with PD. 
 
NOTE: The following chapter presents the findings of the following peer-reviewed 
manuscript, which has been reformatted for the purposes of this dissertation.  
 
Hubble, R. P., Naughton, G. A., Silburn, P. A., & Cole, M. H. (under review). Trunk exercises 
improve gait symmetry in Parkinson disease: A blind phase II randomised-controlled trial. 
Movement Disorders. 
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9.1 Abstract 
Background: Deficits in head and trunk symmetry are linked to gait-related falls in Parkinson’s 
disease (PD) and are often poorly managed with medications, emphasising the need for alternate 
therapies for symptom management. This blind phase II randomised-controlled trial sought to 
establish whether trunk-specific exercises could improve gait symmetry in PD. 
 
Methods: Twenty-four PD patients with a history of falls, completed baseline assessments of 
symptom severity, fear of falling, mobility and quality of life. Head and trunk movement 
symmetry and erector spinae muscle activity were assessed during gait using three-dimensional 
accelerometers and surface electromyography, respectively. Following baseline testing, 
participants were randomly prescribed either 12-weeks of trunk-specific exercises or falls 
prevention education. Baseline tests were repeated post-intervention (12-weeks) and following a 
12-week retention period (24-weeks). This trial is listed with the Australian New Zealand Clinical 
Trials Registry (ACTRN12613001175763). 
 
Results: At 12-weeks, medial-lateral trunk (p=0.002) symmetry declined in the Education group 
relative to the baseline measures. These declines were complemented by clinical reductions in 
peak and baseline activation of the upper (peak: p=0.02; baseline: p<0.001) and lower (peak: 
p<0.001; baseline: p<0.001) erector spinae at 24-weeks. In contrast, the Exercise group 
demonstrated improved anterior-posterior (p=0.04) head symmetry at 24-weeks and improved 
anterior-posterior trunk symmetry at the 12- (p<0.001) and 24-week (p=0.01) time points 
compared with baseline. 
 
Conclusions: These data suggest that trunk-specific exercises improved or, at least maintained, 
head and trunk symmetry during walking, which has implications for improving the 
independence and quality of life of people with PD. The decreased markers of trunk symmetry 
in the Education group over the relatively short period of time warrant further investigation. 
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9.2 Introduction  
Postural instability is one of the most disabling symptoms of Parkinson’s disease (PD) 
and contributes to falls in this population. Unfortunately, these symptoms are poorly managed 
by current pharmacological and surgical interventions [19], which emphasises the need for 
more effective alternative therapies for improving overall management of these patients. 
Exercise-based interventions are an inexpensive and easily-implemented form of therapy that 
has been shown to improve motor symptoms and clinical measures of balance, mobility and 
falls risk in PD [2, 6, 19, 63, 169, 170].  
Despite these improvements, the rate and number of falls experienced by older adults 
[36, 203, 234] and people with PD [6, 36, 200, 203, 234] have not been significantly reduced. 
Previous research often cites insufficient power as the cause of non-significant findings [6], as 
the accuracy of falls data depends upon the honesty and diligence of the reporting participant. 
Objective measures of postural stability are suggested to provide greater insight into changes 
in postural stability in people with PD [105]; suggesting that these measures may be more 
appropriate for assessing subtle, yet meaningful, changes in a patient’s function.  
During locomotion, the maintenance of equilibrium relies upon one’s ability to produce 
smooth and rhythmic movements of the head and trunk, which collectively comprise almost 
60% of the body’s mass [257]. Given the importance of these segments to dynamic postural 
control, researchers have commenced using lightweight body-mounted accelerometers to 
measure medial-lateral (side to side), anterior-posterior (front to back) and vertical (up and 
down) movement symmetry, as a proxy for gait stability [129, 138, 160, 257]. The harmonic 
ratio (HR) is one such measure [13, 130, 160, 237] that, in the context of walking, provides a 
measure of the symmetry of segmental accelerations during a single gait cycle [13]. Higher 
HRs describe improved gait symmetry and, hence are indicative of a more stable gait pattern. 
The harmonic ratio has previously been used to discriminate elderly adult fallers from non-
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fallers [129] and is the most commonly used measure to assess movement symmetry in people 
with PD [104]. Specifically, the HR has identified differences in movement symmetry between 
PD patients and controls [104, 129, 138, 187, 213], PD freezers and non-freezers [250], PD 
patients with different dominant symptoms [95] and can even discriminate PD fallers from 
non-fallers [128, 129, 251].   
While, one study involving people with cognitive deficits has examined the efficacy of 
exercise for improving gait symmetry in people with cognitive deficits [59], it is currently 
unknown whether targeted exercise can improve movement symmetry in people with PD. 
Given PD fallers demonstrate larger medial-lateral head [40, 42, 43] and trunk [40] movements 
during gait and that these movements are less symmetrical than non-fallers and age-matched 
controls [129], it is possible that exercises that target the mobility and endurance of these 
segments may assist with improving dynamic postural control in this population. As such, it 
was the purpose of this phase II randomised controlled trial to determine whether a 12-week 
exercise program that focused on improving the mobility and endurance of the trunk was more 
effective than a fall-prevention education program for improving gait symmetry in PD. It was 
hypothesised that patients would have improved gait symmetry following the exercise 
intervention.  
 
9.3 Methods 
9.3.1 Participants 
This phase II randomised-controlled trial was developed in accordance with the 
Consolidated Standards of Reporting Trials (CONSORT) guidelines [211]. To address the aim 
of this study, the same 22 participants described in Study 3 were invited to complete an 
additional gait assessment during the scheduled Baseline, 12-week and 24-week assessments 
(Table 14).  The methods of participant recruitment and processes involved with assessing the 
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patients’ eligibility to participate are outlined in Section 6.1.Prior to their involvement in this 
study, all volunteers provided written informed consent in accordance with the Declaration of 
Helsinki and the study’s protocol (ACTRN12613001175763) [103] was approved by the 
University’s Human Research Ethics Committee (Appendix E). The recruitment and 
assessment of all participants was completed between February 2014 and December 2015.  
On the basis of an a-priori sample size calculation using medial-lateral trunk harmonic 
ratios recorded for people with PD during walking [138], a minimum of 11 participants was 
required per group to confidently report any significant changes in this gait symmetry (diff = 
0.05, SD = 0.04, Cohen’s d = 1.25, Power = 80%, p = 0.05). Given the longitudinal nature of 
the research, the target of recruiting 15 individuals per group allowed for a 25% attrition rate. 
The referenced study found that those with PD had significantly poorer anterior-posterior and 
medial-lateral gait symmetry (harmonic ratios) than healthy individuals while walking.      
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Table 14: Demographics and scores for the clinical baseline assessments completed by the entire PD cohort and the Exercise and Education sub-groups. 
 All (n = 22) Education (n = 11) Exercise (n = 11)   
 Mean ± SD / N (%) Mean ± SD / N (%) Mean ± SD / N (%) Test Sig. (p) 
Demographics      
Gender (Male) 15 (68.2%) 8 (72.7%) 7 (63.6%) 3 0.65 
Age (years) 65.4 ± 5.7 67.5 ± 5.8 63.3 ± 4.9 2 0.08 
Height (cm) 170.6 ± 7.7 171.6 ± 7.7 169.7 ± 8.0 1 0.58 
Mass (kg) 80.0 ± 20.3 78.6 ± 23.9 81.4 ± 17.0 1 0.76 
Body Mass Index (kg/m2) 27.2 ± 5.5 26.3 ± 5.9 28.2 ± 5.1 1 0.42 
      
Cognition & Vision      
Addenbrooke’s Cognitive Exam 91.5 ± 6.8 92.3 ± 5.4 90.6 ± 8.1 1 0.58 
High Contrast Visual Acuity (LogMAR) 0.01 ± 0.1 0.04 ± 0.1 -0.02 ± 0.1 1 0.09 
      
Mobility, Balance Confidence & Quality of Life      
Timed Up and Go (s) 9.3 ± 1.6 9.87 ± 1.7 8.85 ± 1.9 1 0.31 
Activities-specific Balance Confidence (%) 80.8 ± 20.4 78.4 ± 26.0 83.3 ± 13.8 1 0.77 
39-Item Parkinson’s Disease Questionnaire 22.7 ± 11.6 24.1 ± 11.2 21.3 ± 12.2 1 0.49 
      
Neurological Examination      
Disease Duration (years) 6.7 ± 5.0 7.0 ± 5.0 6.5 ± 5.2 2 0.84 
Unified Parkinson’s Disease Rating Scale (Part III) 19.4 ± 13.0 21.5 ± 11.7 17.3 ± 14.4 2 0.31 
Hoehn & Yahr Stage Score 1.9 ± 0.6 2.0 ± 0.7 1.8 ± 0.6 3 0.50 
Schwab & England Activities of Daily Living Scale 82.5 ± 8.8 81.0 ± 10.0 84.1 ± 7.7 2 0.34 
Gait and Falls Questionnaire 10.7 ± 11.6 12.8 ± 13.5 8.6 ± 9.4 1 0.60 
Freezing of Gait Score 5.3 ± 5.5 6.0 ± 5.9 4.6 ± 5.2 1 0.78 
Retropulsion Test 0.4 ± 0.7 0.6 ± 0.7 0.6 ± 0.7 1 0.27 
Levodopa Daily Equivalent Dose (mg) 716.5 ± 427.7 868.2 ± 475.7 564.8 ± 327.6 1 0.10 
Dopamine Agonists 5 (22.7%) 3 (27.3%) 2 (18.2%) 3 0.61 
Catechol-O-Methyl Transferase Inhibitors 8 (36.4%) 3 (27.3%) 5 (45.5%) 3 0.38 
Monoamine Oxidase Inhibitors 8 (36.4%) 6 (54.5%) 2 (18.2%) 3 0.08 
Benzodiazepines 1 (4.5%) 1 (9.1%) 0 (0.0%) 3 0.31 
Note: Test 1 = One-way analysis of variance; Test 2 = Mann-Whitney U test; Test 3 = Chi-square test 
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9.3.2 Clinical Measures 
Prior to randomisation, each participant completed a baseline assessment, which 
included a battery of clinical assessments that have been described in Section 6.2. All of the 
baseline assessments were conducted approximately 1-2 hours following one of the patient’s 
scheduled doses of anti-parkinsonian medication to ensure that the results were representative 
of similar tasks performed in the real world. Participants with significant visual (Bailey-Lovie 
high contrast visual acuity >0.30 logMAR) and/or cognitive (ACE-R score <82) impairment 
were excluded prior to baseline testing. 
 
Figure 15: Placement of the head and trunk accelerometers (red) and surface electrodes (blue) 
 
9.3.3 Gait Analysis 
Following completion of the clinical assessments, participants were asked to perform 
four walking trials at a self-selected and comfortable speed along a 10-meter long walkway.  
While performing these trials, the three-dimensional acceleration patterns of the head and trunk 
(Figure 15) were assessed via two tri-axial accelerometers (500 Hz), while the activation 
patterns of the erector spinae muscles was evaluated using surface electromyography (1500 
 152 
  
Hz). Prior to placing the accelerometers over the occipital protuberance and the 10th thoracic 
vertebra, each accelerometer was statically calibrating via the methods outlined in Section 
7.3.3. This process served to establish a reference measure of the precise value recorded by 
each sensing axis for 1 gravitational unit. 
To evaluate the muscle activation patterns of the upper and lower erector spinae during 
the walking trials, raw electromyograms were collected for the thoracic and lumbar erector 
spinae. Prior to applying the surface electrodes to these regions, the skin overlying the muscles 
of interest was prepared with an abrasive gel (NuPrep; Weaver & Company, Aurora, CO), and 
then cleaned thoroughly with an isopropyl alcohol wipe to minimise impedance at the 
electrode-skin interface and improve clarity of the myoelectric signal [97]. For individuals with 
excessive body hair, these areas were shaved prior to the application of NuPrep in order to 
maximise the fidelity of the myoelectric signal and ensure the best possible adherence to the 
skin. After skin preparation, four pairs of silver/silver chloride (Ag/AgCl) pre-gelled surface 
electrodes (AMBU Blue Sensor, Ballerup, DK; 34 mm diameter, 10 mm2 sensing area) were 
placed with a centre-to-centre inter-electrode distance of 34 mm. Specifically, these electrode 
pairs were placed bilaterally 5 cm lateral to the spinous process of the T10 vertebral body and 
2 cm lateral to the spinous process of the 3rd lumbar (L3) vertebral body (Figure 15) [242]. The 
erector spinae muscles were chosen for evaluation because individuals with PD are known to 
have more decreased trunk muscle performance than age-matched controls [23], which may 
influence their capacity to control trunk motion during walking. To facilitate synchronisation 
of head and trunk accelerations with trunk muscle activations, both datasets were wirelessly 
telemetered to a Telemyo DTS belt receiver and to a laptop running the MyoResearch XP 
software (Noraxon Inc., Scottsdale, AZ).  
To allow for group and day comparisons, it was important for the muscle activation patterns 
to be normalised to a reference measure to allow for slightly different electrode placements from 
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day to day and/or anthropometric differences between the participants. While different methods of 
normalization have been reported in the literature (e.g. submaximal voluntary contractions, 
isokinetic maximal voluntary contraction), an isometric maximum voluntary isometric contraction 
was selected as it was considered to provide more reliable results [31] and had the ability to provide 
more information on the degree of muscle activation during walking than isokinetic methods [32]. 
Furthermore, submaximal tests do not produce reference values regarding the maximal capacity of 
the muscle, which may make it difficult to make comparisons between participants [91]. To 
facilitate the normalisation process, the activation patterns of the upper and lower erector spinae 
were expressed as a percentage of the peak activation recorded for these muscle during three 
maximum voluntary isometric contractions [91]. As people with PD are known to have more 
variable activation patterns [114] and take longer to achieve peak activity [254], participants were 
required to perform a minimum of three practice trials separated by a minimum of 30 seconds rest. 
This protocol ensured familiarisation with the movement and provided a warm up for the muscles 
before the maximal efforts. Participants were required to lie prone/prostrate on a padded table with 
their hips flexed and their feet on the floor with a Velcro strap placed over the lower torso to secure 
them to the table for safety. Each maximal effort involved simultaneously extending both hips to 
raise the legs to a horizontal position (i.e. 180°) at which point their movements were actively 
resisted by the researcher. This method was chosen in preference to the traditional Biering-
Sorensen test to limit the potential difficulties that older participants may have with this more 
complex movement pattern [242]. The researchers verbally encouraged participants and visually-
inspected each trial to ensure that muscle activation peaked before relaxation. The maximum value 
recorded for each muscle during the three trials was used for normalisation of walking data.   
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9.3.4 Data Processing – Gait symmetry 
The primary outcome measure for this study was the harmonic ratio, which is derived 
from the head and trunk acceleration patterns and provides a measure of gait symmetry. A 
detailed description of the procedures involved in calculating the harmonic ratio has been 
provided in Study 2, but has been briefly summarised here for convenience. Raw head and 
trunk accelerations were transformed to a horizontal-vertical orthogonal coordinate system 
[164] to remove the effect of gravity from the anterior-posterior and medial-lateral axes of the 
sensors [164]. After transformation, accelerations were low-pass filtered using a bi-directional 
fourth order Butterworth filter, with a cut-off frequency of 30 Hz [117]. The time series of the 
filtered anterior-posterior, medial-lateral and vertical head and trunk accelerations were then 
divided into individual gait cycles by identifying the peaks in vertical trunk accelerations, 
which coincide with heel contact [129, 137, 138, 160]. The anterior-posterior, medial-lateral 
and vertical harmonic ratios were then calculated for successive gait cycles within each walking 
trial by dividing the sum of in-phase accelerations by the sum of out-of-phase accelerations 
[160].  
 
9.3.5 Data Processing – Movement Amplitude and Muscle Function 
In addition to the harmonic ratio, the amplitude of head and trunk accelerations was 
also assessed by processing the transformed and filtered anterior-posterior, medial-lateral and 
vertical accelerations using the root mean square (RMS) method outlined in Section 7.3.4.  
For the assessment of muscle function, the three gait cycles completed for each leg 
produced eight peaks of muscle activity (i.e. 4 left and 4 right footfalls, yield 3 left and 3 right 
gait cycles; 1 peak per footfall) and the normalised amplitude of these peaks was then averaged 
to represent peak muscle activation. To evaluate the extent to which these superficial trunk 
muscles ‘switched off’ between strides, the minimum EMG amplitude between successive heel 
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contacts (i.e. within the seven troughs between the eight activation peaks) was determined and 
averaged to represent the baseline level of activation. Processing of the raw electromyograms 
was completed in the MyoResearch MR 3.6.20. As electromyography data from the trunk 
muscles are often contaminated by the electrical activity of cardiac muscle, an adaptive filter 
was initially applied to raw data to attenuate any electrocardiogram artefact. Data were then 
full-wave rectified and low-pass filtered using a 4th order Butterworth filter that had a cut-off 
frequency of 20 Hz [52]. The peak amplitude of the EMG signal throughout the gait cycle was 
evaluated by calculating the root mean square value of the signal over consecutive 50 ms 
windows (i.e. 75 samples) with a 74 sample overlap. To facilitate normalisation of the EMG 
data, the data collected during the maximum voluntary isometric contraction trials were 
processed using the same procedures and the peak value achieved for each muscle during the 
three trials was recorded. Finally, the data collected for each muscle during the walking trials 
were expressed as a percentage of the peak MVC value for the same muscle to facilitate 
comparison between different sites and different participants [91]. 
 
9.3.6 Randomisation, Blinding and Interventions 
Given the somewhat subjective nature of many of the clinical assessments used in this 
study, it was important to ensure that these tests were completed by a member of the research 
team who was blind to each participant’s group allocation. To facilitate this, participants were 
assigned to their group following the baseline assessments by the lead investigator (RPH) using 
a random allocation sequence generated by a co-investigator (GAN), who was not involved in 
participant allocation or assessment (block size=2; 1:1 ratio).  The clinical assessments were 
conducted at Baseline, 12-weeks and 24-weeks by an experienced movement disorders 
scientist who was blinded to participant group assignment (MHC). 
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Following completion of the baseline assessments and group allocation, participants 
allocated to the Exercise intervention group completed the 12-week trunk-specific exercise 
program that is outlined in Section 8.3.5. Similarly, those who were randomised to the 
Education group received a weekly education brochure via mail or email, outlining lifestyle 
changes and/or strategies around the home that they might adopt to minimise their risk of 
falling (Section 8.3.5). 
 
9.3.7 Statistical Analysis 
As was the situation for Study 3, the withdrawal of a small number of participants from 
the study made it impossible to adopt an ‘intention to treat’ approach for this study. Therefore, 
analyses of the clinical and biomechanical outcomes post-intervention were based on per 
protocol analysis. Linear mixed model analyses were conducted to determine whether the 
trunk-specific exercise program was more effective than the education program at improving 
head and trunk symmetry, movement amplitude and muscle activation. These models included 
one repeated factor (Day; 3 levels), one fixed factor (Group; 2 levels) and 2 covariates 
(levodopa and walking speed). Walking speed and levodopa were included as covariates in 
these models, as walking speed is known to influence accelerations [129, 130] and levodopa is 
known to improve motor symptoms in PD [87, 184, 210]. When a significant main effect or 
interaction was identified, the Tukey’s Least Significant Difference (LSD) post-hoc procedure 
was used to identify where the differences lay. All statistical analyses were completed in the 
SPSS v.22 (New York, USA) and the level of significance was set at p<0.05. Furthermore, the 
minimal detectable change (MDC) for each measure was derived to highlight the clinical 
importance of the presented outcomes.  
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9.4 Results 
9.4.1 Study Population Retention and Compliance 
Of the 24 participants assessed at baseline, 22 completed the 12-week intervention and two 
withdrew citing changes in circumstances that made them unable to commit to the project. To limit 
the potential for bias, participants who were unable to complete or who were excluded from 
completing the intervention were not reassessed at the 12- or 24-week mark and their baseline data 
are not presented in the subsequent analyses. Comparisons of the remaining 22 patients at baseline 
indicated that the Exercise and Education groups did not differ for measures of cognition, vision, 
neurological function or mobility. However, individuals in the Exercise group had greater body 
mass index (BMI) at baseline than the Education group (Table 15). In accordance with the strict 
inclusion and exclusion criteria adhered to throughout the participant recruitment phase, all 22 
participants included in this study were free of any significant medical conditions (other than 
PD) that may have influence their balance and/or gait and presented with no significant 
physical, psychological or visual disabilities at the time of testing. 
Between the 12- and 24-week assessments, an additional four participants (two Exercise, 
two Education) were lost to follow-up, with two receiving deep brain stimulation surgery, one not 
contactable via telephone or email and one unable to return for the 24-week assessment. As such, 
the data presented for the 24-week follow-up is based on data for the remaining 18 participants (9 
Exercise; 9 Education). Average participant compliance for the exercise sessions was 90%, with 
individual compliance ranging from 8 (67%) to 12 (100%) of the 12 supervised sessions. 
Participants reported no discomfort or harmful effects associated with either intervention.  
 
9.4.2 Clinical Outcomes 
The results of the linear mixed model analyses returned significant Group effects for the 
PDQ-39 (p=0.03), UPDRS III (p=0.02) and levodopa daily equivalents (p=0.02). These findings 
indicated that, irrespective of day, the Education group had a significantly poorer quality of life, 
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experienced greater motor symptom severity and took larger amounts of levodopa compared with 
the Exercise group. Furthermore, the lack of any significant main effects for Day or any 
significant Group*Day interactions indicated that these group differences remained relatively 
unchanged throughout the study (Table 15). 
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Table 15: Mean (± SD) scores for the clinical assessments of symptom severity, disease stage, mobility, balance confidence and quality of life 
 Education Exercise Main Effects Interaction 
 Baseline 12-Week 24-Week Baseline 12-Week 24-Week Group Day Group*Day 
Mobility and Balance 
Confidence 
         
Timed Up and Go (s) 9.87 ± 1.66 9.96 ± 2.02 8.85 ± 1.90 8.78 ± 1.29 9.26 ± 1.80 8.72 ± 0.90 ns ns ns 
Activities-specific Balance 
Confidence 
78.35 ± 25.96 78.70 ± 23.09 89.06 ± 5.34 83.30 ± 13.78 74.15 ± 30.82 76.39 ± 31.21 ns ns ns 
Quality of Life          
39-Item Parkinson’s 
Disease Questionnaire 
24.13 ± 11.24 22.84 ± 10.77 17.95 ± 7.78 21.33 ± 12.32 21.27 ± 14.38 16.60 ± 9.30 ‡ ns ns 
Neurological Examination         
Unified Parkinson Disease 
Rating Scale III 
21.45 ± 11.73 24.55 ± 10.15 19.50 ± 7.97 17.27 ± 14.40 16.45 ± 11.94 15.11 ± 5.80 ‡ ns ns 
Hoehn & Yahr Stage 
Score 
1.95 ± 0.69 2.14 ± 0.67 1.67 ± 0.41 1.77 ± 0.56 1.55 ± 0.69 1.56 ± 0.68 ns ns ns 
Schwab & England 
Activities of Daily Living  
80.91 ± 9.95 80.00 ± 7.07 85.00 ± 6.32 84.09 ± 7.69 84.55 ± 7.57 86.67 ± 8.29 ns ns ns 
Gait and Falls 
Questionnaire 
12.82 ± 13.50 10.36 ± 10.08 5.83 ± 4.88 8.64 ± 9.45 9.27 ± 12.19 5.44 ± 9.04 ns ns ns 
Freezing of Gait 6.00 ± 5.92 5.27 ± 5.24 3.17 ± 2.64 4.64 ± 5.20 5.00 ± 6.00 2.89 ± 4.62 ns ns ns 
Retropulsion Test 0.55 ± 0.69 0.55 ± 0.82 0.33 ± 0.52 0.27 ± 0.65 0.27 ± 0.65 0.11 ± 0.33 ns ns ns 
Levodopa Daily 
Equivalents (mg) 
868.23 ± 475.71 783.59 ± 530.36 794.00 ± 521.95 564.81 ± 327.58 569.55 ± 343.83 484.11 ± 338.37 ‡ ns ns 
ns = no significant differences; ‡ = Significant Group effect; ¥ = Significant Day effect; i = Significant difference between Baseline and 12-week; ii = Significant difference between 
Baseline and 24-week; iii = Significant difference between 12-week and 24-week; Ŧ = Significant Group*Day interaction; a = Significant difference between Baseline and 12-week 
for Education; b = Significant difference between Baseline and 24-week for Education; c = Significant difference between 12-week and 24-week for Education; d = Significant 
difference between Baseline and 12-week for Exercise; e = Significant difference between Baseline and 24-week for Exercise; f = Significant difference between 12-week and 24-
week for Exercise 
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9.4.3 Primary Outcome: Movement Symmetry 
Analysis of the AP, ML and VT head and trunk movement symmetries showed no 
significant Group effects. However, significant main effects for Day were returned for AP head 
and VT trunk symmetry (Table 16). Pairwise comparisons revealed that AP head symmetry 
was reduced during the 12-week assessment compared with both the baseline (p=0.03) and 24-
week (p=0.05) time points. Furthermore, VT trunk symmetry was lower during the 12- 
(p<0.001) and 24-week (p=0.03) assessments, relative to baseline. 
Post hoc analyses following Group*Day interactions revealed that AP (p=0.01) and VT 
head (p=0.05) symmetry and ML (p=0.002) trunk symmetry were reduced at 12-weeks 
compared with baseline for the Education group (Figure 16). Despite these findings, the 
reported MDCs for these outcomes suggested that the changes in AP and VT head symmetries 
were not clinically meaningful. Group*Day interactions were also evident for the Exercise 
group for AP (p=0.02) and VT (p<0.001) head and AP (p=0.007) trunk movement symmetry. 
Pairwise comparisons revealed that AP head movement symmetry improved at 24-weeks 
compared with the baseline (p=0.04) and 12-week (p=0.02) assessments, while VT head 
movement symmetry also improved at 12-weeks relative to baseline (p=0.01). Similar 
improvements were evident for the trunk segment, which showed increased AP movement 
symmetry at both 12- (p<0.001) and 24-weeks (p=0.007) compared with baseline. While the 
reported MDC values indicated that the majority of these improvements were clinically 
meaningful, the improvement observed in VT head symmetry at 12-weeks did not achieve a 
level that could be considered clinically important (Table 16). 
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Figure 16: Mean (+1 SEM) harmonic ratios for the Exercise and Education groups.
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9.4.4 Secondary Outcomes: Movement Amplitude 
Analysis of the movement amplitude data (RMS accelerations) returned significant 
Group effects for ML head (p=0.05) and AP trunk (p=0.04) acceleration, which indicated 
greater movement amplitudes for the Exercise group (Table 16). Additionally, the main effect 
for Day indicated that AP head movement amplitude was significantly lower at 12-weeks 
compared with baseline, while VT head (p<0.001) and AP (p<0.001), ML (p<0.001) and VT 
(p<0.001) trunk movement amplitudes were all lower at baseline compared with the 12-week 
assessment. AP and ML trunk movement amplitude remained increased during the 24-week 
assessment relative to baseline, while trunk VT movement amplitude increased and head VT 
movement amplitude decreased relative to the 12-week assessment. 
Group*Day interactions were identified for VT head and AP, ML and VT trunk 
movement amplitudes. Pairwise comparisons revealed greater VT head (p<0.001) and AP 
(p<0.001), ML (p<0.001) and VT (p=0.003) trunk movement amplitudes for the Education 
group at 12-weeks relative to baseline (Figure 17). Additionally, VT head (p<0.001) movement 
amplitude decreased by the 24-week assessment, AP (p=0.01), ML (p=0.01) and VT (p<0.001) 
trunk movement amplitudes all remained elevated at 24-weeks relative to baseline. The 
reported MDCs indicate that most of these changes were clinically relevant; however, the 
increased VT head movement amplitude at 12-weeks and ML trunk movement amplitude at 
24-weeks fell short of clinical significance using MDC change statistics. Similar changes were 
highlighted in movement amplitude for the Exercise group, with VT head (p<0.001) movement 
amplitude increasing at 24-weeks relative to baseline and ML trunk movement amplitude 
increased at 24-weeks relative to the baseline (p<0.001) and 12-week (p<0.001) assessments. 
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Figure 17: Mean (+1 SEM) RMS accelerations for the Exercise and Education groups. 
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9.4.5 Secondary Outcomes: Trunk Muscle Function 
The results for the assessment of trunk muscle function revealed no significant Group 
effects (p>0.05). However, significant Day effects for peak (p=0.04) and baseline (p=0.02) 
activation of the lower erector spinae indicated that both measures were reduced at 24-weeks 
relative to baseline, independent of group allocation (Table 16).  
Figure 18: Mean (+1 SEM) erector spinae activity for the Exercise and Education groups. 
 
Group*Day interactions were found for peak and baseline levels of activation for the 
upper and lower erector spinae muscles. Pairwise comparisons indicated that peak activation 
of the upper and lower erector spinae was significantly reduced at 12- and 24-weeks relative to 
baseline for the Education group (Figure 18). Similarly, baseline levels of upper and lower 
erector spinae activity were significantly reduced at 24-weeks for the Education group, relative 
to the baseline and 12-week assessments. In contrast, peak activation of the upper erector 
spinae increased at the 12- (p=0.004) and 24-week (p<0.001) time points for the Exercise 
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group, relative to baseline, while the other outcomes did not significantly change for this sub-
group. While the results from the MDC calculations showed that the changes in upper erector 
spinae activity for the Exercise group post-intervention were not clinically important, the 
reduced peak and baseline erector spinae activity for the Education group at 24-weeks did 
exceed the threshold considered as clinically meaningful.  
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Table 16: Mean (± SD) movement symmetry, movement amplitude and muscle function for the Education and Exercise groups. 
  Education Exercise 95% Main Effects Interaction 
  Baseline 12-Week 24-Week Baseline 12-Week 24-Week MDC Group Day Group*Day 
Primary Outcome           
Movement Symmetry           
 AP 2.27 ± 0.80 2.04 ± 0.72 2.07 ± 0.52 2.02 ± 0.80 2.01 ± 0.90 2.35 ± 0.91 0.29 ns ¥, i, iii Ŧ, a, e, f* 
Head ML 2.08 ± 0.61 2.22 ± 0.59 2.17 ± 0.51 2.31 ± 0.76 2.27 ± 0.77 2.46 ± 0.70 0.24 ns ns ns 
 VT 2.27 ± 0.81 2.04 ± 0.72 2.07 ± 0.52 2.80 ± 0.89 3.03 ± 1.10 3.02 ± 0.84 0.34 ns ns Ŧ, a, d 
 AP 2.27 ± 0.81 2.04 ± 0.72 2.60 ± 0.74 2.14 ± 0.71 2.51 ± 0.75 2.60 ± 0.87 0.22 ns ns Ŧ, d*, e* 
Trunk ML 2.55 ± 0.57 2.15 ± 0.73 2.54 ± 0.95 2.23 ± 0.67 2.39 ± 0.75 2.49 ± 0.66 0.22 ns ns Ŧ, a* 
 VT 3.64 ± 1.03 3.10 ± 1.24 3.23 ± 1.22 3.66 ± 1.35 3.73 ± 1.10 3.39 ± 1.03 0.43 ns ¥, i, ii ns 
Secondary Outcomes           
Movement Amplitude           
 AP 1.06 ± 0.32 0.95 ± 0.25 1.05 ± 0.40 1.14 ± 0.82 0.98 ± 0.38 1.09 ± 0.43 0.20 ns ¥, i ns 
Head ML 0.98 ± 0.19 1.00 ± 0.24 0.98 ± 0.23 1.11 ± 0.36 1.09 ± 0.26 1.23 ± 0.35 0.10 ‡ ns ns 
 VT 2.16 ± 0.34 2.29 ± 0.31 2.19 ± 0.25 2.18 ± 0.49 2.26 ± 0.52 2.47 ± 0.59 0.15 ns ¥, i, iii Ŧ, a, c, e* 
 AP 1.01 ± 0.19 1.12 ± 0.27 1.14 ± 0.17 1.13 ± 0.26 1.16 ± 0.24 1.23 ± 0.19 0.08 ‡ ¥, i, ii Ŧ, a*, b* 
Trunk ML 1.25 ± 0.28 1.36 ± 0.32 1.33 ± 0.38 1.31 ± 0.28 1.34 ± 0.29 1.54 ± 0.34 0.10 ns ¥, i, ii Ŧ, a*, b, e*, f* 
 VT 2.40 ± 0.38 2.59 ± 0.42 2.76 ± 0.74 2.46 ± 0.59 2.43 ± 0.54 2.75 ± 0.50 0.17 ns ¥, i, iii Ŧ, a*, b* 
Muscle Function (%MVC)           
Peak 
Upper ES 15.39 ± 8.77 11.81 ± 5.58 10.91 ± 5.94 14.35 ± 11.49 17.41 ± 12.39 17.30 ± 12.47 3.70 ns ns Ŧ, a, b*, d, e 
Lower ES 33.53 ± 13.09 30.59 ± 8.73 26.28 ± 13.24 22.24 ± 9.73 25.11 ± 12.37 25.59 ± 12.10 4.19 ns ¥, ii Ŧ, a, b* 
Baseline 
Upper ES 3.84 ± 2.45 3.34 ± 3.48 2.08 ± 1.51 2.29 ± 2.06 2.28 ± 1.41 2.45 ± 1.79 0.83 ns ns Ŧ, b*, c* 
Lower ES 4.93 ± 2.46 4.78 ± 2.23 3.10 ± 2.38 2.99 ± 1.96 2.95 ± 1.12 3.40 ± 1.80 0.81 ns ¥, i, ii Ŧ, b*, c* 
            AP = anterior-posterior; ML = medial-lateral; VT = vertical; MDC = minimum detectable change; ns = no significant differences; ‡ = Significant Group effect; ¥ = Significant Day 
effect; i = Significant difference between Baseline and 12-week; ii = Significant difference between Baseline and 24-week; iii = Significant difference between 12-week and 24-week; 
Ŧ = Significant Group*Day interaction; a = Significant difference between Baseline and 12-week for Education; b = Significant difference between Baseline and 24-week for Education; 
c = Significant difference between 12-week and 24-week for Education; d = Significant difference between Baseline and 12-week for Exercise; e = Significant difference between 
Baseline and 24-week for Exercise; f = Significant difference between 12-week and 24-week for Exercise. NOTE: An asterisk (*) after a symbol indicates that the statistically-
significant difference can also be considered clinically important. 
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9.5 Discussion 
This phase II randomised-controlled trial represents the first study to examine the efficacy 
of a 12-week trunk-specific exercise program for improving gait symmetry in PD.  The results 
support the hypothesis that trunk-specific exercises may improve (or at the very least, maintain) 
AP head and trunk symmetry and trunk muscle function in this population.  Furthermore, our 
results suggest that, without specifically focusing on maintaining mobility and core strength, 
medial-lateral trunk symmetry may decline in as little as 12 weeks. 
The findings of this study are commensurate with previous research, which demonstrated 
improvements in vertical trunk movement symmetry for people with mild cognitive impairment 
following a 6-month multi-component exercise program [59]. Additionally, improvements in 
gait symmetry have been observed following different verbal cueing strategies in PD [137]. Our 
results extend existing knowledge by suggesting measures of gait symmetry, such as the 
harmonic ratio, may be suitable for assessing subtle changes in gait symmetry (a proxy for 
postural stability) when the larger cohorts required for prospective falls studies are unobtainable. 
Our results also suggest that the benefits offered by the exercise program can be maintained for 
up to 12-weeks following the cessation of a regular training regime.  These findings are 
important, as they suggest that performing exercises that target trunk strength and mobility as 
little as once per week can improve movement symmetry and reduce falls risk in people with PD. 
The improvements in AP head and trunk symmetry in the Exercise group were 
accompanied by increases in head (VT) and trunk (ML) movement amplitude following the 12-
week intervention. Similar increases in movement amplitude were also evident for the trunk 
segment (AP, ML, VT) for the Education group.  As PD is a hypokinetic disorder [248], it is not 
surprising that some studies [67, 129] have shown that the amplitude and speed of head and trunk 
movements are reduced in this population relative to age-matched controls. Collectively, these 
results suggest that an increase in movement amplitude would be considered an improvement for 
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people with PD, as it would bring their segmental accelerations closer to those values observed 
in age-matched controls. Despite this interpretation, the results presented for the Education group 
should be considered with some caution. Reference to the means and standard deviations 
suggests that head and trunk accelerations were generally higher for the Exercise group at 
baseline than for the Education group. As such, the increased accelerations recorded for the 
Education group during the 12- and 24-week assessments did not result in significantly greater 
head and/or trunk movement than the Exercise group, but rather accounted for the differences 
measured at baseline. 
The reported changes in gait symmetry and movement amplitude were also 
complemented by changes in trunk muscle function.  Specifically, the Education group 
experienced significant and clinically-important declines in trunk movement symmetry at 12-
weeks that were combined with declines in peak and baseline levels of erector spinae activity at 
24-weeks. In contrast, while the targeted exercise intervention resulted in statistically significant 
improvements in trunk muscle function for the Exercise group, these changes were not sufficient 
large to be considered clinically meaningful. Nevertheless, these results provide evidence to 
suggest that the Exercise program was successful at helping to maintain trunk muscle function 
for the Exercise group, which has important implications for clinical practice. For example, the 
phasic bilateral activation of the erector spinae during walking serves to resist the large 
anteriorly-directed torque imposed upon the body at heel contact [256]. As such, the maintenance 
of trunk muscle function in the Exercise group may help to explain the improved AP head and 
trunk symmetry reported for these individuals during the 12- and 24-week assessments.  
As with any study, potential limitations should be considered when interpreting the 
outcomes. First, a slow rate of participant recruitment resulted in a relative small number of 
patients (from a statistical perspective) into the program.  While the comparisons reported 
between the baseline and post-intervention (12-week) assessments are supported by an a-priori 
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power calculation, the loss of 2 participants from each of the groups between the 12- and 24-
week assessments meant that these comparisons may be slightly underpowered.  As such, the 
results presented for the 24-week follow-up should be interpreted with care. Second, the 
Education group reported increased difficulty with motor symptoms and poorer quality of life. 
Collectively, these factors may have impacted their motivation for the MVC trials, which would 
have influenced their normalised EMG results. However, it should be noted that reduced 
motivation during the MVC trials would be expected to result in lower maximum values and, 
hence larger normalised trunk muscle activity during the walking trials. As the results indicate, 
even if these patients were lacking motivation during one or more of the assessments, they still 
recorded significantly lower peak and baseline activity at 12- and/or 24-weeks. 
In conclusion, our results demonstrate that walking symmetry and trunk muscle function 
can degrade quite rapidly in people with PD.  However, by performing as little as one focussed 
exercise session per week it seems possible to offset these changes and statistically and clinically 
improve or, at the very least maintain, gait symmetry. Such improvements in function are likely 
to have significant implications for an individual’s self-confidence and independence, which 
ultimately should contribute to an improved quality of life. Given these findings, exercises that 
target trunk muscle function should be considered when developing an exercise program that 
seeks to improve balance and gait symmetry and reduce falls risk in people with PD. 
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10.0 Overall Discussion and Conclusions 
 This thesis comprised four inter-related studies that sought to determine the utility of 
accelerometers for assessing standing and walking balance and the potential efficacy of a 12-
week trunk-specific exercise program for improving static and dynamic postural stability in 
people with PD.  Overall, this thesis produced a number of important findings. First, 
accelerometers have been placed on numerous anatomical landmarks to assess static and 
dynamic postural stability, an accelerometer placed on the trunk is the most common method 
used for people with PD.  Similarly, while many accelerometer-based measures have been used 
to assess stability in different populations, the harmonic ratio has been the most commonly 
used for assessing gait stability in PD populations. Second, the results presented in this 
dissertation suggest that wearable sensors may offer additional insight into the balance and gait 
deficits experienced by people with PD and appear to be capable of quantifying differences 
that are not easily detected with common clinical assessments. Lastly, it was shown that trunk-
specific exercises performed once a week may be beneficial for managing symptoms of 
postural instability and gait disability in people with PD. While the improvements in standing 
balance were not quite large enough to be considered clinically meaningful, the improvements 
observed during walking were substantial enough to be considered clinically important. Given 
that the vast majority of falls occur during dynamic tasks, such as locomotion, the improved 
head and trunk symmetry observed following the 12-week program may have significant 
implications for falls prevention in this population. The findings presented in this thesis have 
the potential to contribute to improved screening and treatments for symptoms of postural 
instability and gait disability in people with PD and should ultimately help to improve the 
quality of life of people living with this condition.  
Parkinson’s disease poses a significant financial burden to the public health system with an 
estimated $8.3 billion per annum for the Australian population as of 2011 [189]. However, this 
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burden extends far beyond the Australian population, with annual estimated costs of $23 billion 
USD (≈$29.3 billion AUD) in the United States [107] and ₤600 million (≈$1.2 billion AUD) in the 
United Kingdom [68]. With advances in medical science, the average age of the general population 
is increasing, meaning that age-related conditions, such as PD, are likely to become more prevalent 
[189]. Despite the significant physiological and psychological burdens that this rise in cases will 
impose upon those diagnosed and their loved ones, the direct and indirect costs associated with the 
condition’s management will also increase [189]. PD is a condition that directly affects an 
individual’s ability to be productive in their careers and can make even the simplest of everyday 
tasks increasingly difficult. With disease progression, the severity of motor (e.g. tremor, joint 
stiffness, postural instability) and non-motor (e.g. sleep disorders, cognitive problems, depression) 
symptoms become more severe; ultimately reducing the patient’s independence and overall quality 
of life. Given that postural instability is the most disabling symptoms of PD [248] and that it is not 
well managed with traditional therapies, it is unsurprising that research continues to seek better 
strategies for improving these symptoms. Within this context, this program of research addressed 
a series of interconnected issues, which sought to develop improved methods for assessing and 
managing symptoms of postural instability in people with PD. 
Due to the ineffectiveness of pharmacological and surgical intervention on postural 
instability [19], clinicians and scientists have turned to non-invasive and natural therapies such as 
exercise to improve postural stability in PD. Structured and progressive home-based exercise 
programs have been shown to improve strength [47, 85] balance [47], and motor symptoms in PD 
[2, 112, 139]. However, exercise interventions, to date, have also been unable to improve typical 
clinical balance measures [2, 84, 139], falls risk [2], and reduce the rate of falls in PD [6, 84]. This 
highlights the need for more high quality evidence on the ability of exercise to reduce the rate of 
falls in PD [85]. One of the most recent positions on the impact of exercise intervention on 
improving postural instability in PD concluded that programs lack sufficient focus on balance in 
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challenging situations and multi-component home-based exercise programs show little to no 
beneficial effects in improving stability [122]. This thesis has addressed this shortcoming of 
previous research by incorporating current best practices into a randomised controlled trial, the 
highest quality of research. By seeking to incorporate balancing tasks performed under more 
challenging conditions, the progressive exercise-based intervention adopted in this program of 
research would be expected to have greater transferability to similarly challenging situations in 
real-world settings.  
The primary reliance on clinical tests of mobility and physiological function to evaluate the 
efficacy of their program may be a limitation of many previous exercise-based interventions.  The 
systematic evidence generated from Study 1 identified wearable sensors as being a suitable means 
of assessing postural stability in people with PD and while these devices are widely used in 
laboratory-based studies, they have traditionally been lacking in previous high-quality randomised 
controlled trials [104]. Given the findings of Study 1, this program of research combined common 
clinical assessments with outcomes derived from wearable sensors to determine the potential 
benefits of this technology over common procedures. The results of Study 2 supported the 
hypothesis that objective measures of dynamic postural stability would provide greater insight into 
gait deficits than common clinical measures of mobility, gait difficulty, postural stability and 
balance confidence. The findings of this study suggest that previous studies that have relied solely 
on clinical assessments to determine the efficacy of a specific falls prevention intervention may 
have been limited in their capacity to report clinically-meaningful changes in postural stability. The 
results of Study 3 partially supported the hypothesis that a 12-week trunk-specific exercise program 
would be effective at significantly reducing objective measures of postural sway; although the 
reported changes were insufficient to be considered clinically meaningful. Similarly, the results of 
Study 4 supported the hypothesis that the 12-week exercise-based intervention would improve 
accelerometer-based measures of head and trunk symmetry during walking and influence the 
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activation patterns of the trunk muscles. In contrast, however, the results of this research did not 
support the hypothesised improvements in clinical measures of symptom severity, balance 
confidence and gait impairment following the 12-week exercise program. Collectively, these 
findings provide further support for the notion that common clinical assessments of balance, 
mobility and symptom severity may lack the sensitivity to detect small, yet clinically-meaningful 
changes in postural stability for patients with PD. 
For the first time, through the rigor of a randomised controlled trial, this program of 
research has established that objective measures of gait symmetry, postural sway and muscle 
function can provide insight into the efficacy of exercise-based interventions that target improved 
postural stability in people with PD. The exercise intervention produced improvements in head and 
trunk movement symmetry (as measured with the harmonic ratio) during gait that was not only 
statistically significant, but clinically meaningful also. Similar improvements were recorded during 
the posturography assessments when the patients stood on the foam surface with their eyes closed. 
Under this most challenging condition, measures of postural sway decreased for the Exercise group 
following the 12-week intervention, suggesting an overall improvement in postural control. The 
improvement in head and trunk symmetry for the Exercise group were limited to the anterior-
posterior (front-to back) plane of movement, which is commensurate with the findings of previous 
research examining the effect of verbal cueing strategies on gait symmetry in the PD population 
[137]. The reported improvements in movement symmetry and postural sway for the Exercise 
group were strengthened by the findings of increased postural sway and significant and clinically-
meaningful reductions in trunk movement symmetry and erector spinae activity for those in the 
Education group. The lack of any significant changes in postural stability during the simpler 
standing balance tasks (e.g. standing on a firm surface with eyes open) is commensurate with 
previous research [2, 45, 121] and suggests that screening for balance deficits should involve the 
assessment of balance under challenging conditions. Collectively, the findings of this randomised 
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controlled trial highlighted that inactivity may lead to more rapid declines in postural stability and 
trunk muscle function and suggest that regular exercise may not only be useful for improving 
postural stability, but also for maintaining trunk strength and endurance. 
As a phase-II randomised controlled trial (proof-of-concept), this study sought to determine 
the efficacy of a 12-week trunk-specific exercise intervention for the improvement of objective 
measures of standing balance and movement stability in people with PD. While the sample size 
may be considered relatively small, the results reported for the primary outcome measures were 
supported by a-priori sample size calculations. Nevertheless, the transferability of these findings to 
larger patient cohorts is unknown and, hence, further research is warranted. Additionally, a 
potential shortcoming of this research was that trunk muscle endurance (assessed via a front bridge 
static hold) was not assessed for the education group at baseline or during the 12- and 24-week 
assessments. Therefore, while consistent improvements in static hold times were reported for all 
participants in the exercise group after the intervention, it was not possible to establish what 
proportion of this change might simply be attributed to naturally-occurring differences between 
testing dates.  Furthermore, it should be acknowledged that the improvements reported for the 
exercise group may have been enhanced if the weekly training frequency was increased from one 
session per week to three sessions per week (for example). While it was an ancillary aim of this 
program of research to answer this question [103], difficulties with participant recruitment and 
retention made it necessary to forfeit this aspect of the experiment and focus on the primary aim. 
Nevertheless, given the encouraging outcomes of this study, future research might seek to 
establish whether increasing the frequency of exercise leads to greater improvements in static 
and dynamic balance for people with PD.  It should also be noted that the outcomes presented in 
this dissertation were based on a relatively large number of statistical comparisons made between 
the groups, the testing dates and testing conditions. When conducting a large number of statistical 
tests, the risk of reporting a significant outcome simply due to chance (i.e. a Type 1 error) is 
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inflated. As statistical corrections for multiple comparisons are not recommended for exploratory 
studies [15], this risk should be considered when reviewing the reported findings. 
In addition to the abovementioned shortcomings, it is also important to acknowledge a 
number of potential limitations associated with the recruitment and sampling methods used for 
this research. First, the information letter that was sent to all potential participants informed them 
that they would be randomly assigned to either an exercise-based intervention or an education 
program.  As such, it is possible that some of the participants who were randomly allocated to 
the education group may have taken it upon themselves to increase their physical activity levels 
outside of the study; potentially influencing the outcomes.  Second, with any study of this nature 
there is always a risk that the sample will be biased towards people who are more intrinsically 
motivated and/or genuinely believed that they will benefit from the intervention, which may 
impact that representativeness of the sample.  Finally, while the exercise-based intervention used 
in this thesis was designed to conform to the current recommendations for best clinical practice 
[132, 216, 221], it specifically focused on improving dynamic trunk function. Given that postural 
instability is generally considered a multifaceted problem, it is possible that a more general and 
multidisciplinary intervention would have yielded different outcomes to those presented in this 
research. Nevertheless, the improvements made by the participants throughout the 12-week period 
(as evidenced by the increased difficulty of their exercises and the longer static hold times) and the 
improved gait symmetry evident during the follow-up assessments seems to suggest that improving 
trunk control may play an important part in enhancing postural stability for people with PD. 
The findings of this research are strongly relevant to current clinical practice. With the 
integration of inexpensive and objective measuring devices into standard clinical practice, it may 
be possible to measure small, yet meaningful changes in a patient’s function and may facilitate 
early intervention for at-risk patients. Wearable sensors are relatively easy to use, require little set-
up time, and can be easily implemented in real-world and clinical settings. Furthermore, this 
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program of research provides additional support for the benefits of regular exercise in the 
management of PD and its symptoms, indicating that targeted low-intensity core conditioning 
exercises completed as little as once a week can maintain or improve standing and walking stability. 
Given the promise shown by these results, future research should utilise this type of equipment to 
focus on larger sample size multi-site or multi-national clustered randomised control trials to 
investigate the assessment and effects of interventions on postural stability. To this end, improving 
the assessment of postural stability in PD may ultimately inform policies, clinical guidelines and 
practices for reducing falls in people with PD by improving postural stability and, in the long term, 
contribute to improving the quality of life of these individuals. 
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Appendix A: Systematic Review Search Strategy 
 
Research Question: Can wearable sensors be used to measure postural stability in people with 
Parkinson’s disease? 
 
Research Protocol: 
Methods for Literature Search: 
A targeted search was conducted on August 27, 2014 of relevant databases for articles that 
were published within the past 20 years (1994-2014) and reported using wearable sensors to 
assess elements of postural stability in people with Parkinson’s disease (PD). Specifically, the 
databases searched were: 
 
Pubmed 
EMBASE 
The Cochrane Library 
 
Additionally, the bibliographies of the studies that met the inclusion criteria for this review 
were screened for relevant articles that may have been missed during the initial database 
searches. As potential papers were identified, they were added to an Endnote database to 
eliminate duplicate entries of research studies. The following outlines the complete 
combination of search terms that was used to search the titles and abstracts of potential papers 
for each of the three databases: 
 
((((Parkinson's[Title/Abstract]) OR Parkinson[Title/Abstract])) AND 
((((Walk[Title/Abstract]) OR Gait[Title/Abstract]) OR Balance[Title/Abstract]) OR 
Stability[Title/Abstract])) AND (((((Acceleration[Title/Abstract]) OR 
Accelerometer[Title/Abstract]) OR Gyroscope[Title/Abstract]) OR Inertial[Title/Abstract]) 
OR Sensor[Title/Abstract]) 
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Strict Inclusion/Exclusion Criteria: 
To be eligible for inclusion in the systematic review, papers were required to meet the following 
inclusion and exclusion criteria: 
Inclusion Criteria:  For inclusion, papers were required to; i) involve a PD population; 
ii) utilise a body-mounted wearable sensor; iii) present at least one 
outcome measure for balance or postural stability during standing or 
walking; iv) be written in English; v) include a control group or 
control condition (e.g. ON vs. OFF medication); or vi) be a full-text 
article (i.e. not a conference abstract, systematic review or meta-
analysis). 
Exclusion Criteria: Papers were excluded if they had; i) no control group or control 
condition; ii) a mixed neurological participant sample; iii), no 
blinding to intervention status (if applicable); or iv) a wearable 
sensor that was a pedometer. 
 
Paper Review Process: 
A minimum of 2 reviewers performed the initial screening of articles based on the title and 
abstract of the papers identified in the initial search and where discrepancies existed between 
the reviewers, they were discussed until a consensus was reached. The full-text of those papers 
that were considered potentially relevant following title and abstract screening were reviewed 
by 1 of the reviewers and papers that were eligible were subjected to quality assessment and 
data extraction. Where there were uncertainties about the relevance of a paper in the full-text 
review process, the second reviewer was asked to independently evaluate the study and the 
inclusion status of the paper was discussed until a final consensus was reached. 
 
 
 
 191 
  
Quality Assessment: 
The methodological quality of each included paper was assessed using a previously-developed 
checklist described by Downs & Black (1998). This quality assessment checklist uses 27 
questions to assess the reporting of external validity, bias and other potentially confounding 
factors that may have existed due to the study design. Each variable on the checklist was valued 
at 1 point if the criterion was met, with a score of zero being awarded if the criterion was not 
reported. However, the criterion related to the reporting of power calculations was valued at 5 
points due to its increased importance for sample size justification. The sum of the scores for 
each of these items was divided by the maximum possible score and multiplied by 100 to yield 
a percentage that provided an assessment of the manuscript’s methodological quality. 
Manuscripts were classified as having either very low (<25%), low (<50%, but ≥25%), moderate 
(<75%, but ≥50%) or high (≥75%) methodological quality. 
 
Downs, S. H., & Black, N. (1998). The feasibility of creating a checklist for the assessment of 
the methodological quality both of randomised and non-randomised studies of health 
care interventions. Journal of epidemiology and community health, 52(6), 377-384. 
 
Methods for Data Extraction and Analysis: 
The initial step for this process involved a simple descriptive evaluation of each of the studies 
included in this review, which is presented in Table 2 of the dissertation. Furthermore, this 
table included a number of important pieces of information that were extracted from these 
studies and included: 
Demographics – Experimental groups, disease severity, disease duration 
Intervention – Description of intervention (if applicable) 
Sensor Details – Type and placement 
Postural Stability – Measures and modality of assessment 
Findings – Results of the study 
Quality Score – Details regarding the methodological quality of the study 
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Appendix B: Systematic Review Methodological Quality Assessment 
1. Reporting 
1) Is the hypothesis/aim/objective of the study clearly described? 
Yes 1 No 0 
 
2) Are the main outcomes to be measured clearly described in the Introduction or Methods section? 
If the main outcomes are first mentioned in the Results, the question should be answered 'No'. 
Yes 1 No 0 
 
3) Are the characteristics of the patients included in the study clearly described? 
In cohort studies and trials, inclusion and/or exclusion criteria should be given. In case-control 
studies, a case-definition and the source for controls should be given. 
Yes 1 No 0 
 
4) Are the interventions of interest clearly described?¥ 
Treatments and placebo (where relevant) that are to be compared should be clearly described. 
Yes 1 No 0 
 
5) Are the distributions of principal confounders in each group of subjects to be compared clearly 
described? 
A list of principal confounders is provided. 
Yes 2 Partially 1 No 0 
 
6) Are the main findings of the study clearly described? 
Simple outcome data (including denominators and numerators) should be reported for all major 
findings so that the reader can check the major analyses and conclusions. 
N.B. This question does not cover statistical tests which are considered below 
Yes 1 No 0 
 
7) Does the study provide estimates of the random variability in the data for the main outcomes? 
In non-normally distributed data the inter-quartile range of results should be reported. In normally 
distributed data the standard error, standard deviation or confidence intervals should be reported. If 
the distribution of the data is not described it must be assumed that the estimates used were 
appropriate and the questions should be answered ‘Yes’. 
Yes 1 No 0 
 
8) Have all important adverse events that may be a consequence of the intervention been reported? ¥ 
This should be answered ‘Yes’ if the study demonstrates that there was a comprehensive attempt to 
measure adverse events. 
Yes 1 No 0 
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9) Have the characteristics of patients lost to follow-up been described? ¥ 
This should be answered ‘Yes’ where there were no losses to follow-up or where losses to follow-
up were so small that findings would be unaffected by their inclusion. This should be answered 
‘No’ where a study does not report the number of patients lost to follow-up. 
Yes 1 No 0 
 
10) Have actual probability values been reported (e.g. 0.035 rather than <0.05) for the main outcomes 
except where the probability value is less than 0.001? 
Yes 1 No 0 
 
2, External Validity 
All the following criteria attempt to address the representativeness of the findings of the study and 
whether they may be generalised to the population from which the study subjects were derived. 
 
11) Were the subjects asked to participate in the study representative of the entire population from 
which they were recruited? 
The study must identify the source population for patients and describe how the patients were 
selected. Patients would be representative if they comprised the entire source population, an 
unselected sample of consecutive patients, or a random sample. Random sampling is only feasible 
where a list of all members of the relevant population exists. Where a study does not report the 
proportion of the source populations from which the patients are derived, the question should be 
answered as ‘Unable to Determine’. 
Yes 1 No 0 
Unable to Determine 0   
 
12) Were those subjects who were prepared to participate representative of the entire population from 
which they were recruited? 
The proportion of those asked who agreed should be stated. Validation that the sample was 
representative would include demonstrating that the distribution of the main confounding factors 
was the same in the study sample and the source population. 
Yes 1 No 0 
Unable to Determine 0   
 
13) Were the staff, places and facilities where the patients were treated representative of the treatment 
the majority of patients received? 
For the question to be answered ‘Yes’ the study should demonstrate that the intervention was 
representative of that in use in the source population. The question should be answered ‘No’ if, for 
example, the intervention was undertaken in a specialist centre unrepresentative of the hospitals 
most of the source population would attend. 
Yes 1 No 0 
Unable to Determine 0   
 
3. Internal Validity – Bias 
 
14) Was an attempt made to blind study subjects to the intervention they have received? ¥ 
For studies where the patients would have no way of knowing which intervention they received, 
this should be answered ‘Yes’. 
Yes 1 No 0 
Unable to Determine 0   
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15) Was an attempt made to blind those measuring the main outcomes of the intervention? ¥ 
 
Yes 1 No 0 
Unable to Determine 0   
 
16) If any of the results of the study were based on ‘data dredging,’ was this made clear? 
Any analyses that had not been planned at the outset of the study should be clearly indicated. If no 
retrospective unplanned subgroup analyses were reported, then answer ‘Yes’. 
Yes 1 No 0 
Unable to Determine 0   
 
17) In trials and cohort studies, do the analyses adjust for different lengths of follow-up of patients, or 
in case-control studies, is the time period between the intervention and outcome the same for cases 
and controls? ¥ 
Where follow-up was the same for all study patients the answer should be ‘Yes’. If different lengths 
of follow-up were adjusted for by, for example, survival analysis, the answer should be ‘Yes’. 
Studies where differences in follow-up are ignored should be answered ‘No’. 
Yes 1 No 0 
Unable to Determine 0   
 
18) Were the statistical tests used to assess the main outcomes appropriate? 
The statistical techniques used must be appropriate to the data. For example non-parametric 
methods should be used for small sample sizes. Where little statistical analysis has been undertaken 
but where there is no evidence of bias, the question should be answered ‘Yes’. If the distribution of 
the data (normal or not) is not described it must be assumed that the estimates used were appropriate 
and the question should be answered ‘Yes’. 
Yes 1 No 0 
Unable to Determine 0   
 
19) Was compliance with the intervention(s) reliable?¥ 
Where there was non-compliance with the allocated treatment or where there was contamination of 
one group, the question should be answered ‘No’. For studies where the effect of any 
misclassification was likely to bias any association to the null, the question should be answered 
‘Yes’. 
Yes 1 No 0 
Unable to Determine 0   
 
20) Were the main outcome measures used accurate (valid and reliable)? 
For studies were the outcome measures are clearly described, the question should be answered 
‘Yes’. For studies which refer to other work or that demonstrates the outcome measures are 
accurate, the question should be answered ‘Yes’. 
Yes 1 No 0 
Unable to Determine 0   
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4. Internal Validity – Confounding (Selection Bias) 
 
21) Were the patients in different intervention groups (trials and cohort studies) or were the cases and 
controls (case-control studies) recruited from the same population? 
For example, patients for all comparison groups should be selected from the same hospital. The 
question should be answered ‘Unable to Determine’ for cohort and case-control studies where there 
is no information concerning the source of patients included in the study. 
Yes 1 No 0 
Unable to Determine 0   
 
22) Were study subjects in different intervention groups (trials and cohort studies) or were the cases 
and controls (case-control studies) recruited over the same period of time? 
For a study which does not specify the time period over which patients were recruited, the question 
should be answered ‘Unable to Determine’. 
Yes 1 No 0 
Unable to Determine 0   
 
23) Were study subjects randomised to intervention groups? ¥ 
Studies which state that subjects were randomised should be answered ‘Yes’, except where the 
method of randomisation would not ensure random allocation. For example alternate allocation 
would score ‘No’ because it is predictable. 
Yes 1 No 0 
Unable to Determine 0   
 
24) Was the randomised intervention assignment concealed from both patients and health care staff 
until recruitment was complete and irrevocable? ¥ 
All non-randomised studies should be answered ‘No’. If assignment was concealed from patients 
but not from staff, it should be answered ‘No’. 
Yes 1 No 0 
Unable to Determine 0   
 
25) Was there adequate adjustment for confounding in the analyses from which the main findings were 
drawn? 
This question should be answered ‘No’ for trials if the main conclusions of the study were; i) based 
on analyses of treatment rather than intention to treat; ii) the distribution of known confounders in 
the different treatment groups was not described; or iii) the distribution of known confounders 
differed between the treatment groups but was not taken into account in the analyses. In non-
randomised studies if the effect of the main confounders was not investigated or confounding was 
demonstrated but no adjustment was made in the final analyses the question should be answered 
‘No’. 
Yes 1 No 0 
Unable to Determine 0   
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26) Were losses of patients to follow-up taken into account? ¥ 
If the number of patients lost to follow-up is not reported, the question should be answered as 
‘Unable to Determine’. If the proportion lost to follow-up was too small to affect the main findings, 
the question should be answered ‘Yes’. 
Yes 1 No 0 
Unable to Determine 0   
 
5. Power 
 
 
  
27) Did the study have sufficient power to detect a clinically important effect where the probability 
value for a difference being due to chance is less than 5%? 
Sample sizes have been calculated to detect a different of x% and y%. 
 Size of smallest intervention group Power Estimate Score 
A < n1 70% 0 
B n1-n2 80% 1 
C n3-n4 85% 2 
D n5-n6 90% 3 
E n7-n8 95% 4 
F n+ 99% 5 
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Overall Research Quality Score 
 
Randomised Controlled Trials 
Randomised controlled trials are assessed based on the sum of scores for all 27 items, divided by the 
maximum possible score (28) and multiplied by 100 to yield a percentage score that represents the 
overall methodological quality of the manuscript. 
 
Reporting / 11 * 100 % 
External validity / 3  *  100 % 
Internal validity - bias / 7  *  100 % 
Internal validity - selection bias / 6  *  100 % 
Power / 5  *  100 % 
Total score / 32  *  100 % 
 
Cross-Sectional Studies 
Cross-sectional studies or other studies that do not involve one or more interventions are assessed based 
on the sum of scores for items 1-3, 5-7, 10-13, 16, 18, 20-22, 25 and 27 (i.e. 17 items), divided by the 
maximum possible score for these items (18) and multiplied by 100 to yield a percentage score that 
represents the overall methodological quality of the manuscript. 
 
Reporting / 8 * 100 % 
External validity / 3  *  100 % 
Internal validity - bias / 3  *  100 % 
Internal validity - selection bias / 3  *  100 % 
Power / 5  *  100 % 
Total score / 22  *  100 % 
 
Overall Quality Rating 
Quality Score Quality Assessment 
0 - 25% Very Low 
25.1 - 50% Low 
50.1 - 75% Moderate 
75.1 - 100% High 
 
Adapted From: Downs SH, Black N (1998). The feasibility of creating a checklist for the 
assessment of the methodological quality both of randomised and non-randomised studies of 
health care interventions. Journal of epidemiology and community health 52: 377-384. 
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Appendix C: Participant Information Sheet 
PARTICIPANT INFORMATION LETTER 
 
PROJECT TITLE:  Improving postural stability in people with Parkinson’s 
disease  
PRINCIPLE INVESTIGATOR:  Dr Michael Cole  
CO-SUPERVISOR:  Professor Geraldine Naughton  
STUDENT RESEARCHER:  Ryan Hubble  
STUDENT’S DEGREE:   Doctor of Philosophy  
 
Dear Participant,  
 
You are invited to participate in the research project described below.  
 
What is the project about? 
The objective of this project is to assess the effect of different non-invasive interventions on 
standing and walking balance in people with Parkinson’s disease.  Some people with 
Parkinson’s disease may have difficulties that affect their balance, and the results of this study 
could provide new information to gain a better understanding of difficulties to help develop 
better interventions for managing balance problems in this population.  A brief description of 
the tests in this research is given below and we would like to ask you to consider being a part 
of this study.  For each visit, parking will be available at the University and a detailed 
description of all assessments is included with this document for your consideration.   
Who is undertaking the project? 
This project is being conducted by Ryan Hubble and forms the basis of the Doctor of 
Philosophy degree that he is completing at the Australian Catholic University under the 
supervision of Dr Michael Cole.  
Are there any risks associated with participating in this project? 
The preparation and testing phases will involve short periods of standing and walking.  There 
is a chance that you may feel tired and/or uncomfortable, but you will be given rest breaks 
between tests and you may ask for additional breaks if needed.  Furthermore, you will be 
encouraged to do the tests at your own pace and a member or the research staff will always be 
close by during the assessments to ensure your safety.  
Additionally, the testing of muscle function from the skin’s surface will require small areas of 
your skin to be clean and lightly abraded (exfoliated) to help put small sensors on the skin’s 
surface and provide clear results. While unlikely, it is foreseeable that some people could have 
a reaction to this process, but the risk of this is no greater than that experienced with similar 
routines in everyday life.  
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There is a chance that you may be randomly assigned to an exercise program for this study.  
The exercise program has been developed to be achievable, yet challenging, so it is expected 
that some of the exercises may initially be difficult for you to perform properly.  Also, as a 
result of the exercises, you may experience some general muscular soreness known as delayed 
onset muscle soreness (DOMS).  To ensure that the exercise program is challenging enough to 
promote improvement, yet gentle enough to minimise DOMS, the exercises will start at a low 
level of difficulty and will progressively become harder as you improve your muscular 
endurance.  During the exercise visits, the exercise scientist will also demonstrate proper 
technique for performing the exercises and you will be encouraged to complete the exercises 
at your own pace. 
What will I be asked to do? 
If you agree to participate in this research, you will be randomly placed into one of three 
different intervention groups: exercise one day per week, exercise three days per week, or 
education.  Before you are randomly placed into a group however, your falls risk, standing 
balance and walking performance will be assessed with the following tests outlined below: 
1. Questionnaires and Clinical Assessments:  
Clinical assessments will be performed to examine memory and attention, vision and disease 
severity.  Questionnaires will include questions that relate to height and weight, falls, health 
and medical conditions, medications and mobility.  
2. Quiet Stance:  
To assess standing balance, you will be asked to stand as still as possible on different surfaces 
(firm, foam) under multiple conditions (e.g. eyes open, eyes closed).  
3. Walking:  
To examine how your body moves when you are walking at a comfortable speed, small match-
box sized devices (accelerometers) will be placed on your head (via a sports headband) and 
back (using double-sided tape).  Additionally, the way your muscles turn on and off during 
walking will also be examined from the skin’s surface via a non-invasive and safe method 
known as ‘surface electromyography’.  
4. Education Group  
If you are randomly placed into the education group, after your initial assessment you will 
maintain your normal everyday life.  Once a week for 12 weeks you will receive a pamphlet 
with information that may be helpful at improving your balance and quality of life.  After 
completing this protocol, you will be offered the opportunity to participate in the same exercise 
program as the two exercise groups.  
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5. Exercise Groups:  
If you are randomly placed into one of the exercise intervention groups, each week you will be 
asked to attend one supervised exercise session at Australian Catholic University Brisbane 
campus (McAuley at Banyo).  If you are randomly placed in the exercise three times per week 
group, you will be asked to complete an additional two exercise sessions at home for a total of 
three exercise sessions per week.  The exercise program will last for 12 weeks and each session 
will take no more than one hour to complete.  
6. Follow-up Falls Calendars: 
You will be asked to record any falls you experience on a daily falls calendar, which will be 
returned each month via a postage paid envelope over the six months following the 12-week 
education period.  
How much time will the project take? 
 
 
 
 
 
To participate in this research, you will be asked to visit the Australian Catholic University 
Brisbane campus a minimum of 3 times and up to a maximum of 15 times. Your initial visit 
will take up to 120 minutes to complete and will included the clinical tests and the walking and 
balance tests outlined above. You will be asked to return 12 and 24 weeks after this initial 
session to complete the same group of tasks again.  The timeline above shows how your 
participation in this project would progress.  After the initial visit, you will be randomly placed 
into one of three intervention groups.  If you are randomly placed into the education group, you 
will continue your normal everyday life, but you will be sent a brochure with information that 
could help improve your balance and quality of life.  After completing the protocol for the 
education group, you will have the opportunity of participating in the same exercise program 
as the exercise groups.  This will include one 60-minute supervised exercise session a week for 
12 weeks.  This is completely optional but it is provided purely for your benefit.  If you are 
placed in either exercise group, you will be asked to attend a one-hour training session at the 
Australian Catholic University (Brisbane Campus) once a week for 12 weeks.  If you are placed 
in the exercise 3 times per week group, you will be asked to complete two additional sessions 
at home each week at a time convenient for you.  The exercise program will start with a minimal 
difficulty level and progress as you improve with the exercises.  At the end of the training 
session, you will be provided with the same education tips that are being provided to the 
education group.  All groups will be asked to keep a daily diary of their activity levels, which 
could take as little as a couple minutes each day.  After your second visit for assessment you 
will be asked to record any falls in a falls diary for 12 weeks before your third and final visit 
  
  
  
  
  
  
  
  
  
  
Second   Testing   
120   Minutes   
Initial  Testing   
120 minutes   
Third   Testing   
120  Minutes   
 Weeks 12   of:   
Education Group OR   
Exercise 1x per week OR   
Exercise 3x per week   
12  Weeks   
) Normal everyday life (  
Falls Diaries   
12  Weeks   
( Normal everyday life )   
Falls Diaries   
Optional Exercise Program  
( Education Group Only )   
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for assessment.  After your final assessment you will be asked to record any falls in a falls diary 
for another 12 weeks.  Recording your falls involves ticking a few boxes on a questionnaire 
that may take as little as one minute or up to a couple of minutes, and then returning it to the 
research team via a reply-paid envelope. 
What are the benefits of the research project? 
The educational information that you will be provided with over the course of this study may 
be beneficial to you, as it could be useful in improving your balance and quality of life. 
Research has demonstrated that regular exercise can be effective at improving strength, 
balance, mobility and symptoms of tremor and rigidity for people with Parkinson’s disease.  
As such, your involvement in the exercise program associated with this study may have a 
number of health benefits for you.  Furthermore, your involvement in this study is expected to 
benefit the wider community, particularly other people with Parkinson’s disease.  Your 
participation in this study will assist in improving our understanding how exercise affects 
postural stability, and will help form a scientific basis for promoting effective interventions 
aimed at improving postural stability in this population.  Ultimately this knowledge will lead 
to the development of well-planned interventions that may reduce the incidence of falls and 
fall related injuries and improve quality of life in people with Parkinson’s disease.  In addition, 
upon completion of the study, you will be given a $40 Coles group and Myer gift voucher as a 
token of our appreciation for your time and dedication to our research. 
Can I withdraw from the study? 
Taking part in this project is entirely voluntary and we will ask you to sign a written consent 
form (enclosed) to confirm that you agree to participate.  You will also be asked to consent to 
being photographed and/or videotaped.  For the photographs your face will not be 
photographed to keep your identity confidential.  However, due to the need to assess head and 
neck movements during some of the clinical tests, your identity may not be concealed.  This 
data is to be used for clinical training purposes only and will not be released to any individual 
not affiliated with this study. However, if you decide not to consent to being photographed 
and/or videotaped as part of this study, it will not affect your involvement in this study.  
Furthermore, it is important to know that you are free to withdraw consent before, during, or 
after the experiment without comment or penalty.  Under no circumstances will you be 
prejudiced as a result of your actions; your participation or withdrawal of consent will not 
influence your present or future care or your relationship with the research staff at the 
Australian Catholic University.  
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Will anyone else know the results of the project? 
All data will be kept at the Australian Catholic University, in a locked filing cabinet.  Data will 
also be stored in password-protected files on a computer within the University and back-up 
copies will be held on a portable hard-drive for storage off-site.  The researchers will take every 
care to ensure that individually identifying material will be removed from the data as soon as 
it is possible, in order to ensure the privacy and confidentiality of the participants.  You should 
be aware that your identity will not be disclosed in the reporting of the research.  Following 
completion of data collection, the results from the study will be summarised and presented in 
the form of scientific publications. It is important however, to reiterate that the outcomes of 
this research will focus on the averaged data from all participants and will not identify 
individual participants in any way.  
Will I be able to find out the results of the project? 
People who volunteer to take part in this research will be offered verbal feedback on their 
performance on the assessments at the end of the trial.  Due to the prospective design of this 
research, it is likely to be incredibly time-consuming for the HDR Student Researcher to 
produce individualised reports for each patient. However, participants will be given the option 
to receive a summary of the overall findings of the research following its completion to help 
them better understand what they have contributed to.  If you would like a summary of the 
results of the study, you should contact the HDR student Ryan Hubble. His contact details are 
included below on this form.  
Who do I contact if I have questions about the project? 
If you have any questions regarding this study or you require any further information about it, 
please do not hesitate to contact a member of the research team for this project:   
 
Brisbane Campus      
P.O. Box 456 
Virginia QLD 4014  
 
 
 
 
  Name:     Ryan Hubble   
 Telephone:     07 3623 7703  
  Email:     ryan.hubble@acu.edu.au   
  Postal Address:  School of Exercise Science  
        Australian Catholic 
University  
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What if I have a complaint or any concerns? 
The study has been approved by the Human Research Ethics Committee at Australian Catholic 
University (approval number 2013 223Q). If you have any complaints or concerns about the 
conduct of the project, you may write to the Chair of the Human Research Ethics Committee 
care of the Office of the Deputy Vice Chancellor (Research). Any complaint or concern will 
be treated in confidence and fully investigated. You will be informed of the outcome.  
 
Chair, HREC  
c/o Office of the Deputy Vice Chancellor (Research)  
Australian Catholic University  
Melbourne Campus  
Locked Bag 4115  
FITZROY, VIC, 3065  
Ph: 03 9953 3150  
Fax: 03 9953 3315  
Email: res.ethics@acu.edu.au   
 
I want to participate! How do I sign up? 
If you agree to participate in this project, you should contact a member of the research team to 
indicate your interest and sign both copies of the Consent Form.  One of these copies is for you 
to keep for your records and you should return the other copy to the Principal Investigator 
during your first visit to the Australian Catholic University. Thank you for taking the time to 
consider this research and I look forward to discussing this research with you soon.  
  
Yours sincerely,   
  
Ryan Hubble           Dr Michael Cole  
School of Exercise Science        School of Exercise Science    
Australian Catholic University      Australian Catholic University  
Brisbane Campus          Brisbane Campus  
1100 Nudgee Road, Banyo, QLD, 4014      1100 Nudgee Road, Banyo, QLD, 4014   
Phone: 07 3623 7703         Phone: 07 3623 7674  
E-mail: ryan.hubble@acu.edu.au       E-mail: michael.cole@acu.edu.au    
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Full Explanation of Tests:  
1. Questionnaires and Clinical Assessments:  
Falls history and fear of falls; pre-existing medical conditions; current medications; memory and 
attention; freezing of gait and quality of life will be evaluated using a series of previously 
developed and evaluated questionnaires.  The severity of the symptoms that you may experience 
will also be evaluated using standard clinical tests.    
  
2. Quiet Stance  
This test will take place while you are standing as still as possible for a 30 second period with 
your eyes open and closed on a firm, flat surface as well as on a foam surface.  To ensure your 
safety, a member of the research team will be standing beside you at all times.  
  
3. Walking  
To measure your walking ability, you will be asked to walk on a firm surface at a comfortable 
pace.  While you are walking, your movements will be measured using a small matchbox-sized 
measuring devices (accelerometers) that will be attached to your head using a headband and to 
your back using double-sided tape.  The way in which your muscles turn on and off during 
walking will also be assessed using a non-invasive procedure known as ‘surface 
electromyography’.  This will require a small area of your skin to be gently exfoliated and cleaned 
using a medical-grade alcohol wipe, after which multiple small circular dots to be stuck to your 
skin with an adhesive suitable for sensitive skin types.  To assist with the placement of this 
equipment on the body, it is necessary for you to be wearing shorts and a sleeveless shirt so we 
can easily place the measuring equipment on your head and back.   
  
4. Exercise Program  
You will be asked to attend a one-hour supervised group exercise session once a week for a total 
of 12 weeks.  You will be asked to wear or bring a change of clothes that will allow you to 
comfortably move while completing the exercises.  For your consideration, there will be multiple 
exercise sessions scheduled throughout the week that you may choose to attend depending on 
your availability.  Each group exercise session will consist of a warm-up that promotes mobility 
of the upper body and arms, exercises that target at improving endurance of the muscles of the 
back and abdomen, and a cool-down period consisting of walking and light stretching.  At the 
end of the exercise session you will receive an educational pack that will provide you with 
information that may help to reduce your risk of falling and contribute to an improved quality of 
life.  There will be breaks offered during the training sessions, and you may request additional 
breaks if you need them.  At the end of the training session you will be offered morning /afternoon 
tea or coffee.  
  
5. Follow-up Falls Calendar  
You will be asked to record any falls that you may have over the course of a six-month period 
on a questionnaire consisting primarily of tick boxes.  These questionnaires will ask for 
information about the incidence of any falls and the circumstances surrounding their occurrence 
(e.g. what time of day it occurred, cause of the fall, location of the fall, injuries sustained, etc.) 
and will be returned to the investigative team via a postage-paid envelope once a month. 
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Appendix D: Participant Consent Form 
CONSENT FORM 
(COPY FOR PARTICIPANT TO KEEP)  
 
TITLE OF PROJECT:  Improving postural stability in people with Parkinson’s disease  
PRINCIPAL INVESTIGATOR (SUPERVISOR):  Dr Michael Cole  
CO-SUPERVISOR:      Professor Geraldine Naughton  
STUDENT RESEARCHER:     Ryan Hubble  
 
I…………………................................ (the participant) have read (or, where appropriate, have had read 
to me) and understood the information provided in the Letter to Participants. Any questions I have asked 
have been answered to my satisfaction. I agree to participate in this research aimed at improving postural 
stability in people with Parkinson’s disease and understand that this research will involve assessments of 
standing balance, walking and muscle function, realising that I can withdraw my consent at any time, 
without adverse consequences.  I agree that research data collected for the study may be published or may 
be provided to other researchers in a form that does not identify me in any way.  
I consent to my photograph being taken during my participation in this study and understand that 
it may be used in academic publications as a visual description of testing procedures involved.  I 
am consenting to   this with the understanding that the investigators will not photograph my face 
to maintain the confidentiality of my identity.    
I consent to having video taken of me during my participation in this study and understand that 
it will be used for clinical training purposes only.  I am consenting to this with the understanding 
that, due to the need to assess head and neck movements during some of the clinical tests, my 
identity may not be concealed.  This data is to be used for clinical training purposes only and will 
not be released to any individual not affiliated with this study.  
I do not consent to being photographed or videoed during any of the testing procedures for this 
study.  
I understand that there is an equal chance that I may be randomly assigned to either to one of two 
exercise groups or an education group.  If I am randomly placed into the education group, I am 
interested in receiving information regarding the optional exercise program aimed at improving 
postural stability after the completion of the study.  It has also been explained to me that due to 
the study design, details of the training program cannot be provided until after the study is 
completed.   
I am interested in receiving a summary of the results at the end of the study.  I understand that 
the results may take up to two years to finalise, but I will be contacted by a member of the 
research team to make these results available to me at the completion of the study.  
 
NAME OF PARTICIPANT:  ....................................................................  
SIGNATURE:   ......................................................................................... DATE: …............................  
SIGNATURE OF PRINCIPAL INVESTIGATOR: …….….................... DATE: ................................  
SIGNATURE OF STUDENT RESEARCHER: ...................................... DATE: ……………………  
School of Exercise Science  
1100 Nudgee Road  
Banyo, Queensland, 4014   
T: 07 3623 7703 F: 07 3623 7650 E: ryan.hubble@acu.edu.au   
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Human Research Ethics Committee  
Appendix E: Ethics Approval 
 
 
 
Committee Approval Form  
Principal Investigator/Supervisor:  Dr Michael Cole 
Co-Investigators:    Professor Geraldine Naughton 
Student Researcher:   Mr Ryan Hubble 
Ethics approval has been granted for the following project: 
Improving postural stability in people with Parkinson's disease: A randomised controlled trial 
For the period: 01/10/2013 - 30/06/2016  
Human Research Ethics Committee (HREC) Register Number: 2013 223Q  
 
Special Condition/s of Approval  
 
Prior to commencement of your research, the following permissions are required 
to be submitted to the ACU HREC: 
N/A 
 
The following standard conditions as stipulated in the National Statement on Ethical 
Conduct in Research Involving Humans (2007) apply:  
(i) that Principal Investigators / Supervisors provide, on the form supplied by the 
Human Research Ethics Committee, annual reports on matters such as:  
• security of records 
• compliance with approved consent procedures and documentation 
• compliance with special conditions, and 
(ii) that researchers report to the HREC immediately any matter that might affect the 
ethical acceptability of the protocol, such as:  
• proposed changes to the protocol 
• unforeseen circumstances or events 
• adverse effects on participants 
 
The HREC will conduct an audit each year of all projects deemed to be of more than low risk.  
There will also be random audits of a sample of projects considered to be of negligible risk and 
low risk on all campuses each year.  
 
Within one month of the conclusion of the project, researchers are required to complete a Final 
Report Form and submit it to the local Research Services Officer.  
 
If the project continues for more than one year, researchers are required to complete an Annual 
Progress Report Form and submit it to the local Research Services Officer within one month 
of the anniversary date of the ethics approval. 
 
 
 Signed:    Date:  28/10/2013  
 
(Research Services Officer, McAuley Campus) 
U:\Ethics\Ethics Applications 2013\2013 223Q Cole\2013 223Q Approval Form.doc  
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Appendix F: Research Portfolio 
Paper 1: (Published) Trunk muscle exercises as a means of improving postural stability in 
people with Parkinson's disease: a protocol for a randomised controlled trial. 
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group.bmj.com on July 28, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
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Study 1 (Published) “Wearable sensor use for assessing standing balance and walking 
stability in people with Parkinson’s disease: A systematic review.” 
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Study 2 (Published) “Assessing stability in mild and moderate Parkinson’s disease: Can 
clinical measures provide insight?” 
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Study 4 (Under Review) “Exercise improves gait symmetry in Parkinson disease: A blind phase 
II randomised-controlled trial.” 
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Statement of the Contribution of Authors 
 
The following is a description of the contribution of the main and co-authors for each of 
the published/submitted manuscripts supporting this thesis. 
 
1) “Trunk muscle exercises as a means of improving postural stability in people with 
Parkinson's disease: a protocol for a randomised controlled trial.” 
 
 
Author Roles Contribution 
Ryan Hubble 
Conception of study design 
Preparation of initial draft of manuscript 60% 
Dr Michael Cole 
Conception of study design 
Revision of manuscript 25% 
Professor Geraldine Naughton 
Assisted with study design 
Revision of manuscript 10% 
Professor Peter Silburn Revision of manuscript 5% 
 
 
2) “Wearable sensor use for assessing standing balance and walking stability in people 
with Parkinson’s disease: A systematic review.” 
 
 
Author Roles Contribution 
Ryan Hubble 
Conceived and designed experiments 
Performed experiments 
Analysed the data 
Preparation of initial draft of manuscript 
60% 
Dr Michael Cole 
Conceived and designed experiments 
Performed experiments 
Analysed the data 
Contributed reagents/materials/analysis tools 
Revision of manuscript 
25% 
Professor Geraldine Naughton 
Contributed reagents/materials/analysis tools 
Revision of manuscript 10% 
Professor Peter Silburn 
Contributed reagents/materials/analysis tools 
Revision of manuscript 
5% 
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3) “Assessing stability in mild and moderate Parkinson’s disease: Can clinical measures 
provide insight?” 
 
Author Roles Contribution 
Ryan Hubble 
Conceived and designed experiments 
Performed experiments 
Analysed the data 
Preparation of initial draft of manuscript 
60% 
Dr Michael Cole 
Conceived and designed experiments 
Performed experiments 
Analysed the data 
Revision of manuscript 
25% 
Professor Geraldine Naughton 
Contributed reagents/materials/analysis tools 
Revision of manuscript 
10% 
Professor Peter Silburn 
Contributed reagents/materials/analysis tools 
Revision of manuscript 
5% 
 
4) “Exercise improves gait symmetry in Parkinson disease: A blind phase II randomised-
controlled trial” 
 
Author Roles Contribution 
Ryan Hubble 
Conceived and designed experiments 
Performed experiments 
Analysed the data 
Preparation of initial draft of manuscript 
60% 
Dr Michael Cole 
Conceived and designed experiments 
Performed experiments 
Analysed the data 
Revision of manuscript 
25% 
Professor Geraldine Naughton 
Contributed reagents/materials/analysis tools 
Revision of manuscript 
10% 
Professor Peter Silburn 
Contributed reagents/materials/analysis tools 
Revision of manuscript 
5% 
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I hereby declare that my contribution to each of the four published/submitted manuscripts, as 
outlined above, to be accurate and true. 
Main Author: Ryan Paul Hubble 
Signature: ________________________________ Date: 03/08/2016 
Co-Author: Dr Michael H. Cole 
Signature: ________________________________ Date:  29/07/2016 
Co-Author: Professor Geraldine A. Naughton 
Signature: ________________________________ Date:  31/07/2016 
Co-Author: Professor Peter A. Silburn 
Signature: ________________________________ Date:  02/08/2016 
